Article

The cellular and molecular cardiac tissue responses in human inflammatory cardiomyopathies after SARS-CoV-2 infection and COVID-19 vaccination

Received: 12 August 2024

Accepted: 10 January 2025

Published online: 24 February 2025

Check for updates

A list of authors and their affiliations appears at the end of the paper

Myocarditis, characterized by inflammatory cell infiltration, can have multiple etiologies, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or, rarely, mRNA-based coronavirus disease 2019 (COVID-19) vaccination. The underlying cellular and molecular mechanisms remain poorly understood. In this study, we performed single-nucleus RNA sequencing on left ventricular endomyocardial biopsies from patients with myocarditis unrelated to COVID-19 (Non-COVID-19), after SARS-CoV-2 infection (Post-COVID-19) and after COVID-19 vaccination (Post-Vaccination). We identified distinct cytokine expression patterns, with interferon-y playing a key role in Post-COVID-19, and upregulated IL16 and IL18 expression serving as a hallmark of Post-Vaccination myocarditis. Although myeloid responses were similar across all groups, the Post-Vaccination group showed a higher proportion of CD4⁺T cells, and the Post-COVID-19 group exhibited an expansion of cytotoxic CD8⁺T and natural killer cells. Endothelial cells showed gene expression changes indicative of vascular barrier dysfunction in the Post-COVID-19 group and ongoing angiogenesis across all groups. These findings highlight shared and distinct mechanisms driving myocarditis in patients with and without a history of SARS-CoV-2 infection or vaccination.

Coronavirus disease 2019 (COVID-19) is primarily a respiratory disease, but systemic and cardiovascular involvement can occur, and acute cardiac injury^{1,2} with elevation of serum troponins is not uncommon after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Strikingly, the risk and 1-year burden of cardiovascular diseases in survivors of acute COVID-19 are substantial, and the risk to specifically develop myocarditis is approximately fivefold increased³. In children/ young adults, SARS-CoV-2 infection can lead to multisystem inflammatory syndrome (MIS-C), with myocarditis being the most prevalent clinical feature⁴. Cardiac injury can also rarely be induced after receipt of vaccines against COVID-19, in particular those based on mRNA technology^{5,6}. Although evidence for direct SARS-CoV-2-mediated induction of myocardial injury is limited, the infection can elicit intense systemic release of cytokines, possibly leading to a secondary cardiac inflammatory response. Likewise, vaccine-associated myocardial inflammation and injury was shown to be characterized by systemic 'cytokinopathy', activated cytotoxic lymphocytes or induction of IL1-RA in the blood^{7,8}. Using immunohistochemical staining of cardiac tissue from patients with clinically suspected myocarditis after SARS-CoV-2 infection or after COVID-19 mRNA vaccination, in particular a macrophage-dominated infiltrate was consistently observed^{2,9} that also was reported for SARS-CoV¹⁰. Furthermore, in patients with

e-mail: h.maatz@mdc-berlin.de; nhuebner@mdc-berlin.de; carsten.tschoepe@dhzc-charite.de

In the present study, we performed single-nucleus RNA sequencing (snRNA-seq) on cardiac tissue from symptomatic patients who clinically presented with pathological laboratory, electrocardiogram (ECG) and/or non-invasive imaging results of acute myocarditis and had undergone endomyocardial biopsies (EMBs) for diagnostic purposes. We studied EMBs from patients after SARS-CoV-2 infection (including two SARS-CoV-2-related patients with MIS-C) or after SARS-CoV-2 vaccination as well as from patients with histologically confirmed lymphocytic myocarditis that were mostly taken before the pandemic or had no signs of SARS-CoV-2 infection. Comparison of the different myocardial inflammatory modalities revealed common and divergent compositional cellular changes as well as pro-inflammatory and anti-inflammatory transcriptional signatures in patients with Non-COVID-19 myocarditis and those with myocarditis after SARS-CoV-2 infection or vaccination.

Results

Patient cohort and clinical presentation

Our clinical cohort consisted of (1) patients with 'classical' lymphocytic myocarditis (Non-COVID-19, n = 8); (2) patients with signs of acute myocarditis after SARS-CoV-2 infection (Post-COVID-19, n = 10); (3) patients with signs of acute myocarditis after vaccination against COVID-19 (Post-Vaccination, n = 4); (4) patients with MIS-C with signs of acute myocarditis (n = 2); and (5) control donor left ventricular (LV) tissue that we analyzed previously^{12,13}. All patients presented with symptoms including chest pain, palpitations, fever, shortness of breath, malaise and/or general weakness and fatigue and an overall increase of cardiac damage-indicating biomarkers (troponin T, N-terminal prohormone of brain natriuretic peptide (NT-pro-BNP), creatine kinase or creatine kinase MB) and C-reactive protein (CRP) levels (Fig. 1a). ECG, echocardiography or signs of recent or ongoing myocardial damage in cardiac magnetic resonance imaging (MRI). ranging from normal or non-specific to borderline low or abnormal. are summarized in Extended Data Table 1. All patients underwent LV EMBs and left heart catheterization after routine non-invasive diagnostic workup, and angiography had failed to elucidate any other specific cause of heart failure, such as coronary artery disease. Post-COVID-19 patients and patients with MIS-C were previously tested positive for SARS-CoV2 infection by nasopharyngeal swab test polymerase chain reaction (PCR). Most Post-Vaccination patients experienced symptom onset within days after the second dose of the vaccine. Consistent with prior reports^{79,14}, the cohort was predominantly male (87.5%; Non-COVID-19: 87.5%, Post-COVID-19: 80%, Post-Vaccination: 100% and MIS-C: 100%) with an average age of 37 ± 16 years (range, 19–70 years). The age of the two patients with MIS-C was 20 years and 21 years. Post-COVID-19 patients were slightly older than the other patients (Fig. 1a and Extended Data Table 1). Selection of Non-COVID-19 patients was based on positive EMB results showing lymphocytic myocarditis and similarities in sex and age compared to the other disease groups. In the MIS-C group, one patient underwent an additional EMB, 6 months after combined immunosuppression with prednisolone and azathioprine.

Clinical histopathology and immunostaining on EMBs identified substantial widespread increased interstitial macrophage infiltration in all patients and, additionally, lymphocytic myocarditis in 30% of Post-COVID-19 patients, in 25% of Post-Vaccination patients and in 100% of patients with MIS-C (Extended Data Table 1 and Extended Data Fig. 1a,b). Our observations are in agreement with previous reports, where most post-COVID-19 and mRNA-vaccinated patients with signs of myocarditis showed predominantly macrophage infiltrates into the myocardium^{2.9}. No SARS-CoV-2 genome was detected by PCR in EMBs of Post-COVID-19 patients and patients with MIS-C. EMBs that were not used for diagnostic workup were included for snRNA-seq analyses to investigate the cellular and molecular changes of myocardial inflammatory responses across the different disease entities.

Myocarditis-associated changes in cardiac tissue composition

To generate snRNA-seq libraries, we isolated nuclei from EMBs using our previous protocol with modifications (Fig. 1b and Methods). For comparison to healthy hearts, we used reported full-thickness LV snRNA-seq data from 18 healthy controls^{12,13} (Extended Data Table 2). Despite the small amount of input material, the resulting EMB sequencing data were of similar quality to those of the full-thickness healthy heart samples (Extended Data Fig. 1c-f). After pre-processing and quality control filtering, nuclei were integrated using Harmony, followed by constructing manifolds using uniform manifold approximation and projections (UMAPs). In total, we analyzed 205,596 nuclei. Clustering identified 10 major cell types (Fig. 1c, Extended Data Fig. 2a,b and Supplementary Table 1) encompassing cardiomyocytes (CMs), fibroblasts (FBs), mural cells containing pericytes (PCs) and smooth muscle cells (SMCs), endothelial cells (ECs), PKHD1L1-expressing ECs (EC PKHD1L1⁺) comprising mostly endocardial cells and few lymphatic ECs (Extended Data Fig. 2c), adipocytes, neural cells, mast cells and lymphoid and myeloid cells.

Using center log ratio (CLR)-transformed abundance of cell types¹³ (excluding EC_PKHD1L1⁺; see Methods), we compared the cellular composition of healthy versus patient hearts. In line with EMB immunohistochemistry results, myeloid cell proportions were increased in Post-COVID-19 and Post-Vaccination, whereas, in the Non-COVID-19 group, this increase did not reach statistical significance (Fig. 1d and Extended Data Fig. 2d). Surprisingly, we observed increased proportions of lymphoid cells for all patient groups (Fig. 1d) and, indeed, all Post-COVID-19 and Post-Vaccination patients (Extended Data Fig. 2b,d). This was in contrast to the clinical immunohistochemistry results where only a fraction of Post-COVID-19 and Post-Vaccination patients showed lymphocytic myocarditis, defined by the presence of CD3⁺ T cells. Similar to findings in end-stage heart failure¹³ and in hearts of deceased patients with COVID-19 (ref. 15), ECs were significantly expanded in Non-COVID-19 and Post-COVID-19. FB abundance remained unchanged, whereas CM and mural cell proportions were modestly reduced across patient groups.

Patients with MIS-C showed increased proportions of immune cells (lymphoids and myeloids), similar to the other patient groups (Fig. 1d and Extended Data Fig. 2d). Strikingly and as expected, comparing the cellular composition of the matching EMBs from one patient with MIS-C showed a marked reduction of immune cells after treatment, indicating normalization of immune cell numbers (Fig. 1e). Due to the low sample size (n = 2), throughout this paper we report MIS-C results only for differences in cell type and state abundances without statistical testing.

Distinct cytokine and inflammasome expression signatures

We determined differentially expressed genes (DEGs) in cardiac tissue using a pseudo-bulk approach that aggregated all nuclei from the same individual (Supplementary Table 2) and detected increased expression of the pro-inflammatory cytokine genes *TNF* and *IFNG* across patient groups (Fig. 1f). *IFNG* was solely expressed in lymphocytes and especially elevated in the Post-COVID-19 and MIS-C groups (Fig. 1f and Extended Data Fig. 3a). Additional interleukin and leukocyte recruiting chemokine (C-X-C and C-C motif) ligand family member encoding genes were upregulated in the patient groups (Extended Data Fig. 3b), consistent with increased immune cell abundances.

Article



Fig. 1 | Distinct cellular and molecular signatures in Non-COVID-19, Post-COVID-19 and Post-Vaccination inflammatory cardiomyopathies. a, Infographic depicting metadata for Non-COVID-19 (n = 8), Post-COVID-19 (n = 10), Post-Vaccination (n = 4) and MIS-C (n = 2) patients. Left panel, patient age; women and men, light and dark gray, respectively. Middle panels, box plots showing serum levels of troponin T, NT-pro-BNP and CRP; dashed lines and blue areas indicate normal ranges. Right panel, box plots showing left ventricular ejection fraction (EF). b, snRNA-seq workflow schematic: EMBs were lysed and nuclei purified using FACS. Nuclei were processed using 10x Chromium 3' chemistry. Image shows EMB size before nuclei isolation. c, UMAP embedding of 205,596 nuclei delineated 10 cardiac cell types and unassigned populations (gray). d, Upper panel, mean cell type abundances (%) in controls (n = 18). Lower panel, proportional changes of cell types in Non-COVID-19 (n = 8), Post-COVID-19 (n = 10) and Post-Vaccination (n = 4) versus control. Color scale: red (increase) and blue (decrease). Significant P values (FDR ≤ 0.05) are shown. P values were calculated with the two-sided t-test based on CLR-transformed values with Benjamini-Hochberg correction. MIS-C significance was not calculated due to low sample size (n = 2). e, Proportions of myeloid and lymphoid cells in control

(n = 18) and MIS-C (n = 2) groups as well as in a follow-up biopsy from one patient with MIS-C.The patient with MIS-C with pre-treatment and post-treatment EMBs is indicated by a dashed line. Significance was not calculated due to low sample size (n = 2). **f**, Box plots as described in **a** showing snRNA-seq pseudo-bulk expression levels of cytokines in cardiac tissue from patient and control groups (control: n = 18, Non-COVID-19: n = 8, Post-COVID-19: n = 10, Post-Vaccination: n = 4). Significant P values (FDR ≤ 0.05) are shown. P values were calculated using the quasi-likelihood F-test with Benjamini-Hochberg correction. g, Pie charts comparing cell type resolved absolute mean expression levels of IL16 and IL18 between conditions. Pie size reflects absolute detection levels: colors indicate relative cell type contribution. h, Dot plots showing differential expression of IFNy response genes in patient groups relative to controls in major cardiac cell types. Dot colors indicate log2-transformed FCs (log2FCs). Dot sizes indicate absolute \log_2 FC. Black circles indicate significance (FDR \leq 0.05). *P* value calculations are as in **f**. Box plots in **a**, **e** and **f**: boxes show interquartile range (IQR); vertical bars indicate the median; and whiskers extend from minimum to maximum values. Dots show individual measurements per patient. Adipo, adipocyte; Lymph, lymphoid; Myel, myeloid.

Article



Fig. 2 | **Myeloid compositional changes and gene expression alterations in cardiac inflammation. a**, UMAP embedding delineated 16 myeloid cell states. **b**, Upper panel, mean abundance (%) of myeloid cell states in control left ventricles (n = 18). Lower panel, proportional changes of myeloid cell states in the four patient groups (Non-COVID-19: n = 8, Post-COVID-19: n = 10, Post-Vaccination: n = 4). Color scale: red (increase) and blue (decrease). *P* values are indicated for significant proportional changes (FDR ≤ 0.05). *P* values were calculated using the two-sided *t*-test based on CLR-transformed values with Benjamini–Hochberg correction. For MIS-C, significance was not calculated due to low sample size (n = 2). **c**, Condition-split UMAP showing compositional shifts in myeloid cell states across patient groups and controls. **d**,**e**, Box plots showing distribution of Lyve1^{hi}MHCII^{ho} and Lyve1^{ho}MHCII^{hi} (**d**) and CD16⁺ and VCAN⁺ monocytes (**e**) across control and disease groups (control: n = 18,

We noted stronger upregulation of IL34, a macrophage growth and survival factor, in the Non-COVID-19 and Post-Vaccination groups than in the Post-COVID-19 group (Fig. 1f). In an inflammatory context, IL-34-derived macrophages suppress pro-inflammatory polarization of T cells¹⁶. Furthermore, *TGFB1* encoding immunosuppressive TGF-β1 was upregulated in all patient groups but highest in the Post-Vaccination group. IL16 and IL18 expression was uniquely increased in the Post-Vaccination group, and expression of inflammasome components such as pattern recognition receptors NLRP1 and NLRP3 and caspases *CASP1* and *CASP4* necessary for IL18 activation¹⁷ were highest in this group (Fig. 1f and Extended Data Fig. 3c). These genes were expressed in multiple cell types, but contribution of myeloids to their overall expression levels was greater in the Post-Vaccination group compared to all other patient groups (Fig. 1g and Extended Data Fig. 3d), suggesting a distinctive myeloid origin of this pathway in the Post-Vaccination group, consistent with previous findings¹⁸.

Non-COVID-19: n = 8, Post-COVID-19: n = 10, Post-Vaccination: n = 4). Boxes depict the interquartile range (IQR); horizontal bars indicate the median; whiskers extend to $1.5 \times IQR$; and dots show the value of each patient. *P* values are indicated for significant proportional changes, FDR < 0.05. *P* value calculations are as described in **b**. **f**, Dot plots showing differential expression of selected IFN γ response and MHC-II genes in patient groups relative to control across Lyvel^{bi}MHCII^{bo} and Lyvel^{bo}MHCII^{bi} (control: n = 18, Non-COVID-19: n = 8, Post-COVID-19: n = 10, Post-Vaccination: n = 4). Dot colors indicate log₂-transformed FCs (log₂FCs). Dot sizes indicate absolute log₂FC. Black circles indicate significance (FDR ≤ 0.05). *P* values were calculated using the quasi-likelihood *F*-test and were adjusted for multiple testing (Benjamini–Hochberg). Genes are ordered alphabetically.

We then determined DEGs in pseudo-bulks of individual cell types and performed gene set enrichment analyses (GSEAs) on DEGs to identify disease-associated pathways. Strikingly, in the Post-COVID-19 group, upregulated gene sets related to interferon- γ (IFN γ) signaling in multiple cell types (Fig. 1h and Supplementary Table 3).

Myeloid expansion and compositional changes in myocardits

Characterization of myeloid cells identified nine previously described¹³ macrophage states, VCAN⁺ and non-classical CD16⁺ monocytes, two conventional dendritic cell states and one decorin (*DCN*)-expressing proliferative macrophage state (Fig. 2a,b, Extended Data Fig. 4a,b and Supplementary Table 4). Despite the varying extent of the overall myeloid expansion (Extended Data Fig. 2d), we observed similar striking compositional alterations in the myeloid populations in Non-Covid-19, Post-COVID-19 and Post-Vaccination groups compared to control (Fig. 2b and Extended Data Fig. 4a). Among pre-existing resident

macrophages, LYVE1^{hi}MHCII^{lo} with pivotal cardiac repair function¹⁹ was barely detectable, whereas proportions of LYVE1¹⁰MHCII^{hi} that effectively stimulate T cell responses^{19,20} were strongly increased in these three patient groups (Fig. 2b-d). Furthermore, proportions of T cellstimulating cDC2 were increased, whereas FB-interacting MP_OSM macrophages and MP_FOLR2 were decreased (Fig. 2b and Extended Data Fig. 4a). Reduced proliferating macrophage and expanded CD16⁺ and VCAN⁺ monocyte proportions (Fig. 2e and Extended Data Fig. 4a), as well as *CX3CR1* expression (circulating monocyte marker) (Extended Data Fig. 4c), indicated recruited monocytes as a source for the LYVE1^{lo}MHCII^{hi} MP increase. Of note, VCAN⁺ monocytes expressed CCR2 and pro-inflammatory mediators (S100A12, S100A9 and S100A8) (Extended Data Fig. 4d). In a myocarditis mouse model, silencing of CCR2 prevented cardiac monocyte accumulation and chronic decline of LV function²¹. Patients with MIS-C showed different compositional alterations of the myeloid cell population compared to the other patient groups, with no change in pre-existing resident macrophage proportions but an increase in monocyte proportions exceeding, by far, those observed in the other groups (Fig. 2e). Furthermore, DCN-expressing proliferative macrophages were enriched only in patients with MIS-C. Expression of FB genes in macrophages may indicate the acquisition of a fibrogenic phenotype^{22,23}.

DEG analysis comparing myeloid states in patient groups versus control revealed the highest number of upregulated genes in LYVE110-MHCII^{hi} macrophages (Supplementary Table 5), including CARMIL1, MAF, WWP1 and CD83, indicating higher activation and interstitial migration capacities^{24,25} (Extended Data Fig. 4e). Contrary to reports for macrophages from lung of patients with severe COVID-19 and from blood of patients with perimyocarditis after vaccination^{7,26}, we did not observe pro-fibrotic gene expression responses in cardiac myeloids. However, GSEA on DEGs per cell state identified upregulated gene sets related to IFNy signaling in LYVE1^{hi}MHCII^{lo}, LYVE1^{lo}MHCII^{hi} and proliferating macrophages as well as in cDC2 from Post-COVID-19 patients (Fig. 2f and Supplementary Table 3). IFNy is known to increase pro-inflammatory activity in macrophages²⁷ and to induce major histocompatibility complex class II (MHC-II) gene expression²⁸. Indeed, macrophages in the Post-COVID-19 group showed upregulated class II MHC transactivator encoding CIITA and MHC-II genes (Fig. 2f).

Distinct lymphocyte responses in Post-COVID-19 and Post-Vaccination

Subcluster analyses of lymphoid cells revealed 10 T cell and three natural killer (NK) cell states as well as plasma, B cells and a small population of IFNy-producing NK cells (Fig. 3a-c, Extended Data Fig. 5a,b and Supplementary Tables 6 and 7). Within the T cell population, we observed higher CD4⁺ to CD8⁺ T cell ratios in Non-COVID-19, and this effect was even more pronounced in Post-Vaccination, aligning with previously reported predominance of cardiac CD4⁺ lymphocytic infiltrates in response to COVID-19 vaccination¹¹. In contrast, CD8⁺ T cells dominated in the Post-COVID-19 and MIS-C groups (Fig. 3d). Overall, CD8⁺ T cells displayed higher expression of gene sets related to cytotoxicity compared to CD4⁺ T cells (Extended Data Fig. 5c). The differences in T cell ratios between disease groups were attributable especially to a relative increase in regulatory, Tem1 and central memory CD4⁺ T cells in Non-COVID-19 and Post-Vaccination (Fig. 3b,e). Additionally, RORC⁺CD4⁺ T cells were increased in these groups, albeit not statistically significantly. Conversely, cytotoxic GNLY-expressing effector cell proportions and mature NK cells (NK_CD16^{hi}) increased in Non-COVID-19, Post-COVID-19 and MIS-C but not in Post-Vaccination (Fig. 3b). Proliferating T cells were increased only in MIS-C (Extended Data Fig. 5a). CD8⁺ T cells in Post-COVID-19 furthermore showed upregulated expression of activation markers such as CD38 and HLA-DR (Fig. 3f) and higher PRF1 expression levels encoding the cytotoxic effector molecule perforin than Non-COVID-19 and Post-Vaccination (Fig. 3g), suggesting an increased cytotoxic potential of CD8⁺ T cells in hearts of Post-COVID-19 patients. Interestingly, we identified highly activated CD16⁺CD8⁺ T cells (CD8T_act_effector) with strong cytotoxic functions and high similarity to CD16⁺CD8⁺ T cells previously identified in the blood of patients with severe COVID-19 (ref. 29). These cells were significantly enriched in cardiac tissue of Post-COVID-19 patients (Fig. 3b). Nuclei within this cluster expressed TRAC, TRDC and TRGC1/2, indicating a mixed cluster of $\alpha\beta$ and $\gamma\delta$ T cells that could not be separated further.

We explored our snRNA-seq data for transcriptional signatures that may suggest an impact of cytotoxic lymphocytes on non-immune cardiac cells. CD8⁺T cells recognize and kill cells presenting perceived non-self-antigens via MHC-I molecules. Among cardiac non-immune cells, ECs showed the highest human leukocyte antigen (HLA) class I gene expression, whereas control CMs displayed barely detectable levels, consistent with previous findings^{30,31} (Extended Data Fig. 5d). Interestingly, in myocarditis, it was reported that MHC-I is upregulated on CMs and interstitial cells³⁰. In our study, aggregated pseudo-bulk data of non-immune cardiac cells showed elevated, albeit not significant, HLA class I gene expression in disease conditions with higher levels in Post-COVID-19 (Extended Data Fig. 5e). In CMs, HLA-F was specifically upregulated across Non-COVID-19, Post-COVID-19 and Post-Vaccination conditions (Fig. 3h and Extended Data Fig. 5d). Additionally, in CMs and FBs, the MHC class I-like molecule RAET1E was particularly upregulated in Post-Vaccination (Fig. 3i and Extended Data Fig. 5f). RAET1E binds and activates NKG2D-expressing NK and CD8⁺T cells, with RAET family members typically absent on normal cells but overexpressed under stress. This overexpression was reported to contribute to the development of autoimmunity³² and may be linked to an exacerbated inflammatory response.

Elevated HIF1A and VEGFA expression in CMs

Previous in vitro studies reported specific gene expression signatures after infecting induced pluripotent stem cell (iPSC)-derived CMs with SARS-CoV-2 (ref. 33). We did not observe a matching transcriptional response in our snRNA-seq CM data, neither in Post-COVID-19 patients nor in any other of the patient groups. Subclustering of the CM population identified previously reported cell states of the left ventricle¹³ (Fig. 4a,b, Extended Data Fig. 6a,b and Supplementary Tables 8 and 9) and one additional CM state (vCM6) that showed enrichment of genes related to regulation of heart rate by cardiac conduction (including, for example. CAMK2D. KCND3. CACNA2D1. CTNNA3 and CACNA1C). vCM6 proportions were more abundant in all patient groups, especially in Non-COVID-19 and Post-Vaccination (Fig. 4b and Extended Data Fig. 6a), whereas vCM5 proportions were increased only in Post-COVID-19. vCM5 was described to participate in the cardiac conduction system¹². Increased risks of cardiac arrhythmias were observed after a positive SARS-CoV-2 test^{3,34}.

In CMs, we observed a significant upregulation of *HIF1A* in all patient groups compared to controls (Fig. 4c). *HIF1A* encodes the O₂-regulated HIF1 subunit, and its expression can also be induced by various cytokines³⁵. Local oxygen concentration in inflamed areas tends to decrease³⁶. HIF1 functions as a master regulator of cellular and systemic homeostatic response to hypoxia, such as angiogenesis and vascular remodeling³⁷. One notable HIF1A downstream target is the vascular endothelial growth factor A (*VEGFA*). Its product, VEGFA, is a powerful inducer of angiogenesis but can also induce vascular inflammation and increase vascular permeability³⁸. *VEGFA* expression was upregulated in the overall CM population and across CM states in all patient groups (Fig. 4d).

Pro-angiogenic and inflammatory gene expression in vascular cells

Subclustering of vascular cells (ECs and mural cells) delineated previously characterized capillary (EC1), arterial (EC5) and venous (EC6) ECs as well as two SMC states (SMC1.1 and SMC1.2) and three PC







Fig. 3 | Distinct lymphocyte responses in cardiac tissue of Post-COVID-19 and Post-Vaccination patients. a, UMAP embedding of lymphoid cells delineated 19 lymphoid cell states. b, Upper panel, mean abundance (%) of lymphoid cell states in control left ventricles (n = 11). Lower panel, proportional changes of lymphoid cell states in Non-COVID-19 (n = 7), Post-COVID-19 (n = 9) and Post-Vaccination (n = 4). Color scale: red (increase) and blue (decrease). P values are indicated for significant proportional changes (FDR \leq 0.05). *P* values were calculated using the two-sided t-test based on CLR-transformed values with Benjamini-Hochberg correction. For MIS-C, significance was not calculated due to low sample size (n = 2). Only samples with lymphoid counts greater than 30 were considered (Methods). c, Heatmap showing the z-score standardized expression of select marker genes (columns) per T cell cluster (rows). TF, transcription factor. d, Stacked bar chart indicating CD8T/CD4T ratios across conditions. n numbers are as described in b. e, Box plots showing distribution of CD4⁺ effector memory 1 (CD4T_em1), regulatory (CD4T_reg), RORC-expressing (CD4T_RORC⁺) and central memory (CD4T_cm) T cells. Significant P values (FDR \leq 0.05) are shown.

n numbers and P value calculations are as described in **b**. **f**, Dot plot showing differential expression of activation markers in pseudo-bulk CD8T cells across patient groups relative to control. Dot colors indicate log₂-transformed FCs (log₂FCs). Dot sizes indicate absolute log₂FC. Black circles indicate significance (FDR \leq 0.05). *P* values were calculated using the quasi-likelihood *F*-test with Benjamini-Hochberg correction. g, Box plots showing PRF1 snRNA-seq expression levels in pseudo-bulk CD8T cells from patient groups (Non-COVID-19: n = 7. Post-COVID-19: n = 10. Post-Vaccination: n = 4: see Methods. DEG analysis). P value calculations are as described in **f**. P values were FDR > 0.05. **h**, **i**, Box plots showing snRNA-seq pseudo-bulk expression levels of HLA-F in CMs (h) and of RAET1E in CMs (i) (left) and FBs (right) from patient and control groups (control: *n* = 18, Non-COVID-19: *n* = 8, Post-COVID-19: *n* = 10, Post-Vaccination: *n* = 4). Significant *P* values (FDR \leq 0.05) are shown. *P* values were calculated as described in g. Box plots in e, g and h: Boxes show interquartile range (IQR); vertical bars indicate the median; and whiskers extend from minimum to maximum values. Dots show individual measurements per patient.

states (PC1-3)¹³ (Fig. 4e, f, Extended Data Fig. 6c-i and Supplementary Tables 10 and 11). We identified one additional PC state (PC1.1) with enriched expression of genes with anti-angiogenic capacity, including ADAMTS9, ADAMTS1 and HIPK2, and two additional EC states, EC9 and EC10. EC9 was characterized by the expression of interferon-stimulated genes (ISGs). EC10 showed enriched expression of pro-angiogenic stem cell receptor KIT, SMAD1 and tip cell marker genes (including ANGPT2, PGF and PDGFB) (Extended Data Fig. 6e), similar to ECs previously described to promote cardiac repair after myocardial infarction³⁹. We observed across all patient groups decreased canonical PC1 and anti-angiogenic PC1.1 proportions. In contrast, EC5 (arterial) proportions were strongly increased, and EC1 (capillary) and EC6 (venous) proportions were barely increased. This indicated altered vascular cell ratios in all patient groups. ISG-expressing EC9 cells were increased in Post-COVID-19. These cells showed the highest HLA class I gene expression among EC states (Extended Data Fig. 6j), suggesting that they may represent a preferential target for cytotoxic CD8⁺ T cells within the EC population. EC10 cells were almost exclusively found in the patient groups except in MIS-C (Fig. 4f and Extended Data Fig. 6c).

DEG analysis identified consistently decreased *NFKBIA* expression in ECs within all patient groups (Fig. 4g). *NFKBIA* encodes the I κ B α repressor that counteracts the pro-inflammatory transcription factor NF- κ B. We furthermore noted a consistent upregulation of the junctional adhesion molecules encoding genes *JAM2* and *JAM3* in ECs across all patient groups (Fig. 4g). JAM2 and JAM3 are known to facilitate the migration and extravasation of immune cells through the endothelium⁴⁰. We then performed GSEA on DEGs per vascular cell state and observed upregulated gene sets related to IFN γ signaling in EC1, EC5 and EC6 as well as PC1 and PC3 from Post-COVID-19 patients (Fig. 4h).

Elevated angiogenesis-associated intercellular communication

By examining the expression of genes encoding for receptors and ligands, we inferred cell-cell communication using CellChat and detected increased VEGFA signaling from CMs to ECs in all patient groups (Fig. 4i). VEGFA promotes angiogenesis and vascular permeability primarily through its receptor VEGFR2 (KDR). Alternatively, it can bind to its decoy receptor VEGFR1 (FLT1), thus fine-tuning the angiogenic process and ensuring vascular quiescence and stability⁴¹.

Compared to other EC states, *KDR* showed highest and *FLT1* lower expression in EC10 (Fig. 4j), suggesting increased responsiveness to VEGFA. EC activation by VEGFA leads to formation of tip cell filopodia and facilitates migration, proliferation and survival⁴². Gene Ontology (GO) term analysis on genes expressed in EC10 indeed resulted in the identification of related terms (Extended Data Fig. 6k,l).

CellChat analyses furthermore identified increased angiogenesisrelated angiopoietin (ANGPT), ephrin B (EPHB) and NOTCH signaling

Fig. 4 | Vascular cells exhibit pro-angiogenic, inflammation and immune cell recruitment signatures across disease groups. a, UMAP embedding delineated nine CM states. b, Upper panel, mean CM state abundances (%) in controls (n = 18). Lower panel, proportional changes of CM states in Non-COVID-19 (n = 8), Post-COVID-19 (n = 10) and Post-Vaccination (n = 4) versus control. Color scale: red (increase) and blue (decrease). Significant P values (FDR \leq 0.05) are shown. P values were calculated with the two-sided t-test based on CLR-transformed values with Benjamini-Hochberg correction. MIS-C significance was not calculated due to low sample size (n = 2). c, Upper panel, box plots showing HIF1A snRNA-seq pseudo-bulk expression levels in CMs. Boxes depict the interquartile range (IQR); horizontal bars indicte the median; whiskers extend to 1.5× IQR; and dots show the value of each patient. Significant *P* values (FDR \leq 0.05) are shown. Lower panel, dot plots showing differential expression of HIF1A in patient groups relative to control across CM states. Dot colors indicate log₂-transformed FCs (log₂FCs). Dot sizes indicate absolute log₂FC. Black circles indicate significance (FDR \leq 0.05). Upper and lower panel, control: n = 18, Non-COVID-19: n = 8,

in all patient groups (Fig. 4i). Angiopoetin ligand ANGPT1 stabilizes vessels, and ANGPT2 is a VEGFA-dependent modulator of capillary structures and EC survival⁴³. CellChat analyses predicted enhanced signaling of ANGPT1 from CMs and of ANGPT2 from mural cells to ECs (Extended Data Fig. 6m). ANGPT1 and ANGPT2 expression was increased in CMs and mural cells, respectively, across all patient groups (Fig. 4k). Ephrin B ligands and their Eph receptors play important roles in vessel growth and stabilization⁴⁴. Expression of *EFNB2*, encoding a EPHB signaling ligand, was upregulated in ECs (Fig. 41), and CellChat analyses predicted induction of autocrine signaling in ECs and increased signaling to CMs, where EFNB2 signaling was shown to play a protective role⁴⁵. Furthermore, predicted EFNB2-EPHB1 ligand-receptor interactions identified in controls were shifted to EFNB2-EPHA4 in the patient groups (Extended Data Fig. 6n). Activation of EPHA4 in ECs was shown to increase monocyte adhesion⁴⁶ and limit arteriogenesis through attenuated ANGPT2/Tie2 signaling⁴⁷. NOTCH signaling plays a crucial role in regulating smooth muscle differentiation and blood vessel formation. In addition to increased NOTCH signaling between ECs and mural cells, CellChat inference suggested enhanced autocrine signaling in ECs that can be activated by disturbed blood flow⁴⁸. Furthermore, signaling to myeloids was increased (Fig. 4i and Extended Data Fig. 6m) in line with the recent implication of NOTCH signaling in macrophage activation and differentiation⁴⁹.

Fibrosis-associated gene expression profiles

Previous studies reported histopathological findings of fibrosis for post-COVID-19-associated as well as post-vaccination-associated myocarditis⁷. In our patient groups, cardiac MRI showed an increase in late gadolinium enhancement (LGE), which may be a sign of fibrosis development or represents an effect of the increased inflammatory reaction (Extended Data Table 1). snRNA-seq analyses of EMBs did not show a significant increase of total FB numbers (Fig. 1d) but increased collagen gene expression in patient groups compared to control (Fig. 5a). This implied the acquisition of a secretory rather than a proliferative phenotype, as previously observed in dilated cardiomyopathy¹³. Condition-split visualization of the FB latent space supported a transcriptional shift in FB states across patient groups (Extended Data Fig. 7a). Subclustering of FBs identified previously described states (vFB1-4) and one additional state (vFB5) characterized by increased IFN response gene expression (Fig. 5b, Extended Data Fig. 7b.c and Supplementary Tables 12 and 13), vFB1.1 (lipofibroblast) and vFB3 (interacting with MP OSM⁺) proportions were significantly decreased, whereas vFB4 (extracellular matrix (ECM)-organizing) and vFB5 abundances were increased in all patient groups compared to controls. Interestingly, vFB2 (pro-fibrotic TGFβ-activated) expanded in Non-COVID-19 and Post-COVID-19 but not in Post-Vaccination (Fig. 5c and Extended Data Fig. 7b). GSEA revealed upregulation of IFNγ-stimulated and IFNα-stimulated genes in vFB1.0 and vFB5 in

Post-COVID-19: n = 10, Post-Vaccination: n = 4. P values were calculated using the quasi-likelihood F-test with Benjamini–Hochberg correction. d, VEGFA expression in CMs, shown as described in c. e, UMAP embedding delineated 11 vascular cell states. f, Vascular cell state abundances shown as described in b. g, NFKBIA, JAM2 and JAM3 expression in ECs, shown as described in c. h, Dot plots showing differential expression of IFNy response genes in patient groups relative to control across vascular cell states. Dot plots, n numbers and P value calculations are as described in c. i, Circle plots showing significant cell-cell communication differences for the indicated pathways ($P \le 0.05$) between patient groups and controls. Pvalues were computed from the one-sided permutation test withBonferoni correction. Line thickness reflects interaction strength of sending and receiving cells; color indicates changes (orange: increased; blue: decreased); and arrows show signal directionality. j, Dot plot showing FLT1 and KDR expression across EC states. Dot size corresponds to fraction (%) of expressing nuclei; color indicates scaled mean expression levels. k,l, ANGPT1 and ANGPT2 (k) and EFNB2 (l) expression in cell types as described in c. AD, adipocyte; NC, neural cell.





Fig. 5 | **Fibroblast compositional and gene expression changes indicate altered remodeling processes. a**, Collagen scores across FBs in controls (n = 18), Non-COVID-19 (n = 8), Post-COVID-19 (n = 10) and Post-Vaccination (n = 4). Scores were calculated across all expressed collagens. Boxes depict the interquartile range (IQR); horizontal bars indicate the median; whiskers extend to $1.5 \times$ IQR; and dots show the value of each patient. *P* values were calculated using the twosided Wilcoxon rank-sum test and were adjusted for multiple testing (Bonferoni correction). **b**, UMAP embedding delineated seven FB states. **c**, Upper panel, mean abundance (%) of FB states in control left ventricles (n = 18). Lower panel, proportional changes of FB states in the four patient groups (Non-COVID-19: n = 8, Post-COVID-19: n = 10, Post-Vaccination: n = 4). Proportional changes are scaled by color: red (increase) and blue (decrease) in disease versus control. *P* values are indicated for significant proportional changes (FDR ≤ 0.05). *P* values were calculated using the two-sided *t*-test based on CLR-transformed values with Benjamini–Hochberg correction. For MIS-C, significance was not calculated due to low sample size (n = 2). **d**, Pie charts comparing cell type resolved mean absolute expression levels of *TGFB1* and *TGFB2*. The pie size reflects absolute detection levels; the colors indicate the relative contribution per cell type. Colors indicate cell types; color legend is as in **g**. **e**, Circle plot representations of significantly differential interactions of cell–cell communication for the TGFB pathway (adjusted $P \le 0.05$) in patient groups compared to control. *P* values were computed with the one-sided permutation test. The line thickness represents the interaction strength of signals from sending and receiving cells. Color is scaled from zero to maximum in disease versus controls (orange, increased; blue, decreased). The directionality of the signal is indicated with arrows. **f**, Collagen scores across CMs and ECs are as described in **a**. AD, adipocyte; NC, neural cell.

Post-COVID-19 (Extended Data Fig. 7d and Supplementary Table 3). Of note, in MIS-C, vFB2 was not only expanded the most (Extended Data Fig. 7b) but was additionally activated by $TGF\beta$ (Extended Data Fig. 7e), suggesting a more pronounced fibrotic response compared to the other patient groups.

In cardiac tissue, we detected increased expression of *TGFB1* (Fig. 1f) and *TGFB2* (Extended Data Fig. 7f) encoding TGFB signaling ligands and alterations in their cellular sources of expression across all patient groups compared to controls (Fig. 5d). Myeloid and lymphoid

cells contributed greater to the overall *TGFB1* expression levels, particularly myeloid cells in Post-Vaccination and MIS-C and FBs and ECs to the overall *TGFB2* expression levels (Fig. 5d). CellChat analysis suggested upregulated TGFB signaling in all patient groups toward FBs and myeloid and lymphoid cells and additionally to CMs in Non-COVID-19 or to ECs in Post-Vaccination (Fig. 5e). Signaling toward immune cells was especially enhanced in Post-Vaccination. Because of the observed TGFB signaling toward CMs in Non-COVID-19 and ECs in Post-Vaccination, we investigated collagen gene expression in these cell types (Fig. 5h). Although FBs showed the highest expression (Fig. 5a), collagen gene expression was indeed upregulated in CMs (Fig. 5h), suggesting that, besides FBs, there are additional cellular sources for fibrotic gene expression responses.

Discussion

Our current understanding of the cellular and molecular response mechanisms in cardiac inflammation is mainly based on immunohistochemistry findings in EMBs and studies of autopsy heart tissue samples^{2,9,15}. Here we provided single-cell resolved analyses in human EMBs taken during the acute phase of disease from patients with non-COVID-19 lymphocytic myocarditis, myocarditis after SARS-CoV-2 infection and myocarditis after COVID-19 vaccination.

Our results highlighted an important role of *IFNG* expressed in lymphoid cells of post-COVID-19 heart tissue, reflected in ISG expression patterns in multiple cell types and states, and identified upregulated *IL16* and *IL18* expression as hallmarks of post-vaccination myocardial inflammation. This was consistent with previous studies in other organs demonstrating pathogenic IFNγ secretion by recruited T cells and NK cells during SARS-CoV-2 infection⁵⁰ and increased IL16 and 18 serum/ plasma levels in anti-COVID-19 mRNA-vaccine-related myocarditis/ pericarditis^{7,18}. We found these cytokines also expressed during the inflammatory processes within the cardiac microenvironment and, furthermore, noticed differences in the expression of immunosuppressive cytokines, such as TGFB1 and IL34, between groups. These findings suggest a stronger immune response in post-COVID-19 and a more dampened response in post-vaccination myocardial inflammation, further supported by downstream analyses of individual cell types.

Previous studies showed high amounts of CD68⁺ macrophages in cardiac tissue of patients who died or developed myocarditis after SARS-CoV-2 infection or vaccination². In our cohort, both immunohistochemistry and snRNA-seq consistently showed significant expansion of the myeloid cell population. Additionally, snRNA-seq revealed profound compositional changes, including a loss of resident macrophages and an increase in monocytes and monocyte-derived macrophages. These alterations mirrored observations in mice where cardiac injury, myocarditis and stress-induced cardiomyopathy resulted in replacement of resident macrophages by inflammatory monocyte-derived macrophages^{51–53}. Notably, the myeloid compositional changes were similar across Non-COVID-19, Post-COVID-19 and Post-Vaccination groups, suggesting that these responses are non-specific.

Among cardiac myeloid states, we did not detect pro-fibrotic transcriptomic signatures as reported for the lungs of patients with COVID-19 or the blood of patients with perimyocarditis after vaccination⁷. However, Post-COVID-19 patients showed pronounced ISG expression in multiple cardiac myeloid states, which suggested augmented inflammatory activity⁵⁴ and was linked to increased stimulation of T cell responses⁵⁵. Additionally, we noted a loss of tissue repair macrophages, such as Lyve1^{hi}MHCII^{lo} macrophages, which are critical for repair processes. This shift toward pro-inflammatory macrophages, potentially leading to excessive activation of the adaptive immune system at the expense of repair functions, may contribute to cardiac damage.

Although our observation of macrophage expansion was consistent among snRNA-seq, immunohistochemistry and previous reports, T cell abundances, as determined by the detection of CD3⁺ cells in immunohistochemistry, differed from snRNA-seq. snRNA-seq analyses identified transcriptional profiles corresponding to individual T cells, with abundances in post-COVID-19 and post-vaccination myocarditis similar to those observed in non-COVID-19 lymphocytic myocarditis. Notably, Non-COVID-19 patients were specifically selected based on prior confirmed lymphocytic infiltrations using immunohistochemical detection of CD3⁺ T cells. The sensitivity to detect specific lymphocytic infiltrates by immunohistochemistry is estimated to be only up to $40\%^{56}$. Our data raise the question of whether snRNA-seq may be more sensitive than traditional approaches.

The analysis of snRNA-seq-identified lymphocytes showed increased CD4⁺ to CD8⁺ T cell ratios, fewer activated NK cells and a weaker cytotoxic profile of CD8 T cells post-vaccination compared to post-COVID-19. Although a dominance of cardiac CD4⁺ lymphocytic infiltrates in response to the vaccination was described previously^{2,11}. we here show that this aligns with the elevated expression of IL16, a cytokine that governs trafficking and biological properties of CD4⁺ T cells⁵⁷. In Post-COVID-19 patients, we identified significantly enriched highly activated CD16⁺CD8⁺T cells (CD8T act effector), not previously reported for cardiac inflammatory responses. Similar T cells in blood from patients with severe COVID-19 were described to be capable of immune-complex-mediated, T cell receptor-independent degranulation and cytotoxicity promoting microvascular EC injury²⁹. These findings suggest an over-aggressive cytotoxic lymphocyte response in Post-COVID-19 cardiac tissue in contrast with the more attenuated inflammatory processes in Post-Vaccination patients.

Across patient groups, we found evidence for an inflammatory status of the vasculature, such as heightened expression of *JAM2* and *JAM3*, encoding leukocyte adhesion molecules, and reduced NF-κB inhibitor *NFKBIA* expression, suggesting heightened pro-inflammatory NF-κB signaling. Post-COVID-19 patients additionally exhibited a distinct IFNγ response gene signature in ECs. In hamsters, lung ECs respond to SARS-COV-2 infection with strong transcriptional pro-inflammatory chemokine responses without evidence for their direct infection⁵⁸. Human cardiac Post-COVID-19 ECs displayed ISG expression patterns similar to those observed in hamster lungs. Vascular permeabilization, endothelial injury and chronic vascular inflammation are central aspects in COVID-19 (ref. 59). The known role of IFNγ in regulating endothelial monolayer permeability further supports the presence of endothelial barrier dysfunction in the hearts of these patients.

Increased overall EC abundances, identification of pro-angiogenic tip cells and predicted elevated pro-angiogenic signaling indicated ongoing angiogenesis across patient groups. Similarly, angiogenesis was reported for parvovirus B19–associated myocarditis⁶⁰, potentially aiding in restoring blood supply to affected areas. However, alterations in EC state ratios with a particular shift toward arterial ECs and a decrease in overall mural cell abundances as observed in our cohort may affect vascular network function and maturation. Our findings highlight the need for further investigation of the intricate equilibrium between angiogenesis and inflammation and its implications for cardiac inflammatory pathology.

Overall FB populations were not expanded, but FB states were shifted toward activated vFB2, indicating an acquired secretory phenotype in all patient groups except Post-Vaccination. Interestingly, signs of vFB2 hyperactivation, as identified in end-stage failing human hearts¹³, were observed only in patients with MIS-C, who also exhibited the highest ECM gene expression activity despite their young age. The responses within the FB population were generally less pronounced in Non-COVID-19, Post-COVID19 and Post-Vaccination compared to those in end-stage dilated cardiomyopathy failing hearts¹³.

Limitations of our study

We would like to emphasise that the EMBs analyzed in this study are extremely difficult to obtain, leading to limited group sizes. However, we employed advanced, state-of-the-art statistical methods suited to effectively manage small sample sizes. Additionally, the patients in this study represent a clinically heterogeneous group, varying in the onset, degree of clinical symptoms and diagnostic evidence. Non-COVID-19 lymphocytic myocarditis cases were selected to clinically match the other disease groups, excluding fulminant myocarditis cases to align with the mild symptoms typical of COVID-19 myocarditis. However, this selection may influence the comparison.

We also cannot determine whether our findings are influenced by differences in the timespan between infection/vaccination and the patient's hospital admission. On a technical note, we compared EMBs to transmural donor heart controls, as obtaining EMBs from healthy, age-matched controls is impossible, which may affect the sampling of specific cell types. Furthermore, CLR transformation of snRNA-seq data was used to analyze relative compositional changes in cardiac cell types. This method cannot capture absolute values. In contexts like tissue inflammation, where shifts in cell counts are of additional relevance, relative abundance may not fully capture all aspects of the pathology.

Future studies are needed to trace long-term consequences of the here-described changes observed during the acute phase of cardiac inflammation. We expect that our data will advance mechanistic studies to improve treatment and enable preventive strategies and better diagnosis of post-COVID-19 and post-vaccination inflammatory cardiomyopathies.

Methods

Patients and ethics statement

This study complies with all ethical regulations associated with human tissue research. Acquisition and use of samples was approved by the Ethics Committee of Berlin and the Ethics Committee of the Charité -Universitätsmedizin Berlin (institutional review board approval numbers EA2/140/16 and EA2/066/20) and conducted in accordance with the Declaration of Helsinki. All subjects gave their written informed consent for their tissues to be collected for research purposes and the data obtained from that research to be published. All patients underwent LV EMB and left heart catheterization after routine non-invasive diagnostic workup and angiography had excluded any specific cause of heart-failure-like symptoms. All EMBs were evaluated histologically and by immunohistochemical stains as well as performing molecular analysis (RT-PCR) for cardiotropic viral genome detection (adenovirus, enteroviruses, human herpes virus 6 (HHV6), parvovirus B19, Epstein-Barr virus and SARS-CoV2) by the Department of Cardiopathology, Institute for Pathology and Neuropathology, University of Tübingen, Germany. Clinical information for the cardiac tissue is available in Extended Data Table 1.

Cohort samples

Disease samples were collected via LV EMBs from patients with 'classical' lymphocytic myocarditis (Non-COVID-19, n = 8), patients who clinically recovered from COVID-19 but showed persisting cardiac symptoms indicative of cardiac inflammation (Post-COVID-19, n = 10) and patients with cardiac symptoms indicative of cardiac inflammation after vaccination against SARS-CoV-2 (Post-Vaccination, n = 4). In addition, we investigated EMBs from patients diagnosed with MIS-C and indicative of cardiac inflammation as well as a follow-up EMB for one of the patients with MIS-C after treatment (MIS-C follow-up). All patients presented with symptoms including chest pain, palpitations, fever, shortness of breath, malaise and/or general weakness and fatigue and an overall increase of cardiac damage-indicating biomarkers (troponin T, NT-pro-BNP, creatine kinase or creatine kinase MB) and CRP levels (Fig. 1a). ECG, echocardiography or signs of recent or ongoing myocardial damage on cardiac MRI ranged from normal or non-specific to borderline low or abnormal and are summarized in Extended Data Table 1. All patients underwent LV EMBs and left heart catheterization after routine non-invasive diagnostic workup and angiography had failed to elucidate any other specific cause of heart failure, such as coronary artery disease.

Patients in the Post-COVID-19 and MIS-C groups were previously tested positive for SARS-CoV-2 infection by nasopharyngeal swap test PCR but tested negative at the timepoint of the actual study. Healthy heart snRNA-seq data were recently generated by us using LV free wall and apical samples from 18 unused donor hearts^{12,13}. Cell composition, states and transcript counts across the free wall and apex showed high similarities¹³ and, therefore, are reported grouped together as LV.

EMB immunhistochemistry

EMBs were fixed in 4% phosphate-buffered formaldehyde and embedded in paraffin. Four-micrometer-thick tissue sections were stained with hematoxylin and eosin and examined by light microscopy. For immunohistological detection of cardiac immune cells, a monoclonal rabbit-anti-CD3 antibody (Novocastra Laboratories, clone SP7, 1:500), a monoclonal mouse anti-human CD68 antibody (DAKO, clone PG-M1, 1:50), a monoclonal rabbit anti-CD4 (Zytomed, clone SP35, 1:50) and a monoclonal mouse anti-CD8 (DAKO, clone C8/144B 1:300) were used. Immunohistochemical analysis was performed on an automated immunostainer following the manufacturer's protocol (Ventana Medical Systems, Benchmark) and using the ultraView detection system (Ventana Medical Systems) and diaminobenzidine as substrate. Tissue sections were counterstained with hematoxylin. Positive cells were counted using an Axioskop 40 (Zeiss) microscope, and results are given per mm². Representative pictures are shown at ×200 magnification.

Isolation of cardiac single nuclei from EMBs and processing on the 10x Genomics platform

The isolation of cardiac nuclei and the 10x library preparation were performed at the Max Delbrück Center for Molecular Medicine following our published protocol⁶¹ with adaptations to low-sized tissue pieces. Next, 1-4-mg-sized flash-frozen cardiac biopsies were placed in a pre-cooled dish and an equally sized droplet of homogenization buffer (250 mM sucrose, 25 mM KCl, 5 mM MgCl₂, 10 mM Tris-HCl, 1 μM DTT, 1× protease inhibitor, 0.4 U μl⁻¹RNaseIn, 0.2 U μl⁻¹ SUPERaseIn and 0.1% Triton X-100 in nuclease-free water) was added. Buffer-encapsulated tissue pieces were sliced with a scalpel. The tissue pieces were then transferred to a 7-ml glass Dounce tissue grinder (Merck), and nuclei were isolated and stained with NucBlue Live ReadyProbes Reagent (Thermo Fisher Scientific). Hoechst⁺ single nuclei were sorted via fluorescence-activated cell sorting (FACS) (BD Biosciences, FACSAria Fusion). The forward scatter (FSC)/side scatter (SSC) gating strategy is shown in Supplementary Fig. 1. Purity and integrity of nuclei were confirmed microscopically, and nuclei numbers were counted using a Countess II (Life Technologies) before processing with the Chromium Controller (10x Genomics) per the manufacturer's protocol. Single-nucleus 3' gene expression libraries were created using version 3.1 Chromium Single Cell Reagent Kits (10x Genomics) following the manufacturer's instructions. cDNA library quality control was performed using Bioanalyzer High Sensitivity DNA Analysis (Agilent Technologies) and a KAPA Library Quantification Kit. cDNA libraries were sequenced on an Illumina NovaSeq with a targeted read number of 30,000-50,000 reads per nucleus (Supplementary Fig. 1b-d).

Sequencing data pre-processing and transcriptome mapping

The binary base call (BCL) sequence files were converted to FASTQ format using bcl2fastq (version 2.20). Mapping of sequencing reads from each sample to a modified pre-mRNA version of the human reference genome (version GRCh38, .gtf file from Ensembl release 84) was performed using the Cell Ranger suite (version 3.0.2). The Cell Ranger reference file was created following the instructions from the 10x Genomics website (https://www.10xgenomics.com/support/single-cell-gene-expression) and the specifications provided in the DCMheart GitHub repository (https://github.com/heiniglab/DCM_heart_cell_atlas/)¹³. Reads mapping to exonic and intronic regions were counted. Sequencing mapping quality was assessed using Cell Ranger summary statistics. Reads mapping multiple genome features were discarded.

Count data and data matrix annotation

The identification of empty droplets was performed using empty-Drops, implemented in the Cell Ranger workflow. The filtered_ feature_bc_matrix.h5 files and the metadata information were integrated into an annotated data object (AnnData).

Annotated data quality control, batch correction and clustering

Quality control and downstream analyses of the concatenated annotated matrices were performed using the Single-Cell Analysis in Python toolkit Scanpy (version 1.5.1)^{62,63}. Doublet identification and removal was performed using Solo (version 0.3)⁶⁴. Scrublet scores with prior log transformation were used as an independent doublet detection and filtering method (version 0.2.1)⁶⁵. Nuclei with n_counts (\leq 300), genes ($300 \leq$ n_genes \leq 5,000), mitochondrial genes (\leq 1%), ribosomal genes (percent_ribo \leq 1%) and softmax Solo scores (\leq 0.5) were excluded from downstream analyses.

Normalized and log-transformed read counts were used to identify highly variable genes. The data were corrected and scaled to unit variance to account for the effects of the percentage of mitochondrial genes expressed. To select the principal axes of variation, denoise the data and compute the neighborhood relations of cells, a dimensionality reduction using principal component analysis (PCA) and the elbow methods were used. To remove potential batch effects within our data, before the dimensionality reduction using the UMAP method, principal components were adjusted using Harmony⁶⁶ with 'Patient' as batch_key. Clustering of nuclei using the community detection based on optimizing the modularity algorithm Leiden^{67,68} was performed. Next, differential gene expression analyses were performed using the two-sided Wilcoxon rank-sum test, and clusters displaying low differences in their gene expression profiles were merged. Nuclei were assigned to cell types and posteriorly subclustered to identify cell states. The cell state annotation step revealed nuclei, denoted as unassigned in Fig. 1c (n = 11,832 'Nuclei'; 5.8%), that correspond to droplets with chimeric transcriptional profiles. Whether these droplets represent true data, background noise or multiplets is unclear.

Differential gene expression analysis

DEGs per cell type and state were calculated using the two-sided Wilcoxon rank-sum test as implemented in Scanpy⁶². Testing for DEGs was done using log-transformed and normalized to library size count values. Only genes with mean expression greater than 0.0125 were considered. Genes with a false discovery rate (FDR) < 0.05 and absolute log₂ fold change (FC) > 0.5 were considered differentially expressed. For rare cell states (\leq 3 samples with \leq 5 nuclei), DEG differences were not calculated.

To identify disease-specific expression profiles, DEG analyses were performed between control and myocarditis groups. For this, transcript counts per gene of all nuclei for a given sample (tissue level), cluster (cell type level) or subcluster (state level) from the same individual were aggregated to create 'pseudo-bulk' samples. Testing for DEGs in pseudo-bulks was performed using the empirical Bayes quasi-likelihood *F*-test function (glmQLFtest) available in the R package edgeR (version 3.28.1)^{69,70}.

Compositional analysis

To identify disease-specific changes in the proportion of cells between control and disease groups, a CLR-based approach excluding unassigned nuclei was used¹³ to account for the compositional nature of the data. For this, count data were transformed using CLR transformation. Zeros in the data, assumed to result from insufficient sampling depth, were imputed using the multiplicative replacement method⁷¹. Statistical differences between disease groups and controls were assessed by fitting a linear model to the CLR-transformed values, with the group encoded as an indicator variable. Significance was determined using a two-sided *t*-test on the regression coefficient. Differential abundance of all cell types or states was analyzed separately for each disease group compared to controls. For cell state analyses within each cell type, only the counts assigned to that specific cell type were considered, effectively normalizing cell states within each type to 100%. Samples with fewer than 10 cells per cell type were excluded from the cell state analysis. For analysis of lymphoid state abundances, samples with fewer than 30 total lymphoid cells were excluded.

In addition to CLR values, abundance differences were expressed as the mean percentage differences between groups, and statistical significance was determined from the CLR-transformed values. Positive values indicate higher abundance in the disease group. *P* values were adjusted for multiple testing using the Benjamini–Hochberg method, and only significant results are reported.

 $EC_PKHD1L1^+$ comprised mostly endocardial (EC7) and few lymphatic (EC8) ECs (Supplementary Fig. 2b). We noticed that controls barely, and EMB samples to a variable extent, contributed to this cluster, likely due to a sampling bias when collecting EMBs compared to transmural sections (Supplementary Fig. 2b). We, therefore, decided to exclude EC_PKHD1L1⁺ from analyses where amounts may influence results.

At this point, samples with fewer than 10 nuclei per cell type were excluded from the analyses. To calculate compositional differences of lymphocyte states, only samples with a minimum of 30 nuclei were included to account for the high cellular heterogeneity within the lymphoid cell population. Differences in mean percentages between groups were reported using the statistical significance obtained in the CLR step. For interpretation, disease groups with positive values suggest an increase in abundance. Benjamini–Hochberg correction for multiple testing was applied (only significant results are shown).

GO enrichment analysis and GSEA

GO and GSEA analyses^{72,73} were performed using GSEApy version 0.10.5–a Python implementation for Enrichr with default settings⁷⁴. GO analyses were performed with the gene set libraries 'GO_Biological_Process_2021' and 'KEGG_2021_Human', and DEGs identified per cell type or state were used as input. GSEAs were performed with the collections of gene sets in the Molecular Signatures Database 'MSigDB_Hallmark_2020', and DEGs identified per condition on the tissue, cell type or cell state level, respectively, were used as input. Gene background was defined using all genes that were expressed in the given cell type or cell state (mean expression > 0.0125).

Gene set score enrichment

The score_genes functionality implemented in Scanpy was used on log-transformed and scaled transcript counts to compute enrichment of individual gene sets⁶². The MHC-I score was based on the expression of MHC-I genes in aggregated non-immune cardiac cells (excluding lymphoids, myeloids and mast cells as well as unassigned, EC_PKHD1L1⁺, adipocytes and neural cells). The collagen score was based on all expressed collagens per cell type. TGFB activation score was based on a list of genes curated from ref. 75 with logFC > 0.7 and FDR < 0.05. The cytotoxic⁷⁶ and cytotoxic cytokine⁷⁷ scores were calculated using Seurat's (version 5.1) AddModuleScore function⁷⁸ on the log-transformed and normalized counts from aggregated CD4⁺ or CD8⁺T cells. Patients with fewer than five CD4⁺ or CD8⁺T cells were excluded from the analysis.

Intercellular signaling cross-talk and differential cell-cell interaction network analysis

To infer, visualize and analyze intercellular communication among all assigned cell types and cell states, we used CellChat, an open-source R package (version 1.6.1, http://www.cellchat.org/cellchatdb/)⁷⁹. We first excluded genes expressed in less than 1% of the nuclei per cell state before running CellChat. We then used the CellChat database (http://www.cellchat.org/cellchatdb/) and log-transformed normal-ized gene counts to identify and select overexpressed signaling genes (default parameters). Due to the differences in abundances across cell states, we computed the communication probabilities considering the cell state had fewer than 10 nuclei. The communication probabilities

on signaling pathways were filtered using $P \le 0.05$. We used network centrality measures in all inferred pathway communication networks (default parameters) to identify cell states that act as dominant senders, receivers, mediators and influencers. We compared the differences in the results obtained for cell-cell interactions from control and medical conditions to highlight significant changes.

Pathway-specific differences in interaction strength between control and diseases across cell types were calculated using the communication probabilities per cell state and CellChat's aggregateNet() function. We then aggregated the communication probabilities per cell state from the same cell type using the mergeInteractions() and plotted these data using netVisual_diffInteraction() CellChat functions.

Statistics and reproducibility

Replicates and statistical tests are described in the figure legends. Sample sizes were not predetermined using statistical methods. No sample size calculations were performed. Sample size was governed by tissue availability, and input tissue mass was on the basis of endomyocardial biopsy size. No samples were excluded. All snRNA-seq analyses including clustering were done using unbiased techniques. Investigators were blinded to the groups when performing initial analyses.

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability

All data generated and analyzed in this study have been deposited at the European Genome-phenome Archive (EGA) (https://ega-archive.org), which is hosted by the European Bioinformatics Institute and the Centre for Genomic Regulation, under accession number EGAS50000000769. Raw data can be downloaded from the EGA after completing the data access agreement (DAA) of the Max Delbrück Center. The DAA is in place to ensure that all users who request data adhere to the General Data Protection Regulation of the European Union and to protect the confidentiality of the research participants. Instructions on how to register with the EGA and how to access the data are available at https://ega-archive.org/access/request-data/how-to-request-data/. Processed single-nucleus transcriptomic data will be available through the CELLxGENE platform in the h5ad format (https://cellxgene.cziscience.com/collections/328d71f0-0ed7-4518-966f-be6bd0797324) and on Zenodo (https://zenodo.org/records/14258362). Metadata sheets and patient information are available in Extended Data Table 1.

Code availability

All code used to generate the figures in this publication are available on GitHub (https://github.com/Norbert-Hubner-Lab/Heart_Biopsy_ Covid). All scripts run on Jupyter notebooks are available as .ipynb files, and scripts executed in the command line are available as .txts or .sh files. R scripts are available as .R. Anaconda environments are available as .yml files containing information on package versions.

References

- Ammirati, E. et al. Prevalence, characteristics, and outcomes of COVID-19–associated acute myocarditis. *Circulation* 145, 1123–1139 (2022).
- Basso, C. et al. Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study. *Eur. Heart J.* 41, 3827–3835 (2020).
- Xie, Y., Xu, E., Bowe, B. & Al-Aly, Z. Long-term cardiovascular outcomes of COVID-19. *Nat. Med.* 28, 583–590 (2022).
- Belot, A. et al. SARS-CoV-2-related paediatric inflammatory multisystem syndrome, an epidemiological study, France, 1 March to 17 May 2020. *Euro Surveill.* 25, 2001010 (2020).

- Bozkurt, B., Kamat, I. & Hotez, P. J. Myocarditis with COVID-19 mRNA vaccines. *Circulation* 144, 471–484 (2021).
- 6. Wong, H.-L. et al. Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases. *Lancet* **399**, 2191–2199 (2022).
- 7. Barmada, A. et al. Cytokinopathy with aberrant cytotoxic lymphocytes and profibrotic myeloid response in SARS-CoV-2 mRNA vaccine–associated myocarditis. *Sci. Immunol.* **8**, eadh3455 (2023).
- 8. Thurner, L. et al. IL-1RA antibodies in myocarditis after SARS-CoV-2 vaccination. *N. Engl. J. Med.* **387**, 1524–1527 (2022).
- Heidecker, B. et al. Myocarditis following COVID-19 vaccine: incidence, presentation, diagnosis, pathophysiology, therapy, and outcomes put into perspective. A clinical consensus document supported by the Heart Failure Association of the European Society of Cardiology (ESC) and the ESC Working Group on Myocardial and Pericardial Diseases. *Eur. J. Heart Fail.* 24, 2000–2018 (2022).
- 10. Oudit, G. Y. et al. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. *Eur. J. Clin. Invest.* **39**, 618–625 (2009).
- Baumeier, C. et al. Intramyocardial inflammation after COVID-19 vaccination: an endomyocardial biopsy-proven case series. *Int. J. Mol. Sci.* 23, 6940 (2022).
- 12. Litviňuková, M. et al. Cells of the adult human heart. *Nature* **588**, 466–472 (2020).
- 13. Reichart, D. et al. Pathogenic variants damage cell composition and single cell transcription in cardiomyopathies. *Science* **377**, eabo1984 (2022).
- Fairweather, D. et al. Sex and gender differences in myocarditis and dilated cardiomyopathy: an update. *Front. Cardiovasc. Med.* 10, 1129348 (2023).
- 15. Delorey, T. M. et al. COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets. *Nature* **595**, 107–113 (2021).
- 16. Boulakirba, S. et al. IL-34 and CSF-1 display an equivalent macrophage differentiation ability but a different polarization potential. *Sci. Rep.* **8**, 256 (2018).
- Yang, Y., Wang, H., Kouadir, M., Song, H. & Shi, F. Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors. *Cell Death Dis.* **10**, 128 (2019).
- Won, T. et al. Increased interleukin 18-dependent immune responses are associated with myopericarditis after COVID-19 mRNA vaccination. *Front. Immunol.* 13, 851620 (2022).
- Chakarov, S. et al. Two distinct interstitial macrophage populations coexist across tissues in specific subtissular niches. *Science* 363, eaau0964 (2019).
- 20. Epelman, S. et al. Embryonic and adult-derived resident cardiac macrophages are maintained through distinct mechanisms at steady state and during inflammation. *Immunity* **40**, 91–104 (2014).
- 21. Leuschner, F. et al. Silencing of CCR2 in myocarditis. *Eur. Heart J.* **36**, 1478–1488 (2015).
- 22. Haider, N. et al. Transition of macrophages to fibroblast-like cells in healing myocardial infarction. *J. Am. Coll. Cardiol.* **74**, 3124–3135 (2019).
- 23. Li, R. et al. Macrophages in the infarcted heart acquire a fibrogenic phenotype, expressing matricellular proteins, but do not undergo fibroblast conversion. *J. Mol. Cell. Cardiol.* **196**, 152–167 (2024).
- Aziz, A., Soucie, E., Sarrazin, S. & Sieweke, M. H. MafB/c-Maf deficiency enables self-renewal of differentiated functional macrophages. Science 326, 867–871 (2009).
- 25. Peckert-Maier, K. et al. CD83 expressed by macrophages is an important immune checkpoint molecule for the resolution of inflammation. *Front. Immunol.* **14**, 1085742 (2023).

- Wendisch, D. et al. SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis. *Cell* 184, 6243–6261 (2021).
- Ivashkiv, L. B. IFNY: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. *Nat. Rev. Immunol.* 18, 545–558 (2018).
- King, D. P. & Jones, P. P. Induction of Ia and H-2 antigens on a macrophage cell line by immune interferon. *J. Immunol.* 131, 315–318 (1983).
- 29. Georg, P. et al. Complement activation induces excessive T cell cytotoxicity in severe COVID-19. *Cell* **185**, 493–512 (2022).
- Hengstenberg, C., Hufnagel, G., Haverich, A., Olsen, E. G. J. & Maisch, B. De novo expression of MHC class I and class II antigens on endomyocardial biopsies from patients with inflammatory heart disease and rejection following heart transplantation. *Eur. Heart J.* 14, 758–763 (1993).
- Rose, M. L., Coles, M. I., Griffin, R. J., Pomerance, A. & Yacoub, M. H. Expression of class I and class II major histocompatabi lity antigens in normal and transplanted human heart. *Transplantation* 41, 776–780 (1986).
- Wei, L., Xiang, Z. & Zou, Y. The role of NKG2D and its ligands in autoimmune diseases: new targets for immunotherapy. *Int. J. Mol. Sci.* 24, 17545 (2023).
- 33. Perez-Bermejo, J. A. et al. SARS-CoV-2 infection of human iPSCderived cardiac cells reflects cytopathic features in hearts of patients with COVID-19. *Sci. Transl. Med.* **13**, eabf7872 (2021).
- Patone, M. et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. *Nat. Med.* 28, 410–422 (2022).
- Jung, Y.-J., Isaacs, J. S., Lee, S., Trepel, J. & Neckers, L. IL-1β mediated up-regulation of HIF-lα via an NFkB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J. 17, 2115–2117 (2003).
- Murdoch, C., Giannoudis, A. & Lewis, C. E. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. *Blood* **104**, 2224–2234 (2004).
- 37. Semenza, G. L. Hypoxia-inducible factor 1 and cardiovascular disease. *Physiology* **76**, 39–56 (2014).
- Sindermann, J. R. & March, K. L. Balancing luminal size and smooth muscle proliferation—a key control point in atherosclerosis and arteriogenesis. In *Mechanisms of Angiogenesis* (eds Clauss, M. & Breier, G.) 193–205 (Springer, 2005).
- Reboll, M. R. et al. Meteorin-like promotes heart repair through endothelial KIT receptor tyrosine kinase. Science **376**, 1343–1347 (2022).
- Johnson-Léger, C. A., Aurrand-Lions, M., Beltraminelli, N., Fasel, N. & Imhof, B. A. Junctional adhesion molecule-2 (JAM-2) promotes lymphocyte transendothelial migration. *Blood* **100**, 2479–2486 (2002).
- Jakobsson, L. et al. Endothelial cells dynamically compete for the tip cell position during angiogenic sprouting. *Nat. Cell Biol.* 12, 943–953 (2010).
- 42. Gerhardt, H. et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. *J. Cell Biol.* **161**, 1163–1177 (2003).
- Brindle, N. P. J., Saharinen, P. & Alitalo, K. Signaling and functions of angiopoietin-1 in vascular protection. *Circ. Res.* 98, 1014–1023 (2006).
- 44. Månsson-Broberg, A. et al. Modulation of ephrinB2 leads to increased angiogenesis in ischemic myocardium and endothelial cell proliferation. *Biochem. Biophys. Res. Commun.* **373**, 355–359 (2008).
- 45. Nicin, L. et al. A human cell atlas of the pressure-induced hypertrophic heart. *Nat. Cardiovasc. Res.* **1**, 174–185 (2022).
- Poitz, D. M. et al. EphrinB2/EphA4-mediated activation of endothelial cells increases monocyte adhesion. *Mol. Immunol.* 68, 648–656 (2015).

- Okyere, B. et al. EphA4/Tie2 crosstalk regulates leptomeningeal collateral remodeling following ischemic stroke. J. Clin. Invest. 130, 1024–1035 (2019).
- 48. Souilhol, C. et al. JAG1-NOTCH4 mechanosensing drives atherosclerosis. Sci. Adv. **8**, eabo7958 (2022).
- 49. Keewan, E. & Naser, S. A. The role of Notch signaling in macrophages during inflammation and infection: implication in rheumatoid arthritis? *Cells* **9**, 111 (2020).
- 50. Hsu, R.-J. et al. The role of cytokines and chemokines in severe acute respiratory syndrome coronavirus 2 infections. *Front. Immunol.* **13**, 832394 (2022).
- Lavine, K. J. et al. Distinct macrophage lineages contribute to disparate patterns of cardiac recovery and remodeling in the neonatal and adult heart. *Proc. Natl Acad. Sci. USA* **111**, 16029– 16034 (2014).
- Dick, S. A. et al. Self-renewing resident cardiac macrophages limit adverse remodeling following myocardial infarction. *Nat. Immunol.* 20, 29–39 (2019).
- Liao, X. et al. Cardiac macrophages regulate isoproterenol-induced Takotsubo-like cardiomyopathy. JCI Insight 7, e156236 (2022).
- Hu, X., Chakravarty, S. D. & Ivashkiv, L. B. Regulation of interferon and Toll-like receptor signaling during macrophage activation by opposing feedforward and feedback inhibition mechanisms. *Immunol. Rev.* 226, 41–56 (2008).
- Siebeler, R., de Winther, M. P. J. & Hoeksema, M. A. The regulatory landscape of macrophage interferon signaling in inflammation. *J. Allergy Clin. Immunol.* **152**, 326–337 (2023).
- 56. Heymans, S., Eriksson, U., Lehtonen, J. & Cooper, L. T. The quest for new approaches in myocarditis and inflammatory cardiomyopathy. *J. Am. Coll. Cardiol.* **68**, 2348–2364 (2016).
- 57. Center, D. M., Kornfeld, H. & Cruikshank, W. W. Interleukin 16 and its function as a CD4 ligand. *Immunol. Today* **17**, 476–481 (1996).
- Nouailles, G. et al. Temporal omics analysis in Syrian hamsters unravel cellular effector responses to moderate COVID-19. *Nat. Commun.* 12, 4869 (2021).
- 59. Martínez-Salazar, B. et al. COVID-19 and the vasculature: current aspects and long-term consequences. *Front. Cell Dev. Biol.* **10**, 824851 (2022).
- 60. Ackermann, M. et al. Parvovirus B19-induced angiogenesis in fulminant myocarditis. *Eur. Heart J.* **41**, 1309–1309 (2020).
- 61. Nadelmann, E. R. et al. Isolation of nuclei from mammalian cells and tissues for single-nucleus molecular profiling. *Curr. Protoc.* **1**, e132 (2021).
- 62. Wolf, F. A., Angerer, P. & Theis, F. J. SCANPY: large-scale single-cell gene expression data analysis. *Genome Biol.* **19**, 15 (2018).
- 63. Hao, Y. et al. Integrated analysis of multimodal single-cell data. *Cell* **184**, 3573–3587 (2021).
- 64. Bernstein, N. J. et al. Solo: doublet identification in single-cell RNA-seq via semi-supervised deep learning. *Cell Syst.* **11**, 95–101 (2020).
- Wolock, S. L., Lopez, R. & Klein, A. M. Scrublet: computational identification of cell doublets in single-cell transcriptomic data. *Cell Syst.* 8, 281–291 (2019).
- 66. Korsunsky, I. et al. Fast, sensitive, and accurate integration of single cell data with Harmony. *Nat. Methods* **16**, 1289–1296 (2019).
- Traag, V. A., Waltman, L. & van Eck, N. J. From Louvain to Leiden: guaranteeing well-connected communities. *Sci. Rep.* 9, 5233 (2019).
- Blondel, V., Guillaume, J.-L. & Lambiotte, R. Fast unfolding of communities in large networks: 15 years later. J. Stat. Mech. https://doi.org/10.1088/1742-5468/ad6139 (2024).
- Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics* 26, 139–140 (2010).

Article

Article

- McCarthy, D. J., Chen, Y. & Smyth, G. K. Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation. *Nucleic Acids Res.* 40, 4288–4297 (2012).
- Martín-Fernández, J.-A., Hron, K., Templ, M., Filzmoser, P. & Palarea-Albaladejo, J. Bayesian-multiplicative treatment of count zeros in compositional data sets. *Stat. Model.* **15**, 134–158 (2015).
- Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genomewide expression profiles. *Proc. Natl Acad. Sci. USA* **102**, 15545–15550 (2005).
- Mootha, V. K. et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. *Nat. Genet.* 34, 267–273 (2003).
- Fang, Z., Liu, X. & Peltz, G. GSEApy: a comprehensive package for performing gene set enrichment analysis in Python. *Bioinformatics* 39, btac757 (2023).
- 75. Schafer, S. et al. IL-11 is a crucial determinant of cardiovascular fibrosis. *Nature* **552**, 110–115 (2017).
- Li, H. et al. Dysfunctional CD8 T cells form a proliferative, dynamically regulated compartment within human melanoma. *Cell* 181, 747 (2020).
- Szabo, P. A. et al. Single-cell transcriptomics of human T cells reveals tissue and activation signatures in health and disease. *Nat. Commun.* **10**, 4706 (2019).
- Hao, Y. et al. Dictionary learning for integrative, multimodal and scalable single-cell analysis. *Nat. Biotechnol.* 42, 293–304 (2024).
- 79. Jin, S. et al. Inference and analysis of cell-cell communication using CellChat. *Nat. Commun.* **12**, 1088 (2021).

Acknowledgements

We thank the MDC Flow Cytometry Technology Platform and the BIH/MDC Genomics Technology Platform for their fantastic support. This publication is part of the Human Cell Atlas (https://www. humancellatlas.org/publications/#). This project was made possible, in part, by the Chan Zuckerberg Foundation (2019-202666) to N.H., M.N., C.E.S., J.G.S. and S.A.T.; the Leducq Foundation (16CVD03) to N.H., C.E.S. and J.G.S.; the British Heart Foundation and Deutsches Zentrum für Herz-Kreislauf-Forschung (BHF/DZHK: SP/19/1/34461) to N.H., M.N. and S.A.T.; the German Center for Cardiovascular Research (DZHK) (Personify program) to C.T.; and German Research Foundation (DFG) SFB-1470 to N.H. (project BO3), C.T. (project BO2) and S.V.L. (project A07). N.H. was supported by a European Research Council advanced grant under the European Union's Horizon 2020 Research and Innovation Program (AdG788970). S.K. received support from the DZHK, Partner Site Berlin. S.K. was supported by an unrestricted research grant by Philips Healthcare and partially funded by DFG SFB-1470-B06. G.O. was funded by the Canadian Institutes of Health Research and the Heart and Stroke Foundation and was a member of the Canadian Long COVID Web. C.E.S. received partial support from the Howard Hughes Medical Institute, and J.G.S. received partial support from the National Heart, Lung, and Blood Institute (HL080494).

Author contributions

Conceptualization: N.H., H. Maatz and C.T. Methodology: H. Maaatz, E.L.L., E.A., N.L.-A., A.P.-S., L.C.O., G.P., D.R., A.M., S.S., A.E. and O.K. Patient recruitment, clinical data analyses, tissue procurement and biobanking: C.T., K.K., S.K., U.K., S.V.L., G.O., H. Milting, S.A.T., C.E.S. and J.S. Data analysis: H. Maatz, E.E.L., E.A., N.L.-A., A.P.-S., G.P., A.M., E.W., M.L., S.Y. and S.H. Data interpretation: all authors. Initial manuscript draft: H. Maatz, E.L.L., E.A., N.L.-A., A.P.-S., L.C.O. and N.H. Final manuscript: all authors.

Funding

Open access funding provided by Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft (MDC).

Competing interests

The following authors report competing interests. C.E.S. and J.G.S. (Maze, BridgeBio and Bristol Myers Squibb); board of directors: C.E.S. (Burroughs Wellcome Fund US and Merck). In the past 3 years, S.A.T. has consulted or been a member of scientific advisory boards at GlaxoSmithKline, Qiagen, ForeSite Labs and Element Biosciences and is an equity holder of Transition Bio and EnsoCell Therapeutics. All companies were not involved in any aspect of the study's experimental design, execution and analyses or in the preparation of the manuscript. B.H. (together with Joshua M. Hare) is inventor on a granted patent application (application number EP2152916A1, European Patent Office) filed by the University of Miami that uses RNA for diagnosis of myocarditis. This patent application does not cover specific aspects of this paper. All other authors do not declare any competing interests.

Inclusion and ethics

This study followed ethical guidelines with informed consent obtained for all samples and protocols approved by institutional ethics committees. Data were analyzed with awareness of potential biases. We are committed to promoting equity and inclusion in research while advancing scientific understanding.

Additional information

Extended data is available for this paper at https://doi.org/10.1038/s44161-025-00612-6.

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s44161-025-00612-6.

Correspondence and requests for materials should be addressed to Henrike Maatz, Norbert Hubner or Carsten Tschöpe.

Peer review information *Nature Cardiovascular Research* thanks Kory Lavine, Han Zhu and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons. org/licenses/by/4.0/.

© The Author(s) 2025

Henrike Maatz^{1,2,26,27} , Eric L. Lindberg^{1,3,26}, Eleonora Adami¹, Natalia López-Anguita¹, Alvaro Perdomo-Sabogal¹, Lucía Cocera Ortega¹, Giannino Patone¹, Daniel Reichart^{3,4,5}, Anna Myronova¹, Sabine Schmidt¹, Ahmed Elsanhoury^{2,6}, Oliver Klein^{2,6}, Uwe Kühl^{2,6}, Emanuel Wyler⁷, Markus Landthaler^{7,8}, Schayan Yousefian⁷, Simon Haas^{7,9,10,11}, Florian Kurth¹, Sarah A. Teichmann¹, Gavin Y. Oudit^{15,16}, Hendrik Milting¹⁷, Michela Noseda¹, Birgit Sawitzki²², Jonathan G. Seidman⁴, Christine E. Seidman^{4,5,20}, Bettina Heidecker²¹, Leif E. Sander^{6,12}, Birgit Sawitzki²², Karin Klingel²³, Patrick Doeblin^{2,24}, Sebastian Kelle^{2,24}, Sophie Van Linthout^{2,6}, Norbert Hubner^{1,2,9,25,27}

¹Cardiovascular and Metabolic Sciences, Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany, ²DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany. ³Department of Medicine I, University Hospital, LMU Munich, Munich, Germany. ⁴Department of Genetics, Harvard Medical School, Boston, MA, USA. ⁵Cardiovascular Division, Brigham and Women's Hospital Boston, Boston, MA, USA, ⁶Berlin Institute of Health (BIH) at Charité – Universitätsmedizin Berlin, BIH Center for Regenerative Therapies (BCRT), Berlin, Germany. 7Berlin Institute for Medical Systems Biology (BIMSB), Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany. 8Institut für Biologie, Humboldt Universität zu Berlin, Berlin, Germany. 9Charité – Universitätsmedizin Berlin, Berlin, Germany. ¹⁰German Cancer Consortium (DKTK), Partner Site Berlin, DKFZ and Charité – Universitätsmedizin Berlin, Berlin, Germany. ¹¹Berlin Institute of Health at Charité – Universitätsmedizin Berlin, Berlin, Germany.¹²Department of Infectious Diseases, Respiratory Medicine and Critical Care, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt – Universität zu Berlin, Berlin, Germany. 13 Cellular Genetics Programme, Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, UK.¹⁴Cavendish Laboratory, Department of Physics, University of Cambridge, Cambridge, UK. 15 Division of Cardiology, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada. ¹⁶Mazankowski Alberta Heart Institute, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada. ¹⁷Erich and Hanna Klessmann Institute, Heart and Diabetes Center NRW, University Hospital of the Ruhr–University Bochum, Bad Oeynhausen, Germany.¹⁸National Heart and Lung Institute, Imperial College London, London, UK. ¹⁹British Heart Foundation Centre for Research Excellence and Centre for Regenerative Medicine, Imperial College London, London, UK.²⁰Howard Hughes Medical Institute, Chevy Chase, MD, USA.²¹Department of Cardiology, Angiology and Intensive Medicine CBF, Deutsches Herzzentrum der Charité – Universitätsmedizin Berlin, Berlin, Germany. 22 Translational Immunology, Berlin Institute of Health at Charité – Universitätsmedizin Berlin, Berlin, Germany. 23 Cardiopathology, Institute for Pathology and Neuropathology, University Hospital Tübingen, Tübingen, Germany.²⁴Department of Cardiology, Angiology and Intensive Care, Campus Virchow, Deutsches Herzzentrum der Charité – Universitätsmedizin Berlin, Berlin, Germany.²⁵Helmholtz-Institute for Translational AngioCardioScience (HI-TAC) of the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC) at Heidelberg University, Heidelberg, Germany.²⁶These authors contributed equally: Henrike Maatz, Eric L. Lindberg. 27 These authors jointly supervised this work: Henrike Maatz, Norbert Hubner, Carsten Tschöpe. 🖂 e-mail: h.maatz@mdc-berlin.de; nhuebner@mdc-berlin.de; carsten.tschoepe@dhzc-charite.de



 $\label{eq:constraint} Extended \, Data \, Fig. \, 1 | \, See \, next \, page \, for \, caption.$

Extended Data Fig. 1 | **Immunohistochemistry and snRNAseq library quality metrics. a)** Images of Hematoxylin eosin- (HE), CD3-, and CD68-stained and **b)** of CD4- and CD8- stained EMB sections. Representative images from each group are shown. Stainings on EMB sections were performed for all patients (Non-COVID-19: n = 8, Post-COVID-19: n = 10, Post-Vaccination: n = 4, MISC: n = 2). Cell counts are presented in Extended Data Table 1. c) Size of human left ventricular endomyocardial cardiac biopsies (EMBs) for snRNA-seq. The image shows different EMB tissue sizes and their weight before nuclei isolation in a 5 cm dish on ice. **d)** Violin plots showing number of detected genes (n_genes), detected UMIs (n_counts), fraction of UMIs mapping to mitochondrial-encoded genes and ribosomal genes and doublet probabilities according to scrublet and solo per nucleus within a cell-type. Distributions have been computed for all samples and subsetted for explants and EMB samples only. **e**) Barcode rank plots across all EMB (n = 25) and explant samples (controls n = 18). Clear distinction between nuclei containing droplets and empty droplets (background ambient RNA) indicated a low overall background. **f**) Box plots showing snRNA-seq library quality metrics. Boxes depict the interquartile range (IQR), horizontal bars represent the median, whiskers extend to $1.5 \times IQR$. Data points outside the whiskers show measurements beyond Q1 or Q3 ± 1.5^{*} IQR. Estimated numbers of nuclei pre-QC filtering, mean reads per nucleus in the fastq files, median UMI counts per cell and the cDNA concentration per sample were depicted between EMB (Non-COVID-19, Post-COVID-19, Post-Vaccination, PIMS; n = 25) and explant tissue material (controls n = 18).



Extended Data Fig. 2 | **Cell-type composition of EMBs and control transmural cardiac tissues. a**) Dot plot shows expression of the top five selected marker genes for each cardiac cell type. Dot size corresponds to fraction (%) of expressing nuclei; colour indicates scaled mean expression level. **b**) Stacked bar plots showing the cell type composition of each sample. The numbers above each bar show the total number of recovered nuclei. **c**) *Upper left panel:* Box plot showing PKHD1L1 + EC frequency in LV for patients and control groups (Control: n = 18, Non-COVID-19: n = 8, Post-COVID-19: n = 10, Post-Vaccination: n = 4, MISC: n = 2). Boxes depict the interquartile range (IQR), horizontal bars represent the median, whiskers extend to 1.5 × IQR, dots show the value of each patient. *Upper right panel:* UMAPs highlighting endocardial EC (EC7) or lymphatic EC (EC8) cell states within the EC_PKHD1L1+ cell population. All other cell types are shown in grey; Lower left *panel*: Stacked barplot showing EC state distribution (%) within the EC_PKHD1L1+ population (*top*) and splitted by condition (*bottom*); Lower *right panel*: Dot plot shows marker genes of EC7 and EC8 cell states. Dot size corresponds to fraction (%) of expressing nuclei; colour indicates mean expression level. **d**) Box plots showing cell type frequencies in LV per patient and control groups (Control: n = 18, Non-COVID-19: n = 8, Post-COVID-19: n = 10, Post-Vaccination: n = 4, MISC: n = 2). Boxes depict the interquartile range (IQR), horizontal bars represent the median, whiskers extend to 1.5 × IQR, dots show the value of each patient. *P*-values are shown in Fig. 1d.



Extended Data Fig. 3 | **Elevated gene expression of pro-inflammatory markers. a**) Matrix plot showing *IFNG* expression levels per cell-type. The Colour scale corresponds to the average expression level per cardiac cell-type. **b,c**) Box plots showing snRNA-seq expression levels (pseudo-bulk) in cardiac tissue from control (n = 18), Non-COVID-19 (n = 8), Post-COVID-19 (= 10) and Post-Vaccination (n = 4) of (b) differentially expressed cytokines, chemokines and (c) components of the inflammasome complex. Boxes depict the interquartile range (IQR),

horizontal bars represent the median, whiskers extend to 1.5 × IQR, dots show the value of each patient. P-values were calculated using the quasi-likelihood F-test and were adjusted for multiple testing (Benjamini Hochberg). **d**) Pie charts comparing mean absolute expression levels of inflammatory marker genes that are upregulated particularly in the Post-Vaccination group (*NLRP1, NLRP3, CASP1, CASP4*). The pie size reflects absolute detection levels, colours indicate the relative contribution per cell type.



Extended Data Fig. 4 | **The cellular and molecular signatures of myeloid cells in cardiac inflammation. a**) Box plots showing myeloid state frequencies in LV per patient in Non-COVID-19 (n = 8), Post-COVID-19 (n = 10), Post-Vaccination (n = 4), MIS-C (n = 2), and control (n = 18) groups. Boxes depict the interquartile range (IQR), horizontal bars represent the median, whiskers extend to $1.5 \times IQR$, dots show the value of each patient. *P*-values are shown in Fig. 2b. **b**) Dot plot showing the expression of the top five marker genes for each myeloid cell state. Dot size corresponds to fraction (%) of expressing nuclei; colour indicates scaled

mean expression levels. c) Condition-split UMAP showing *CX3CR1* expression per myeloid nuclei across control and myocarditis groups. d) Matrix plot showing selected gene expression levels per myeloid state. Color scale corresponds to the scaled average expression levels. e) Dot plots showing differential expression of genes identified to be upregulated in Lyve1loMHCIIhi MP in patient groups relative to control. Dot colours indicate log2-transformed fold changes (log2FC). Dot sizes indicate absolute log2FC. Black circles indicate significance (FDR \leq 0.05). Genes are ordered alphabetically.

Article



Extended Data Fig. 5 | See next page for caption.

Extended Data Fig. 5 | **The cellular and molecular signatures of lymphoid cells** in cardiac inflammation. a) Box plots showing lymphoid state frequencies in LV per patient in Non-COVID-19 (= 8), Post-COVID-19 (n = 10), Post-Vaccination (n = 4), MIS-C (n = 2), and control (n = 18) groups. Boxes depict the interquartile range (IQR), horizontal bars represent the median, whiskers extend to $1.5 \times IQR$, dots show the value of each patient. *P*-values are shown in Fig. 4b. **b**) Dot plot showing the expression of the top five marker genes for each lymphoid cell state. Dot size corresponds to fraction (%) of expressing nuclei; colour indicates scaled mean expression levels. **c**) Cytotoxicity (right) or cytotoxic cytokines cores (left) across aggregated CD4+ or CD8 + T cells (control: n = 11; Non-COVID-19: n = 7; Post-COVID-19: n = 9; Post-Vaccination: n = 4). Scores were calculated across 'cytotoxicity'³⁷ and 'cytotoxic cytokine'³⁸ gene sets, respectively. Boxes depict the interquartile range (IQR), horizontal bars represent the median, whiskers extend to $1.5 \times IQR$, dots show the value of each patient. P-values were calculated using the two-sided Wilcoxen rank-sum test and were adjusted for multiple testing (Bonferoni correction). **d**) Dot plots showing expression of MHC-1 genes across conditions in CM, EC, FB and mural cells. **e**) MHC-1 gene expression score across aggregated non-immune cardiac cells shown as described in c); control: n = 18, Non-COVID-19: n = 8, Post-COVID-19: n = 10, Post-Vaccination: n = 4. Scores were calculated across all MHC-1 genes. P-value calculations as described in c). **f**) Dot plots as described in b) showing differential expression of *RAET1E* in CM, EC, FB and murals cells in patient groups relative to control.



Extended Data Fig. 6 | See next page for caption.

Extended Data Fig. 6 | The cellular and molecular signatures in cardiomyocytes and vascular cells in cardiac inflammation. a) Box plots showing CM state frequencies in LV per patient in Non-COVID-19 (= 8), Post-COVID-19 (n = 10), Post-Vaccination (n = 4), MIS-C (n = 2), and control (n = 18) groups. Boxes depict the interquartile range (IQR), horizontal bars represent the median, whiskers extend to 1.5 × IQR, dots show the value of each patient. *P*-values are shown in Fig. 5b. b) Dot plot showing the expression of the top five marker genes for each CM state. Dot size corresponds to fraction (%) of expressing nuclei; colour indicates scaled mean expression levels. c) Box plots showing EC state frequencies as described in a). *P*-values are shown in Fig. 5f. d) Dot plot as described in b) showing the expression of the top five marker genes for each EC and mural cell state. e-g) Dot plots as described in a) showing the expression of e) selected EC10-enriched genes f) MHC-1/-II genes and g) INF response genes across EC states. h, i) UMAP showing expression levels of selected genes per vascular cell nuclei across control and patient groups. **j**) Dot plots as described in a) showing the expression of MHC-I genes across EC states. **k**, **l**) Bar plots showing significant gene sets for EC10 from the k) GO Biological Process 2021 and l) KEGG 2021 Human gene lists. -log10 of the FDR is shown on the x-axis. P-values were calculated using GSEAs Fisher exact test. P-values were adjusted for multiple-testing using the Benjamini-Hochberg correction. **m**) Circle plot representations of significantly differential interactions of cell-cell communication for the ANGPT1 and ANGPT2 pathways (adjusted P-value ≤ 0.05) in patient groups compared to control. The line thickness represents the interaction strength of signals from sending and receiving cells. Colour is scaled from zero to maximum in disease versus controls (orange, increased; blue, decreased). The directionality of the signal is indicated with arrows. P-values were computed from the one-sided permutation test. **n**) Stacked bar plots showing the relative contribution of ephrin signalling ligand-receptor (L-R) pairs to the EPHB net signalling related to Fig. 4i in patient and control groups.



Extended Data Fig. 7 | The cellular and molecular signatures in fibroblasts in cardiac inflammation. a) Condition-split UMAP showing transcriptional shifts in FB states across patient groups and controls. b) Box plots showing FB state frequencies in LV per patient in Non-COVID-19 (= 8), Post-COVID-19 (n = 10), Post-Vaccination (n = 4), MIS-C (n = 2), and control (n = 18) groups. Boxes depict the interquartile range (IQR), horizontal bars represent the median, whiskers extend to $1.5 \times IQR$, dots show the value of each patient. *P*-values are shown in Fig. 5c. Dots show proportions per patient. c) Dot plot showing the top five marker genes of each FB state. Dot size corresponds to fraction (%) of expressing nuclei; colour indicates scaled mean expression level. d) Dot plots showing differential expression of selected interferon- γ response genes in patient groups relative to controls across FB states. Dot colours indicate log2-transformed fold changes (log2FC). Dot sizes indicate absolute log2FC. Black circles indicate significance (FDR \leq 0.05). Cell types and genes are ordered alphabetically.

e) TGFB Activation score within the vFB2 state across patient and control groups (Control: n = 18, Non-COVID-19: n = 8, Post-COVID-19: n = 10, Post-Vaccination: n = 4). Boxes depict the interquartile range (IQR), horizontal bars represent the median, whiskers extend to $1.5 \times IQR$, dots show the value of each patient. P-values were calculated using a two-sided wilcoxon rank-sum test. Dots show scores per patient. **f)** Box plot showing snRNA-seq pseudo-bulk expression levels of *TGFB2* in cardiac tissue from patient and control groups (Control: n = 18, Non-COVID-19: n = 8, Post-COVID-19: n = 10, Post-Vaccination: n = 4). Boxes depict the interquartile range (IQR), horizontal bars represent the median, whiskers extend to $1.5 \times IQR$, dots show the value of each patient. P-values are indicated for significant changes compared to control, FDR ≤ 0.05 . P-values were calculated using the quasi-likelihood F-test and were adjusted for multiple testing (Benjamini Hochberg).

Extended Data Table 1 | Clinical metadata of patients

| | | | |
 |
 | | | | . . |
 | | | In
 | munohi | stochen | nistry | |

 | Vir | us Dia
 | gnostic | | | Hear
 | t parame | ters (echo
 | EKG) |
|--|--|---|---
--
---|---|---|---|--

--	---	---
--|---
--
--|---
--|--|---
--|---
--|---|--|
| Patient | Sex | Age |) : | Symptoms
 | s/Reason fo
 | r admissi | on to ho | spital | differential | diagnosis
 | | EMB-diagnosis | CD
 | | CD4 | CD8 | ADV | HHV6

 | B19V | EBV
 | Entero- | SARS- CoV | -2 EF (% |) LVEDD (mm
 | n) peric | ardial fluid
 | Changes in EKG |
| Non-COVID-191 | m | 26 | Cardi | iogenic sh
 | ock ventric
 | ular fihrills | tion | | Acute Mv | ocarditis
 | | Lymphocytic MC | 16
 | 35 | na | na | 0 | 0

 | 0 | 0
 | 0 | ND | 15 | 46
 | | ves
 | nsVT |
| Non-COVID-19.2 | | 20 | Dysp | nea and ta
 | achycardia,
 | | | | Muncarritie |
 | Lymphocytic MC | 14 | 16
 | 3 | 3 | 0 | 1 | 1*

 | 0 | 0
 | ND | 60 | 54 | -
 | , |
 | |
| 101 0010 102 | | - | hospi | talization 8
 | 8 months aft
 | ter sympto | om onse | et | , | 10.00
 | _ | 2, |
 | 10 | L. | - | Ů | · ·

 | · · | -
 | , , , , , , , , , , , , , , , , , , , | | |
 | _ |
 | |
| Non-COVID-193 | m | 30 | hospi | t pain and talization of
 | ca. 1 week a
 | mia,
after symp | otom on | set | Acute my | ocarditis
 | | Lymphocytic MC | 38
 | 44 | 16 | 15 | 0 | 0

 | 0 | 0
 | 0 | N.D. | 60 | 48
 | | no
 | no |
| Non-COVID-19.4 | | 49 | Ches | t pain and
 | l troponinaer
 | mia, | | | Acute my | ocarditis
 | | Lymphocytic MC | 22
 | 42 | 3 | 15 | 0 | 0

 | 0 | 0
 | 0 | ND | 62 | 47
 | | 00
 | 00 |
| | | | hospi | talization
 | 5 days after
 | symptom | onset | | |
 | _ | -, -, -, |
 | - | - | | - |

 | |
 | | | |
 | _ |
 | |
| Non-COVID-195 | m | 52 | Hosp | italization
 | 4 months af
 | ter sympt | om ons | et | Myoca | rditis
 | - | Lymphocytic MC | 15
 | 28 | 3 | 1 | 0 | 0

 | 0 | 0
 | 0 | N.D. | 50 | 61
 | _ | no
 | no |
| Non-COVID-196 | m | 26 | Ches | t pain, hos
 | spitalization
 | 6 days aft | er symp | otom onset | Myoca | irditis
 | _ | Lymphocytic MC | 15
 | 38 | 3,5 | 1 | 0 | 0

 | 0 | 0
 | 0 | N.D. | 55 | 42
 | _ | no
 | no |
| Non-COVID-197 | m | 27 | Ches | t pain, hos
 | spitalization
 | 1 week af | ter sym | ptom onset [| Decompensatio | on myocard
 | ditis | Lymphocytic MC | 31
 | 27 | 10 | 4 | 0 | 0

 | 1* | 0
 | 0 | N.D. | 57 | 50
 | _ | no
 | no
Protorminal |
| Non-COVID-198 | m | 25 | Malai
after : | se, heada
symptom
 | onset
 | alization 2 | months | | Subacute m | vocarditis
 | | Lymphocytic MC | 18
 | 65 | 15,5 | 3,5 | 0 | 0

 | 0 | 0
 | 0 | N.D. | 50 | 48
 | | yes
 | negative T wave in
I+II+aVL+V6 |
| | 1 | 24 | Dysp | nea and ta
 | achvcardia.
 | suspecte | d mvoca | arditis. | Post-COV | ID acute
 | - | Increased |
 | | 2.5 | | |

 | |
 | | 0 | 45 | 40
 | - |
 | ein in tenkiinendin |
| posicovid-131 | | 31 | 9 wee | eks after (
 | COVID-19
 | | | | heart failure | symptoms
 | ; | macrophages | - "
 | 20 | 2,5 | <u> </u> | Ů |

 | Ŭ | Ŭ
 | Ů | | ** | 40
 | | 110
 | allius tacriycal dia |
| post-COVID-192 | w | 52 | Impai | ired systol
 | lic LV functio
 | on, suspec | ted my | ocarditis, | Post-COV | ID acute
 | | Increased | 6
 | 21 | 5 | 7,5 | 0 | 1#

 | 0 | 0
 | 0 | 0 | 24 | 65
 | | no
 | left bundle branch |
| | - | | 4 W66 | rts alter G
 | 0410-19
 | | | | nearrianure | symptoms
 | , | I umphosutio MC with | _
 | - | - | - | |

 | |
 | | | |
 | - |
 | |
| post-COVID-193 | m | 70 | Fever | r, general
arditis, 3 v
 | weakness,
weeks after
 | troponina
COVID-1 | emia, sı
9 | uspected | Worsening r | nyocarditis
 | • | dominant macrophage | s 52
 | 93 | 18,75 | 10 | 0 | 0

 | 0 | 0
 | 0 | 0 | 33 | 54
 | | yes
 | TAA |
| port COVID-19.4 | - | 64 | Suspe | ected myo
 | carditis, 8 w
 | veeks afte | r COVII | D-19 | Post-COV | ID acute
 | - | Increased |
 | 10 | 4 | | 0 | 0

 | 0 | 0
 | 0 | 0 | 44 | 46
 | |
 | sigue tachycardia |
| postoonbrid | | | pneur | monia and
 | ARDS
 | | | | heart failure | symptoms
 | • | macrophages |
 | 10 | - | - | Ů |

 | | Ŭ
 | Ů | • | |
 | | 110
 | Sinds tacify cardia |
| post-COVID-195 | m | 61 | Suspe | ected myo
monia and
 | carditis 6 w
ARDS
 | eeks after | COVIE | 0-19 | Post-COV
heart failure | ID acute
symptoms
 | . | Increased
macrophages | 6
 | 16 | 0,5 | 0,75 | 0 | 0

 | 0 | 0
 | 0 | 0 | 44 | 51
 | | no
 | no |
| post-COVID-196 | | 31 | Palpit | tations, su
 | spected my
 | ocarditis, | | | Post-COV | ID acute
 | - | Increased | 4
 | 13 | 1.5 | 1 | 0 | 0

 | 0 | 0
 | 0 | 0 | 60 | 53
 | | 00
 | sinus tachycardia |
| p | | - | 8 wee | eks after C
 | COVID-19
 | | | | heart failure | symptoms
 | • | macrophages |
 | | , | <u> </u> | | -

 | - | -
 | | - | |
 | _ |
 | |
| post-COVID-197 | m | 27 | Suspe
with s | ected myo
evere AR
 | carditis, 6 w
 | veeks afte | r COVII | D-19 | heart failure | symptoms
 | , | dominant macrophage | 95 14
 | 31 | 5 | 4,5 | 0 | 0

 | 0 | 0
 | 0 | 0 | 35 | 55
 | | yes
 | sinus tachycardia |
| | | | 0 |
 |
 | | | | Cardiogenic sh | ock followi
 | ing | Increased |
 | | | | |

 | |
 | | | |
 | |
 | |
| post-COVID-198 | m | 61 | 13 we | ogenic sh
eks after
 | COVID-19
 | DS by aty | pical pr | eumonia, | atypical SA | RS-CoV-2
 | - | macrophages | 6
 | 33 | 5 | 5 | 0 | 0

 | 0 | 0
 | 0 | 0 | 39 | 59
 | | no
 | no |
| | - | | Chor | topio dur
 |
 | octod mur | oorditie | | Port COV | ID acuta
 | + | Increased | -
 | - | - | - | |

 | | -
 | | | - |
 | - |
 | |
| post-COVID-19 9 | m | 55 | 13 we | eks after
 | COVID-19
 | pneunom | ia | | heart failure | symptoms
 | . | macrophages | 1
 | 16 | 3 | 1 | 0 | 0

 | 0 | 0
 | 0 | 0 | 45 | 48
 | | no
 | no |
| | | | Malai | se, heada
 | che. fever.
 | suspected | d mvoca | rditis. | Post-COVID | mvocarditi
 | is | Lymphocytic MC with | 1 47
 | | | _ | _ |

 | | _
 | | 0 | 0.5 | 40
 | |
 | |
| post-COVID-19 10 | m | 24 | 12 we | eeks afte
 | er COVID-19
 | Э | | | /fatigue sy | Indrome
 | | dominant macrophage | es 17
 | 45 | 5 | 3 | 0 | 0

 | 0 | 0
 | 0 | 0 | 65 | 49
 | | no
 | elevations v2-6 |
| | | | Ches | t pain, fev
 | er and dissi
 | ness with | suspect | led | |
 | | |
 | | | | |

 | |
 | | | |
 | |
 | |
| Post-Vaccination 1 | m | 28 | myoo | arditis 3 n
 | nonths after
 | second v | accinati | on with | Acute post-v
induced m | accination
vocarditis
 | 1 | Increased
macrophages | 4
 | 24 | 2,6 | 0,3 | 0 | 0

 | 0 | 0
 | 0 | N.D. | 58 | 41
 | | no
 | no |
| | - | | Trees | ecrophize
 |
 | dod muon | naty) | dava effect | |
 | - | |
 | | | | |

 | |
 | | | |
 | _ |
 | |
| Post-Vaccination 2 | , | 32 | secon | ininaemia
id vaccina
 | tion with Mo
 | ted myoc
derna® (r | nRNA-1 | days after
1273/ | Acute post-v | accination
 | , | Increased | 3
 | 18 | 8 | 3.5 | 0 | 0

 | 0 | 0
 | 0 | ND | 67 | 46
 | | 00
 | Toeg |
| | | | (AZD1 | vax), follo
1222/ChAo
 | wing first va
dOx1-S/Vax
 | ccination
zevria) | with Ast | razeneca® | induced m | yocarditis
 | | macrophages |
 | | ľ | 0,0 | Ť | ľ

 | - | ľ
 | | | |
 | |
 | |
| | | | Chest | t pain, feve
 | er and mala
 | ise, tropo | ninaem | ia and | Acute post- | accination
 | , | Increased | 1.
 | | | | |

 | |
 | | | |
 | - |
 | |
| Post-Vaccination 3 | m | 21 | with B | cted myor
BionTech/F
 | carditis, 4 da
Pfizer® (BTN
 | ays after s
N162b2/C | econd)
omirnat | vaccination | induced m | yocarditis
 | | macrophages | 5
 | 24 | 3,5 | 1,5 | 0 | 1#

 | 0 | 0
 | 0 | N.D. | 60 | 49
 | | no
 | no |
| Deet Vessionting | | 20 | Acute | myocardi
 | itis forwarde
 | d by othe | r clinic, | 2 weeks | Acute post- | accination
 | , | Lymphocytic MC with | . 25
 | 50 | 14.05 | 0.75 | |

 | |
 | 0 | ND | 0.5 | AE
 | |
 | Preterminal |
| Post-vaccination 4 | | 30 | (BTN) | 162b2/Cor
 | mirnaty)
 | recrimize | 3160 | | induced m | yocarditis
 | | inflammation | M 30
 | 50 | 14,25 | 0,75 | 0 | 0

 | 0 |
 | | N.D. | 65 | 40
 | | no
 | II, III, aVF. |
| MIS-C 1 | m | 21 | Cardi | iogenic sh
 | ock, fever, r
 | malaise, g | eneral | weakness, | Cardiogenic s | hock by MI
 | IS | Lymphocytic MC with | 1 48
 | 150 | 111,5 | 68,5 | 0 | 0

 | 0 | 0
 | 0 | 0 | 30 | 53
 | | no
 | sinus tachycardia |
| | | | suspe | ected myo
 | carditis 4 we
 | eeks atter | COVID | -19 | | ,
 | | high macrophages |
 | | | | |

 | |
 | | | |
 | _ |
 | |
| | | | Fever | , ocular, c
 | utaneous, i
 | ntestinal, | polyser | ositic and | Polyseros | sitis and
 | | Lymphocytic MC, |
 | | | | |

 | |
 | | | | borderline L
 | v |
 | incomplex right |
| MIS-C 2 | m | 19 | shock | anical invo
, 6 weeks
 | after COVI
 | flammato
D-19 | ry cardi | ogenic | cardiogenic st | nock by MI
 | s | high macrophages | 120
 | 380 | 58,33 | 43 | 0 | 0

 | 0 | 0
 | 0 | 0 | 38 | biatrial
 | | yes
 | block, changes in ST |
| | - | | - |
 |
 | | | | Desetion |
 | - | Lymphocytic MC. | +
 | - | - | - | |

 | |
 | | | - | dilatation
 | - |
 | |
| MIS-C 1 follow-up | m | 21 | Follov | w-up EMB
hisolone a
 | l, 6 months a
Ind Azathiop
 | after treati
irene | ment wi | th | under co | mbined
 | | less immune cell
infiltrates compared tr | 17
 | 28 | 5 | 2 | 0 | 0

 | 0 | 0
 | 0 | 0 | 62 | 55
 | | no
 | no |
| | | | |
 |
 | | | | immunosų | ppression
 | | pre-treatment |
 | | | | |

 | |
 | | | |
 | |
 | |
| | | | |
 |
 | | | | |
 | | |
 | | | | |

 | |
 | | | |
 | |
 | |
| | | | |
 |
 | | | Card | diac MRT |
 | | |
 | | | | |

 | Labor | atory p
 | arameters | | | HF Risk fact
 | lors |
 | Relevent engeling |
| Patient | Scanner | EF | LVEDD | LVEDV
 | Native
 | Native | ECV | Cardiac MR
Acute Myocard | ditac MRT
Non-
Ischemic | Edema F
 | Perica | rdial Pericardial A | cute
 | Cabro | Other | Tro | opT pea
(ng/l) | ik NTp
peak

 | roBNP C
(ng/l) | atory p
K peak
(U/I)
 | CK-MB peak
(U/I) | CRP peak
(mg/l) | вмі | HF Risk fact
 | tors
Smoking | Diabetes
 | Relevant ongoing
therapy at the time of
FMB collection |
| Patient | Scanner
(Tesla) | EF
(%) | LVEDD
(mm) | LVEDV
(mL)
 | Native
T1 (ms)
 | Native
T2 (ms) | ECV
(%) | Cardiac MR
Acute Myocard
(Lake Louis
Criteria) | diac MRT
RI
ditis
B
Ischemic
LGE | Edema F
 | Perica
Eden | rdial Pericardial A
Fibrosis Per | cute
icarditis
 | Cabno |)ther
srmalitie | rro
HS | opT pea
(ng/l)
<14 | k NTp
peak

 | Labor
roBNP C
(ng/l) | atory p
K peak
(U/I)
<190
 | CK-MB peak
(U/I)
<24 | CRP peak
(mg/l)
<5 | BMI
(kg/m2) | HF Risk fact
 | tors
Smoking | Diabetes
 | Relevant ongoing
therapy at the time of
EMB collection |
| Patient S
Non-COVID-191 | Scanner
(Tesla)
NA | EF
(%)
NA | LVEDD
(mm) | LVEDV
(mL)
 | Native
T1 (ms)
NA
 | Native
T2 (ms)
NA | ECV
(%) | Cardiac MR
Acute Myocarr
(Lake Louis
Criteria)
no | diac MRT
RI
ditis
Ischemic
LGE
yes | Edema F
 | Perica
Eden
no | rdial Pericardial A
Fibrosis Peri
yes | cute
icarditis
no
 | Cabno | Other
ormalitie
no | HS Tro | opT pea
(ng/l)
<14
257 | IK NTpipeak

 | Labor
roBNP (
(ng/l)
97
14 | atory p
K peak
(U/I)
<190
222
 | CK-MB peak
(U/I)
<24
95,1 | CRP peak
(mg/l)
<5
2,1 | BMI
(kg/m2)
20,8 | HF Risk fact
Hypertension
 | tors
Smoking
yes | Diabetes
 | Relevant ongoing
therapy at the time of
EMB collection
Catecholamine /
Sedation therapy |
| Patient S
Non-COVID-191 | Scanner
(Tesla)
NA | EF
(%)
NA | LVEDD
(mm)
NA | LVEDV
(mL)
NA
 | Native
T1 (ms)
NA
 | Native
T2 (ms)
NA
46 | ECV
(%)
NA
25 | Cardiac MR
Cardiac MR
Acute Myocare
(Lake Louis
Criteria)
no | diac MRT
Non-
lachemic
LGE
yes | Edema F
 | Perica
Eden
no | rdial Pericardial A
Fibrosis Peri
yes | cute
icarditis
no
 | Cabro | Other
prmalitie | IS Tro | opT pea
(ng/l)
<14
257 | IK NTpi
peak

 | Labori
roBNP (
(ng/l)
97
14 | atory p
K peak
(U/I)
<190
222
84
 | arameters
CK-MB peak
(U/I)
<24
95,1 | CRP peak
(mg/l)
<5
2,1 | BMI
(kg/m2)
20,8 | HF Risk fact
Hypertension
 | lors
Smoking
yes | Diabetes
 | Relevant ongoing
therapy at the time of
EMB collection
Catecholamine /
Sedation therapy
since 24h
BB_ACEL |
| Patient S
Non-COVID-19 1
Non-COVID-19 2 | Scanner
(Tesla)
NA
3 | EF
(%)
NA
56 | LVEDD
(mm)
NA
53 | LVEDV
(mL)
NA
155
 | Native
T1 (ms)
NA
1261
 | Native
T2 (ms)
NA
46 | ECV
(%)
NA
25 | Cardiac MR
Acute Myocarr
(Lake Louis
Criteria)
no
no | diac MRT
Riditis Non-
Ischemic
LGE
yes
yes | Edema F
 | Perica
Eden
no
no | rdial Pericardial A
Fibrosis Peri
yes no | cute
icarditis
no
no
 | abno | other
prmalitie
no
no | | opT pea
(ng/l)
<14
257
3 | k NTpi
peak
2'
4

 | Labor.
roBNP (
(ng/l)
77
14
2 | atory p
K peak
(U/I)
<190
222
84
 | arameters CK-MB peak
(U/I) <24 | CRP peak
(mg/l)
<5
2,1
1,9 | BMI
(kg/m2)
20,8
24,7 | HF Risk fact
Hypertension
no
yes
 | tors
Smoking
yes
no | Diabetes
no
no
 | Relevant ongoing
therapy at the time of
EMB collection
Catecholamine /
Sedation therapy
since 24h
BB, ACEI |
| Patient S
Non-COVID-191
Non-COVID-192
Non-COVID-193 | Scanner
(Tesla)
NA
3
NA | EF
(%)
NA
56
NA | LVEDD
(mm)
NA
53
NA | LVEDV
(mL)
NA
155
NA
 | Native
T1 (ms)
NA
1261
NA
 | Native
T2 (ms)
NA
46
NA | ECV
(%)
NA
25
NA | Card
Cardiac MR
Acute Myocarr
(Lake Louis
Criteria)
no
no
NA | diac MRT
Nditis
Ischemic
LGE
yes
yes
NA | Edema
no
NA
 | Perica
Eden
no
no
NA | rdial Pericardial A
Fibrosis Peri
yes no
NA I | cute
icarditis
no
no
NA
 | Cabno | Dther
prmalitie
no
no
NA | PS Tro | opT pea
(ng/l)
<14
257
3
90 | Ik NTppeak

 | Labor. roBNP C (ng/l) 0 97 14 2 75 | atory pa
K peak
(U/I)
<190
222
84
64
 | arameters
CK-MB peak
(U/I)
<24
95,1
31
NA | CRP peak
(mg/l)
<5
2,1
1,9
27,8 | BMI
(kg/m2)
20,8
24,7
33,4 | HF Risk fact
Hypertension
no
yes
yes
 | tors
Smoking
yes
no
no | Diabetes
no
no
no
 | Relevant ongoing
therapy at the time of
EMB collection
Catecholamine /
Sedation therapy
since 24h
BB, ACEI
BB, ACEI |
| Patient § Non-COVID-19 1 Non-COVID-19 2 Non-COVID-19 3 Non-COVID-19 4 | Scanner
(Tesla)
NA
3
NA
1.5 | EF
(%)
NA
56
NA
53 | LVEDD
(mm)
NA
53
NA
NA | LVEDV
(mL)
NA
155
NA
167
 | Native
T1 (ms)
NA
1261
NA
1088
 | Native
T2 (ms)
NA
46
NA
58 | ECV
(%)
NA
25
NA
NA | Card
Cardiac MR
Acute Myocar
(Lake Louis
Criteria)
no
no
NA
yes | diac MRT
Ridits Non-
LGE
yes
yes
NA
yes | Edema F
no i
NA i
yes
 | Perica
Eden
no
no
NA | rdial Pericardial A
Fibrosis Peri
yes no
NA 1 | cute
icarditis
no
no
NA
no
 | Cabno | no
NA
no | | opT pea
(ng/i)
<14
257
3
90
728 | NTppeak < <s< td=""> 2' 4 11 15</s<>

 | Labor.
roBNP C
(ng/l)
77
14
2
75 | atory pa
K peak
(U/I)
<190
222
84
64
131
 | arameters
CK-MB peak
(U/I)
<24
95,1
31
NA
26,3 | CRP peak
(mg/l)
<5
2,1
1,9
27,8
1,9 | BMI
(kg/m2)
20,8
24,7
33,4
22,3 | HF Risk fact
Hypertension
no
yes
yes
no
 | lors
Smoking
yes
no
no
no | Diabetes
no
no
no
no
 | Relevant ongoing
therapy at the time of
EMB collection
Catecholamine /
Sedation therapy
since 24h
BB, ACEI
BB, ACEI
none |
| Patient § Non-COVID-19 1 Non-COVID-19 2 Non-COVID-19 3 Non-COVID-19 3 Non-COVID-19 4 Non-COVID-19 4 | Scanner
(Tesla)
NA
3
NA
1.5 | EF
(%)
NA
56
NA
53 | LVEDD
(mm)
NA
53
NA
NA | LVEDV
(mL)
NA
155
NA
167
 | Native
T1 (ms) NA 1261 NA 1088
 | Native
T2 (ms)
NA
46
NA
58 | ECV
(%)
NA
25
NA
NA | Cardiac MR
Cardiac MR
Acute Myocar
(Lake Louis
Criteria)
no
no
NA
yes | diac MRT
R
ditis
Ischemic
LGE
yes
yes
NA
yes | Edema F
no i
NA i
yes i
 | Perica
Eden
no
no
NA
no | rdial Pericardial A Peri
Fibrosis Peri
no NA I
NA I | no
NA
 | Cabro | Dther
prmalitie
no
NA
NA | | opT pea
(ng/l)
<14
257
3
90
728 | NTppeak <<5

 | Labor.
roBNP C
(ng/l)
77
14
2
75
95 | atory p:
K peak
(U/I)
<190
222
84
64
131
74
 | arameters
CK-MB peak
(U/I)
<24
95,1
31
NA
26,3
15.6 | CRP peak
(mg/l)
<5
2,1
1,9
27,8
1,9 | BMI
(kg/m2)
20,8
24,7
33,4
22,3
25 | HF Risk fact
Hypertension
no
yes
yes
no
 | lors
Smoking
yes
no
no
no | Diabetes
no
no
no
no
 | Relevant ongoing
therapy at the time of
EMB collection
Catecholamine /
Sedation therapy
since 24h
BB, ACEI
BB, ACEI
none |
| Patient 5 Non-COVID-19 1 Non-COVID-19 2 Non-COVID-19 3 Non-COVID-19 4 Non-COVID-19 5 | Scanner
(Tesla)
NA
3
NA
1.5
NA | EF
(%)
NA
56
NA
53
NA | LVEDD
(mm)
NA
53
NA
NA
NA | LVEDV
(mL)
NA
155
NA
167
NA
 | Native
T1 (ms)
NA
1261
NA
1088
NA
 | Native
T2 (ms)
NA
46
NA
58
NA | ECV
(%)
NA
25
NA
NA
NA | Cardiac MR
Cardiac MR
Acute Myocar
(Lake Louis
Critteria)
no
no
NA
yes
NA | diac MRT
Reference
in Schemic
LGE
yes
NA
yes
NA | Edema F
no 1
NA 1
yes 1
NA 2
 | Perica
Eden
no
NA
no
NA | rdial Pericardial A
Fibrosis Peri
yes /
no /
NA /
NA / | no
NA
NA
 | Cabho | NA
NA
NA | | ppT pea
(ng/l)
<14
257
3
90
728
9 | NTppeak <

 | Labor.
roBNP C
(ng/l)
77
14
2
75
95
00 | atory pa
K peak
(U/I)
<190
222
84
64
131
74
 | arameters
CK-MB peak
(U/I)
<24
95,1
31
NA
26,3
15,6 | CRP peak
(mg/l)
<5
2,1
1,9
27,8
1,9
0,5 | BMI
(kg/m2)
20,8
24,7
33,4
22,3
25 | HF Risk fact
Hypertension
no
yes
yes
no
no
 | lors
Smoking
yes
no
no
no | Diabetes
no
no
no
no
no
 | Relevant ongoing
therapy at the time of
EMB collection
Catecholamine /
Sedation therapy
since 24h
BB, ACEI
BB, ACEI
none |
| Patient 5 Non-COVID-19 1 1 Non-COVID-19 2 1 Non-COVID-19 3 1 Non-COVID-19 4 1 Non-COVID-19 5 1 Non-COVID-19 6 1 | Scanner
(Tesla)
NA
3
NA
1.5
NA
1.5 | EF
(%)
NA
56
NA
53
NA
52 | LVEDD
(mm)
NA
53
NA
NA
NA
NA | LVEDV
(mL)
NA
155
NA
167
NA
188
 | Native
T1 (ms) NA 1261 NA 1088 NA 1055-1088
 | Native
T2 (ms)
NA
46
NA
58
NA
48-62 | ECV
(%)
NA
25
NA
NA
NA
NA | Cardiac MR
Cardiac MR
Acute Myocar
(Lake Louis
Critteria)
no
no
NA
yes
NA
yes | diac MRT
R
Is Non-
lschemic
LGE
yes
yes
NA
yes
NA
yes | Edema F
no 1
NA 1
yes 1
yes 2
 | Perica
Eden
no
NA
no
NA
no | rdial Percardial A
Fibrosis Per
yes /
NA /
NA /
NA /
NA / | no
NA
NA
NA
NA
 | abno | no
no
NA
no
NA
no
NA | | ppT pea
(ng/l)
<14
257
3
90
728
9
9
428 | k NTppeak <<5

 | Labor.
roBNP (
(ng/i))
377
14
2
2
75
35
35
30
00 | atory pa
K peak
(U/I)
<190
222
84
64
131
74
119
 | arameters CK-MB peak
(U/I) <24 | CRP peak
(mg/l) <5 | BMI
(kg/m2)
20,8
24,7
33,4
22,3
25
23,15 | HF Risk fact
Hypertension 7
yes
yes
no
no
no
 | smoking
yes
no
no
no
no
no | Diabetes
no
no
no
no
no
no
 | Relevant ongoing
therapy at the time of
EMB collection
Catecholamine /
Sedation therapy
since 24h
BB, ACEI
BB, ACEI
BB, ACEI
BB, ACEI, MRA |
| Patient 4 Non-COVID-19 1 Non-COVID-19 2 Non-COVID-19 3 Non-COVID-19 4 Non-COVID-19 5 Non-COVID-19 6 Non-COVID-19 7 | Scanner
(Tesia)
NA
3
NA
1.5
NA
1.5
1.5 | EF
(%)
NA
56
NA
53
NA
52
49 | LVEDD
(mm)
NA
53
NA
NA
NA
NA
NA | LVEDV
(mL)
NA
155
NA
167
NA
188
188
 | Native
T1 (ms) NA 1261 NA 1088 NA 1055-1088 1005-1056
 | Native
T2 (ms)
NA
46
NA
58
NA
48-62
39-50 | ECV
(%)
NA
25
NA
NA
NA
NA
32 | Cardiac MR
Cardiac MR
Acute Myocar
(Lenteria)
no
no
NA
yes
NA
yes
yes | liac MRT
Non-
lischer
yes
yes
NA
yes
yes
yes
yes
yes | Edema F
no i
NA i
yes i
yes i
 | Perica
Eden
no
NA
no
NA
no | rdial Pericardial A Peri
Fibrosis / Peri
0 NA 1
NA 1
NA 1
NA 1
NA 1 | no
NA
NA
NA
no
NA
 | abno | no
no
NA
no
NA
no
NA
no
no | | ppT pea
(ng/l)
<14
257
3
90
728
9
428
NA | Ik NTppeak <

 | Labor.
roBNP C
(ng/l) 0
377 0
14 2
2 0
355 0
00 1
11 0
0 | atory p
K peak
(U/I)
<190
222
84
64
131
74
119
91
 | arameters
CK-MB peak
(U/I)
95,1
31
NA
26,3
15,6
16,7
13,7 | CRP peak
(mg/l) <5 | BMI
(kg/m2)
20,8
24,7
33,4
22,3
25
23,15
27,2 | HF Risk fact
Hypertension
no
yes
yes
no
no
no
no
 | smoking
yes
no
no
no
no
no
no | Diabetes
no
no
no
no
no
no
no
 | Relevant ongoing
therapy at the time of
EMB collection
Sedation therapy
area VAR
BB, ACEI
BB, ACEI
BB, ACEI
BB, ACEI
BB, ACEI,
ACEI, MRA
BB, ACEI,
Acaylisalic/ilic acid |
| Patient 5 Non-COVID-19 1 1 Non-COVID-19 2 1 Non-COVID-19 3 1 Non-COVID-19 4 1 Non-COVID-19 5 1 Non-COVID-19 6 1 Non-COVID-19 7 1 | Scanner
(Tesia)
NA
3
NA
1.5
NA
1.5
1.5 | EF (%)
NA
56
NA
53
NA
52
49 | LVEDD
(mm)
NA
53
NA
NA
NA
NA
NA
NA | LVEDV
(mL)
NA
155
NA
167
NA
188
188
170
 | Native
T1 (ms) NA 1261 NA 1088 NA 1055-1088 1005-1056
 | Native
T2 (ms)
NA
46
NA
58
NA
48-62
39-50 | ECV
(%)
NA
25
NA
NA
NA
32 | Cardia Myocar
Cardia Myocar
(Lake Myocar
(Cardia Myocar
Criteria)
no
no
NA
yes
NA
yes | liac MRT R I I I I I I I I I I I I I I I I I I | Edema F
no i
NA i
yes i
yes i
 | Perica
Eden
no
NA
no
NA
no | rdial Pericardial A Peri
Fibrosi 1 Peri
yes 1
0 NA 1
0 NA 1
1
0 NA 1
1
0 NA 1 | no
no
NA
NA
no
NA
no
no
 | Cabno | no
no
NA
no
NA
no
NA
no
no | | ppT pea
(ng/l)
<14
257
3
90
728
9
428
NA | Ik NTppeak <<5

 | Labor roBNP C (ng/l) 2 14 2 25 2 95 2 11 2 00 2 | atory p: K peak (U/i) 2222 84 64 131 74 119 91
 | arameters
(CK-MB peak
(U/)
<24
95,1
31
NA
26,3
15,6
16,7
13,7 | CRP peak
(mg/l) <5 | BMI
(kg/m2)
20,8
24,7
33,4
22,3
25
23,15
27,2 | HF Risk fact
Hypertension
no
yes
yes
no
no
no
no
 | smoking
yes
no
no
no
no
no
no | Diabetes
no
no
no
no
no
no
no
 | Relevant ongoing therapy at the time of
EMB collection. Categorian in a
Sedation therapy
since 24h
BB, ACEI
BB, ACEI
none
BB, ACEI, MRA
BB, ACEI, MRA
BB, ACEI, NRA
BB, ACEI, ACEI, NRA
BB, ACEI, ACEI, ACEI, ACEI, ACEI, ACEI, ACEI, ACEI, |
| Patient 8 Non-COVID-19 1 1 Non-COVID-19 2 1 Non-COVID-19 3 1 Non-COVID-19 4 1 Non-COVID-19 5 1 Non-COVID-19 6 1 Non-COVID-19 7 1 Non-COVID-19 8 1 | Scanner
(Tesla)
NA
3
NA
1.5
NA
1.5
1.5
NA | EF
(%)
NA
56
NA
53
NA
52
49
NA | LVEDD
(mm)
NA
53
NA
NA
NA
NA
NA | LVEDV
(mL)
NA
155
NA
167
NA
188
188
170
NA
 | Native
T1 (ms) NA 1261 NA 1088 NA 1055-1088 1005-1056 NA
 | Native
T2 (ms) NA 46 NA 58 NA 48-62 39-50 NA | ECV
(%)
NA
25
NA
NA
NA
32
NA | Cardie Mycean
Acute Mycean
(Lalee Louis
Criteria)
no
no
NA
yes
NA
yes
yes | liac MRT
Non-
for voice
yos
yos
yos
yos
NA
yos
NA
yos
NA | Edema F
no 1
NA 1
yes 1
yes 1
yes 1
NA 1
 | Perica
Eden
no
NA
no
NA
no
NA | rdial Percardial A Per
Percardial A Per
1 Percardial A Per
1 NA 1
NA 1
NA 1
NA 1
NA 1 | no
NA
NA
NA
NA
NA
NA
 | Cabno | no
no
NA
no
NA
no
no
no
no | PS // Tro | ppT pea
(ng/l)
<14
257
3
90
728
9
428
NA
1371 | Ik NTppeak <

 | Labor. roBNP C (ng/l) 2 14 2 25 2 95 2 11 2 12 2 14 2 14 2 14 2 14 2 14 2 14 2 14 2 14 2 15 2 16 2 17 1 18 2 19 2 10 2 10 2 | atory p.
KK peak
(U/I)
<190
222
84
64
131
74
119
91
58
 | arameters
(CK-MB peek
(U/))
<24
95,1
31
NA
26,3
15,6
16,7
13,7
13,2 | CRP peak (mg/l) <5 | BMI
(kg/m2)
20,8
24,7
33,4
22,3
25
23,15
23,15
27,2
24 | HF Risk fact
Hypertension
no
yes
yes
no
no
no
no
yes
 | smoking
yes
no
no
no
no
no
yes | Diabetes
no
no
no
no
no
no
no
no
 | Relevant ongoing
therapy at the time of
EMB collection
Sedato therapy
since 24M
BB, ACEI
BB, ACEI
BB, ACEI
BB, ACEI, MRA
BB, ACEI, MRA
MBB, ACEI
MBB, AC |
| Patient 4 Nen-COVID-19 1 Nen-COVID-19 2 Nen-COVID-19 2 Nen-COVID-19 3 Nen-COVID-19 4 Nen-COVID-19 4 Nen-COVID-19 5 Nen-COVID-19 6 Nen-COVID-19 7 Nen-COVID-19 8 | Scanner
(Tesla)
NA
3
NA
1.5
NA
1.5
1.5
NA | EF (%)
NA
56
NA
53
52
49
NA | LVEDD
(mm)
NA
53
NA
NA
NA
NA
NA
NA | LVEDV
(mL)
NA
155
NA
167
NA
188
170
NA
 | Native
T1 (ms) NA 1261 NA 1088 NA 1055-1088 1005-1056 NA
 | Native
T2 (ms) NA 46 NA 58 NA 48-62 39-50 NA | ECV
(%)
NA
25
NA
NA
NA
32
NA | Cardiec Myocar
Acute Myocar
(Lalee Louis
Criteria)
no
no
NA
yes
NA
yes
yes | liac MRT
Non-
for Volume
yos
yos
yos
yos
NA
yes
NA
yos
NA | Edema F
no 1
NA 1
yes 1
yes 2
yes 2
yes 2
 | Perica
Eden
no
NA
no
NA
no
NA | Ana Percardial A
Percosa yes //////////////////////////////////// | no no NA no NA no NA
 | Hypok | NA
no
NA
no
NA
no
no
no
no
no
no
no | and attent | cypT peae <14 | Ik NTppeak <

 | Labor. roBNP C (ng/n) 2 114 2 75 2 95 2 00 2 0 2 | atory p.
(K peak
(U/I)
<190
222
84
64
131
74
119
91
58
 | arameters
(CK-MB peak
(U/)
-<24
95,1
31
NA
26,3
15,6
16,7
13,7
13,2 | CRP peak
(mg/l)
<5
2,1
1,9
27,8
1,9
0,5
159,9
1,7
1,3 | BMI
(kg/m2)
20,8
24,7
33,4
22,3
25
23,15
27,2
24 | HF Risk fact
Hypertension
no
yes
yes
no
no
no
yes
 | smoking
yes
no
no
no
no
no
yes | Diabetes
no
no
no
no
no
no
no
 | Relevant ongoing
therapy at the time of
EMB collection
Catecholosmine /
Sedation therapy
amo 2Ab
BB, ACEI
BB, ACEI
BB, ACEI
BB, ACEI
BB, ACEI
BB, ACEI,
MCA
BB, ACEI,
MCA
BB, ACEI,
MCA
BB, ACEI,
MCA
BB, ACEI,
MCA
BB, ACEI,
MCA
BB, ACEI,
MCA
BB, ACEI,
MCA
BB, ACEI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI,
MCA
SCI, |
| Patient 4 Nen-COVID-19 1 Nen-COVID-19 2 Nen-COVID-19 3 Nen-COVID-19 3 Nen-COVID-19 4 Nen-COVID-19 4 Nen-COVID-19 5 Nen-COVID-19 6 Nen-COVID-19 7 Nen-COVID-19 8 post-COVID-19 1 | Scanner
(Tesla)
NA
3
NA
1.5
NA
1.5
1.5
NA
3 | EF (%)
NA
56
NA
53
NA
52
49
NA
51 | LVEDD
(mm)
NA
53
NA
NA
NA
NA
NA
51 | LVEDV
(mL)
NA
155
NA
167
NA
188
170
NA
149
 | Native
T1 (ms) NA 1261 NA 1088 NA 1055-1088 1005-1056 NA 1275
 | Native
T2 (ms) NA 46 NA 58 NA 48-62 39-50 NA 43 | ECV
(%)
NA
25
NA
NA
NA
32
NA
23 | Cardise Mycoar
Cardise Mycoar
(Lake Louis
(Lake Louis
(Lake Louis
(Lake Louis
(Lake Louis
(Lake Louis
(Lake Louis)
NA
yes
NA
yes
NA
no | Hack MRT
dills
dills
uschemer
yes
yes
NA
yes
yes
yes
NA
no
no | Edema F
no 1
NA 1
yes 1
yes 1
yes 1
NA 1
yes 1
 | Perica
Eden
no
NA
no
NA
no
NA | Ana Percardia A
Fbross Per
, yes (
, NA (
) NA (
, NA (
) | no cute icarditis no NA NA no NA NA NA NA NA NA NA | Hypok
boderti
T1-R
 | NA no | and dated yr | appr peage (ng/l) <14 | k NTppeak e<5
 | Labor. roBNP C (ng/n) 2 14 2 95 2 96 2 11 2 12 2 14 2 14 2 15 2
 | atory p. K peak (U/I) <190 | arameters
(CK-MB peak
(U/)
-<24
95,1
31
NA
26,3
15,6
16,7
13,7
13,2
25,7
 | CRP peak
(mgn) <5 | BMI
(kg/m2)
20,8
24,7
33,4
22,3
25
23,15
27,2
24
19,9 | HF Risk fact
Hypertension
no
yes
yes
no
no
no
yes
yes
no
 | smoking
yes
no
no
no
no
no
yes | Diabetes
no
no
no
no
no
no
no
no
no | Relevant ongoing of the time of the consolution of |
| Patient 5 Non-COVID-19 1 Non-COVID-19 2 Non-COVID-19 3 Non-COVID-19 3 Non-COVID-19 4 Non-COVID-19 6 Non-COVID-19 6 Non-COVID-19 6 Non-COVID-19 8 post-COVID-19 1 post-COVID-19 12 Non-COVID-19 10 | Scanner
(Tesla)
NA
3
NA
1.5
NA
1.5
NA
3
3 | EF (%)
NA
56
NA
53
NA
52
49
NA
51
25 | LVEDD
(mm)
NA
53
NA
NA
NA
NA
NA
S1
NA | LVEDV
(mL)
NA
155
NA
167
NA
167
NA
188
170
NA
149
277
 | Native
T1 (ms) NA 1261 NA 1088 NA 1005-1088 1005-1056 NA 1275 1087 - 1095
 | Native
T2 (ms)
NA
46
NA
58
NA
48-62
39-50
NA
43
49-52 | ECV
(%)
NA
25
NA
NA
NA
32
NA
22
NA | Cardise Mycoars
Cardise Mycoars
(Lake Louis
(Lake Louis
(Lake Louis
(Lake Louis
(Lake Louis
(Lake Louis
(Lake Louis)
NA
yes
yes
NA
yes
NA
no | Hack MRT
dills (schemic)
(schemic)
yes
yes
NA
yes
yes
yes
yes
nA
yes
yes
yes
ves | Edema F
no i
NA i
yes i
yes i
yes i
NA i
no i
 | Perica
Eden
no
NA
no
NA
no
NA
no | rdial Percardial A
Fbross Per
0 00 1
0 0 0 0 1
0 0 0 0 1
0 0 0 0 0 0 0
0 0 0 0 0 0 0
0 0 0 0 | no
NA
no
NA
no
NA
no
NA
no
no
no
no
no
no
no
no
no
no | Hypolo
 | no
NA
no
NA
no
NA
no
no
no
no
no
no
no
no
no
no | and ated on micro reference of the second se | appr pega (ng/l) <14 | Ik NTppeak vest 2° 4 11 11 11 15 4(33 3 56 9 9 29
 | Labor Labor roBNP C 377 14 2 365 365 11 0 0 56 56 52
 | atory p.
K peak
(U/I)
222
84
64
131
74
119
91
58
75 | arameters
CK-MB peak
(U/)
- <24
95,1
31
NA
26,3
15,6
16,7
13,7
13,2
25,7
15,4
 | CRP peak
(mgn) <5 | BMI
(kg/m2)
20,8
24,7
33,4
22,3
25
23,15
27,2
24
19,9
21,4 | HF Risk fact
Hypertension
no
yes
yes
no
no
yes
yes
no
no
 | nors
Smoking
yes
no
no
no
yes
no | Diabetes
no
no
no
no
no
no
no
no
no
no | Relevant ongoing the time of the constraints of the state of the constraints of the state of the constraints |
| Patient 4 Non-COVID-19 1 Non-COVID-19 2 Non-COVID-19 3 Non-COVID-19 3 Non-COVID-19 4 Non-COVID-19 4 Non-COVID-19 5 Non-COVID-19 6 Non-COVID-19 7 Non-COVID-19 7 Non-COVID-19 8 post-COVID-19 1 post-COVID-19 2 | Scanner
(Tesla)
NA
3
NA
1.5
1.5
1.5
NA
3
1.5 | EF (%)
NA
56
NA
53
83
49
NA
51
51
25 | LVEDD
NA
53
NA
NA
NA
NA
NA
51
NA | LVEDV
(mL)
NA
155
NA
167
NA
188
170
NA
149
2277
 | Native
T1 (ms) NA 1261 NA 1088 NA 1055-1088 1005-1056 NA 1275 1087 - 1095
 | Native
T2 (ms)
NA
46
NA
58
8
8
8
8
8
9
9
50
NA
43
49-52 | ECV
(%)
NA
25
NA
NA
NA
32
NA
22
NA | Cardiae Mycoara
Cardiae Mycoara
(Lake Louis
(Lake Louis
(Lake Louis
(Lake Louis
(Lake Louis
(Lake Louis
(Lake Louis)
NA
yes
NA
yes
NA
no
no | Hac MRT
dills
dills
schore
vos
vos
vos
NA
vos
vos
NA
vos
vos
NA
vos
vos
nA
vos
nA
vos
vos
nA
vos
vos
nA
vos
vos
nA
vos
vos
nA
vos
vos
nA
vos
vos
nA
vos
vos
nA
vos
vos
nA
vos
vos
nA
vos
vos
vos
nA
vos
vos
vos
vos
vos
vos
vos
vos | Edema F
no i
NA i
yes i
yes i
yes i
na i
 | Perica
no
no
NA
no
NA
no
no
NA
no | Paricardial Paricardial Paricardial Ves Paricardial Paricardial NA NA I NA I I I I I I I I I I I I I I I I I I I I I I I I I I </td <td>no
no
NA
no
NA
no
NA
no
NA
no
no</td> <td>Hypoid
bordent
times s
Redu</td> <td>no
NA
no
NA
no
NA
no
no
no
inesia a
ejetal ap
izced LV</td> <td>and and and and and and and and and and</td> <td>opp peasition <14</td> 257 3 90 728 9 428 NA 1371 7 87 | no
no
NA
no
NA
no
NA
no
NA
no
no
 | Hypoid
bordent
times s
Redu | no
NA
no
NA
no
NA
no
no
no
inesia a
ejetal ap
izced LV | and | opp peasition <14 | kk NTppeak v 22' 4 111 111 111 112 44(4) 33 33 33 55(9) 99 229
 | LabornoBNP C (rogN)
 | atory p.
K.K peak
(U/I)
222
84
64
131
74
119
91
58
75
138
 | CK-MB peak
(U/)
 | CRP peak
(mg/l)
<5
2,1
1,9
27,8
1,9
0,5
159,9
1,7
1,3
0,7
2,79 | BMI
(kg/m2)
20.8
24.7
33.4
22.3
23.15
27.2
24
19.9
21.4 | HF Risk fact
Hypertension
no
yes
no
no
no
yes
no
yes
no
 | iors
Smoking
yes
no
no
no
no
yes
no | Diabetes
no
no
no
no
no
no
no
no
no
no
no
 | Relevant ongoing or
EMB politection
EMB politection
Categoholdmine /
Section threapy
arrow 240
BB, ACEI
BB, ACEI
BB, ACEI
BB, ACEI
BB, ACEI
BB, ACEI
BB, ACEI, MRA
BB, ACEI, MRA
BB, ACEI, MRA
BB, ACEI, MRA
BB, ACEI, MRA
BB, ACEI, MRA
BB, ACEI, MRA
MILLIONG
BB, ACEI, MRA
Advisationific acid
(100mg)
Districts. |
| Patient 4 Nen-COVID-19 1 Nen-COVID-19 2 Nen-COVID-19 3 Nen-COVID-19 3 Nen-COVID-19 4 Nen-COVID-19 4 Nen-COVID-19 5 Nen-COVID-19 5 Nen-COVID-19 7 Nen-COVID-19 7 Nen-COVID-19 8 post-COVID-19 1 post-COVID-19 1 post-COVID-19 2 post-COVID-19 3 | Scanner
(Tesla)
NA
3
NA
1.5
NA
1.5
NA
3
1.5
1.5 | EF NA 56 NA 53 NA 52 49 51 25 33 33 | LVEDD
(mm)
NA
53
NA
NA
NA
NA
NA
S1
S1
S7 | LVEDV
(mL) N NA 1 155 0 167 0 188 1 1700 0 NA 0 149 2777 142 0
 | Native
T1 (ms) NA 1261 NA 1088 NA 1055-1088 1005-1056 NA 1275 1087 - 1095 1034-1113
 | Natives
T2 (ms)
NA
46
NA
58
8
NA
48-62
39-50
NA
49-52
49-51 | ECV
(%)
NA
25
NA
NA
NA
32
NA
23
29
29.5 | Cardiae Mkycoan
Cardiae Mkycoan
(Loten Louis)
no
NA
yes
NA
yes
yes
NA
no
no | Jac ART
dilla
dilla
dilla
scher
yes
yes
NA
yes
NA
yes
NA
yes
NA
yes
yes
yes
yes
yes
yes
yes
yes | Edema F
no 1
NA 1
yes 1
yes 2
yes 1
NA 1
no 1
yes 1
 | Perica
Eden
no
NA
no
NA
no
NA
no
NA | Percardial Percardial with the percardial A percardial < | no no NA | Hypolo
boyters
Redu
 | htter
no
no
NA
NA
no
no
no
no
no
no
no
no
no
no
no
no
no | and and anonce in the second s | <pre>crypt pease
(righ)
<14
257
3
90
728
9
9
428
NA
1371
7
87
276</pre> | k NTp:peak v<5
 | LabornorBNP C (ng/r) (1 (ng/r) (2 (n
 | atory p.
K peak
(U/I)
222
84
64
131
74
119
91
58
75
138
383 | arameters
(CK-MB peak
(CK-MB peak
(CK-MB peak
(-24
95,1
31
26,3
15,6
16,7
13,7
13,2
25,7
15,4
32,1
 | CRP peak
(mg/l)
<5
2,1
1,9
27,8
1,9
0,5
159,9
1,7
1,3
0,7
2,79
457,8 | BMI
(kg/m2)
20,8
24,7
33,4
22,3
25
23,15
27,2
24
19,9
21,4
35,6 | HF Risk fact
Hypertension
no
yes
yes
no
no
no
yes
no
no
yes | rors
Smoking
yes
no
no
no
no
yes
no
no
 | Diabetes
no
no
no
no
no
no
no
no
no
no
no
no
no | Relevant ongoing
therapy at the time of
EBB collections
Seaton therapy
amought
be a collection of
the seaton therapy
amought
be a collection of
BB, ACEI
mone
BB, ACEI, MRA
BB, ACEI, MRA
BB |
| Patient 4 Nen-COVID-19 1 Non-COVID-19 2 Non-COVID-19 3 Non-COVID-19 3 Non-COVID-19 4 Non-COVID-19 4 Non-COVID-19 5 Non-COVID-19 6 Non-COVID-19 7 Non-COVID-19 7 Non-COVID-19 8 post-COVID-19 1 post-COVID-19 1 post-COVID-19 2 post-COVID-19 3 sept 00/07/07 10 | Scanner
(Tesla)
NA
3
NA
1.5
NA
1.5
NA
3
1.5
1.5
1.5 | EF NA 56 NA 53 NA 52 49 NA 51 25 33 | LVEDD
(mm)
NA
53
NA
NA
NA
NA
S1
S1 | LVEDV
(mL)
NA
155
NA
167
NA
188
170
NA
188
170
NA
149
277
142
 | Native
T1 (ms)
NA
1261
NA
1088
NA
1055-1088
1005-1056
NA
1275
1087 - 1095
1087 - 1095
 | Native
T2 (ms)
NA
46
NA
58
S8
NA
48-62
39-50
NA
49-52
49-51 | ECV
(%)
NA
25
NA
NA
NA
32
NA
22
29
29.5 | Cardiae Mkyocar
Cardiae Mkyocar
(Laten Louis)
no
NA
yes
NA
yes
yes
NA
no
no
no | Hac MRT
dils
dils
lschemic
yos
yos
NA
yos
yos
NA
yos
yos
yos
yos
yos
yos
yos
yos | Edema F no 1 no 1 NA 1 yes 1 yes 1 yes 1 no 1 yes 1 no 1 no 1 no 1 no 1 yes 1 no 1 yes 1
 | Perica
no
no
NA
no
NA
no
NA
no
NA | Percardial
PErcosi A
Per 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 | Incute cute cute cute cute cute cute cute
 | C abno | htter
no
no
NA
no
NA
no
no
no
no
no
no
no
no
no
no
no
no
no | and difference of the second s | opp peasing <14 | k NTp peak <
 | Laborn (c)(g)(f) C (c)(g)(f) C (f)(g)(f) C (g)(g)(f) C (g)(g)(f) C (g)(g)(f) C (g)(g)(g)(f) C (g)(g)(g)(g)(g)(g)(g)(g)(g)(g)(g)(g)(g)(
 | attory p. KK peeds v(M) v(M) v(M) 84 64 131 74 119 91 58 75 138 383 24
 | arameters CK-MB peak <ck-mb peak<="" td=""> 95.1 31 NA 265.3 15.6 16.7 13.7 13.2 25.7 15.4 32.1</ck-mb> | CRP peak
(mg/i)
<5
2,1
1,9
27,8
1,9
0,5
159,9
1,7
1,3
0,7
2,79
457,8 | BMI
(kg/m2)
20.8
24,7
33,4
22,3
25
23,15
27,2
24
19,9
21,4
35,6 | HF Risk fact
Hypertension
no
yes
yes
no
no
no
yes
no
yes
no
yes
 | tors Smoking yes no | Diabetes no | Relevant ongoing
therapy at the time of
EMB collection
Catecholomine /
Sedation therapy
aino 24M
BB, ACEI
none
BB, ACEI
None
BB,
ACEI,
ACEI,
ACEI,
ACCI,
ACEI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACCI,
ACC |
| Patient 4 Non-COVID-19 1 Non-COVID-19 2 Non-COVID-19 3 Non-COVID-19 3 Non-COVID-19 4 Non-COVID-19 4 Non-COVID-19 5 Non-COVID-19 5 Non-COVID-19 7 Non-COVID-19 7 Non-COVID-19 1 post-COVID-19 1 post-COVID-19 2 post-COVID-19 3 post-COVID-19 4 | Scanner
(Tesla)
NA
3
NA
1.5
1.5
1.5
1.5
1.5
1.5
3 | EF NA 56 NA 53 33 54 33 55 33 58 58 | LVEDD
(mm)
33
53
NA
NA
NA
NA
S1
S1
S1
47 | LVEDV
(ML)
NA
155
NA
167
NA
188
170
NA
127
NA
2277
142
2113
 | Native
T1 (ms) NA 1261 NA 1088 NA 1055-1088 1005-1056 NA 1275 1084-1113 1287
 | Native
T2 (ms)
NA
46
NA
58
NA
48-62
39-50
NA
49-52
49-52
49-51 | ECV
(%)
NA
25
NA
NA
NA
32
NA
22
29
29.5
24 | Cardiae Myocar
Cardiae Myocar
(L'Critens)
no
NA
yes
NA
yes
yes
NA
no
no
no | Hace MRT
Head Mits
Hore
Head Mits
Head M | Edema F no 1 no 1 NA 1 yes 1 yes 1 yes 1 no 1 yes 1 no 1 no 1 no 1 no 1 yes 1 no 1 no 1 no 1
 | Perica
Eden
no
NA
no
NA
no
NA
no
NA
no
NA | Percardial
Procession Percardial
Percossion 0 NA Percession 0 Percession | no no NA no NA no NA no NA no | bypol
bodotri
TI-R
times s
Redu
 | htter
rrmalitie
no
NA
NA
NA
NA
NA
no
NA
no
no
cedtexatic
ceptal ap
rcced LV
no | and aled aled aled aled aled aled aled ale | approprime ppp perform <14 | k NTp peak <
 | Laborn (c)(g/f) C
 | attory p. ick peak vik peak vik peak 64 131 74 119 91 58 775 138 3833 34 | arameters
(CK-MB peak
95,1
31
NA
263,3
15,6
16,7
13,7
13,2
25,7
15,4
32,1
18,6
 | CRP peak
(mg/i)
<5
2,1
1,9
27,8
1,9
0,5
159,9
1,7
1,3
0,7
2,79
457,8
30,1 | BMI
(kg/m2)
20.8
24,7
33,4
22,3
25
23,15
27,2
24
19,9
21,4
35,6
22,3 | HF Risk fact
Hypertension
no
yes
no
no
no
yes
no
yes
no
yes | tors
Smoking
yes
no
no
no
yes
no
no
no
no
no
 | Diabetes no | Relevant ongoing the time of
therapy at the time of
EMB collection of
Sedatori therapy
since 24M sedatori ther |
| Patient C Non-COVID-19 1 Non-COVID-19 2 Non-COVID-19 3 Non-COVID-19 3 Non-COVID-19 4 Non-COVID-19 4 Non-COVID-19 5 Non-COVID-19 6 Non-COVID-19 7 Non-COVID-19 7 Non-COVID-19 8 post-COVID-19 1 post-COVID-19 1 post-COVID-19 3 post-COVID-19 4 post-COVID-19 4 | Scanner
(Tesla)
NA
3
NA
1.5
1.5
1.5
1.5
1.5
1.5
3
3
3 | EF K NA 56 NA 53 53 53 54 53 55 33 58 44 | LVEDD
(mm)
NA
53
NA
NA
NA
NA
S1
S1
S1
47
55 | LVEDV
(mL)
NA
155
NA
167
188
170
NA
149
277
142
142
113
 | Native
T1 (ms)
NA
1261
NA
1088
NA
1055-1088
1005-1056
NA
1275
1087 - 1095
1087 - 1095
1034-1113
1287
 | Native
T2 (ms) NA 46 NA 46 NA 58 NA 48-62 39-50 NA 43 49-52 49-51 40 45 | ECV
(%)
NA
25
NA
NA
NA
32
23
29
29.5
24
27 | Cardiae Mycoan
Cardiae Mycoan
(Lechnens)
no
NA
yes
yes
yes
NA
no
no
no
no
no | Hace MRT
Head Market
Head Mar | Edema F no 1 no 1 NA 1 yes 1 yes 1 yes 1 no 1 yes 1 yes 1 no 1 no 1 no 1 yes 1 no 1 no 1 no 1 no 1 no 1 no 1
 | Perica
Eden
no
NA
no
NA
no
NA
no
NA
no
NA
no
no | Percardial Percardial Percardial 100 100 100 100 100 | no no NA NA no NA | Hypok
bordeni
TT-R
Redu
Terr
Peri
 | htter
mo
no
NA
no
NA
no
NA
no
no
no
no
no
no
no
no
no
no
no
no
no | and dated yn can ar fer fer fer fer fer fer fer fer fer fe | approprime approprime <14 | k NTpipak -<
 | Laboro
(1997) C
(1997) C
 | atory p.
K peak
(U/n)
222
84
64
131
74
119
91
58
75
75
138
383
34
78 | arameters
(CK-MB peak
95,1
95,1
95,1
131
NA
226,3
15,6
16,7
13,7
13,2
25,7
15,4
32,1
18,6
20,7
 | CRP peak
(mg/) k
2.1
1.9
2.7.8
1.9
0.5
159,9
1.7
1.3
0.7
2.79
457,8
30,1
9,4 | BMI
(kg/m2)
20.8
24.7
33.4
22.3
25
23.15
27.2
24
19.9
21.4
35.6
22.3
24.8 | HF Risk fact
Hypertension
no
yes
yes
no
no
yes
no
yes
no
yes
no
yes
no
no | tors
Smoking
yes
no
no
no
no
yes
no
no
no
no
no
 | Diabetes no | Relevant ongoing
EMB volketion
Soldenbalamine /
Soldenbalamine /
Soldenbalamine /
Soldenbalamine /
Soldenbalamine /
Soldenbalamine /
BB, ACEI
BB, ACEI
BB, ACEI
BB, ACEI, MRA
BB, ACEI, MRA
ACEI, MRA
AC |
| Patient S Non-COVID-19 1 Non-COVID-19 2 Non-COVID-19 2 Non-COVID-19 3 Non-COVID-19 4 Non-COVID-19 4 Non-COVID-19 5 Non-COVID-19 5 Non-COVID-19 6 Non-COVID-19 6 Non-COVID-19 7 Non-COVID-19 7 Non-COVID-19 8 post-COVID-19 1 post-COVID-19 1 post-COVID-19 3 post-COVID-19 4 post-COVID-19 4 post-COVID-19 5 post-COVID-19 4 | Scanner
(Tesia)
NA
3
NA
1.5
NA
1.5
NA
1.5
NA
3
1.5
3
3
3 | EF (%) NA 56 NA 53 S3 04 52 49 NA 51 255 33 58 44 | LVEDD
(mm)
NA
53
NA
NA
NA
NA
S1
S1
S1
47
S5 | LVEDV
(ML)
NA
155
NA
167
188
170
NA
149
277
142
142
113
142
 | Native
T1 (ms)
NA
1281
1088
NA
1055-1088
1005-1086
NA
1275
10087 - 1095
1034-1113
1237
 | Native
T2 (ms) NA 46 NA 46 NA 58 NA 48-62 39-50 NA 48-62 39-50 NA 43 49-52 49-51 40 45 | ECV
(%)
NA
25
NA
NA
NA
32
NA
23
29
29.5
24
27 | Cardiae Myocar
Cardiae Myocar
NA
no
NA
yes
NA
yes
NA
no
no
no
no | Histo MAT
dills Schemic
dills Ischemic
yes
NA
yes
NA
yes
NA
yes
NA
yes
yes
no
no
no | Edema F no 1 no 1 NA 1 yes 1 NA 1 yes 1 no 1
 | Perica
no
NA
no
NA
no
NA
no
NA
no
NA
no
no | Percardial Percardial Percardial in Percardial Percardial Percardial in no Percardial Perc | no cute cicarditis no NA | Hypox
boddeni
T1-R
Redu
Redu
 | htter
rmalitie
no
NA
no
NA
no
NA
no
no
no
ineeleaxatio
eptal ap
icced LVU
minated | and atted yn o far | App T pesa (ng/l) <14 | k NTppak <
 | Laboro (GRMP C) (C) (GM) (C) (GM) (C) (C) (GM) (C) (C) (GM) (C) (C) (C) (C) (C) (C) (C) (C) (C) (C
 | atory p. K peak (190) 222 84 64 131 74 119 91 58 75 138 383 34 78 | arameters CK-MB peak CK-MB peak 224 95,1 31 NA 26,3 15,6 16,7 13,7 13,2 25,7 15,4 32,1 18,6 20,7 -
 | CRP peak
(mg/)
<5
2,1
1,9
27,8
1,9
0,5
159,9
1,7
1,3
0,7
2,79
457,8
30,1
9,4 | BMI
(kg/m2)
20.8
24.7
33.4
22.3
25
23.15
27.2
24
19.9
21.4
35.6
22.3
24.8 | HF Risk fact
Hypertension
no
yes
no
no
no
yes
no
yes
no
yes
no
no
yes
 | tors
Smoking
yes
no
no
no
no
yes
no
no
no
no
no | Diabetes Doubleses Diabetes Di | Relevant ongoing of the time of
therapy at the time of
EMB collection of
Sedecholonine /
Sedecholonine /
Sedecholonine /
Sedecholonine /
BB, ACEI
None
BB, ACEI
None
BB, ACEI, MRA
BB, ACEI, |
| Patient 4 Non-COVID-19 1 Non-COVID-19 2 Non-COVID-19 3 Non-COVID-19 3 Non-COVID-19 4 Non-COVID-19 6 Non-COVID-19 6 Non-COVID-19 7 Non-COVID-19 7 Non-COVID-19 8 post-COVID-19 1 post-COVID-19 1 post-COVID-19 3 post-COVID-19 3 post-COVID-19 4 post-COVID-19 4 post-COVID-19 5 post-COVID-19 6 | Scanner
(Tesia)
NA
3
NA
1.5
NA
1.5
NA
1.5
NA
3
1.5
3
3
3
3
3 | EF (%) NA 56 NA 53 53 64 54 94 55 33 58 44 58 58 | LVEDD
(VMM)
33
30
30
30
40
51
55
47
55
55 | LVEDV
(mL)
NA
155
NA
167
NA
188
170
NA
188
170
NA
149
2777
142
113
113
158
 | Native T1 (ms) NA 1281 NA 108-008 NA 1005-008 NA 1005-108 1005-108 1007-108 1087-1085 1087-1085 1087-1085 1087-1085 1034-1113 1287 1322 1214
 | Native
T2 (ms) NA 46 NA 46 NA 39-50 NA 43 49-52 49-52 40 45 | ECV
(%)
NA
25
NA
NA
32
NA
23
23
29
29.5
24
24
27
23 | Cardiae Myocan
Cardiae Myocan
(L'Crittenia)
NA
yes
NA
yes
NA
yes
NA
no
no
no
no
no
no | Hace MRT
Hill Storm
Composition
Hill Storm
Hill St | Edema F no 1 no 2 NA 2 NA 2 yes 1 yes 1 no 1 yes 1 no 1 no 1 no 1 yes 1
 | Perica
no
NA
no
NA
no
NA
no
NA
no
NA
no
no
no | Percardial Percardial 1 Percardial A 1 Percardial Percardial 1 Percardial Percardial 1 NA 1 | Incute cicarditis inconditional cicarditis inconditional inconditinational inconditional inconditional inconditional incondition | Hypok
bogier
Redu
Redu
Point; | hter
mo
no
NA
no
NA
no
NA
no
no
no
no
no
no
coed LV
minesia a
coed LV
minesia a
coed LV
minesia a
coed LV
 | and ated ated ated ated ated ated ated ate | ppT peae
(ng/i)
< <u><14</u>
257
3
90
728
9
428
NA
1371
7
87
276
48
6
56 | k NTppeak <
 | Laborn C 1 1 1 2 1 1 2 1 1 2 1 1 36 1 1 0 1 1 <
 | attorp p. K peai K peai (U/n) K peai (U/n) 222 84 64 131 74 119 91 58 75 138 383 34 78 118 | Arameters
CK-MB peek
-24
95,1
31
NA
26,3
15,6
16,7
13,7
13,2
25,7
15,4
32,1
18,6
20,7
20,4
 | CRP pask (Cmp) <5 | BMI
(kg/m2)
20.8
24.7
33.4
22.3
25
23.15
27.2
24
19.9
21.4
35.6
22.3
24.8
22.3
24.8
22.5 | HF Risk fact
Hypertension
no
yes
no
no
no
yes
no
yes
no
yes
no
yes
no
no
no
yes | tors Smoking yes no no no no no yes no
 | Diabetes Doubleses Diabetes Di | Relevant ongoing the target the concernent of the conc |
| Patient C Non-COVID-19 1 Non-COVID-19 2 Non-COVID-19 3 Non-COVID-19 3 Non-COVID-19 4 Non-COVID-19 4 Non-COVID-19 5 Non-COVID-19 6 Non-COVID-19 7 Non-COVID-19 7 Non-COVID-19 8 post-COVID-19 1 post-COVID-19 1 post-COVID-19 3 post-COVID-19 4 post-COVID-19 4 post-COVID-19 5 post-COVID-19 5 post-COVID-19 6 post-COVID-19 5 | Scanner
(Tosia)
NA
3
NA
1.5
1.5
1.5
1.5
1.5
3
3
3
3
3 | EF (%) NA 56 NA 53 S3 NA 52 49 A9 51 33 51 33 58 44 58 | LVEDD
NA
53
NA
NA
NA
NA
NA
51
51
55
47
55
55 | LVEDV
(M)////////////////////////////////////
 | Native
Native
T (ms)
NA
1281
1281
1084
1085
1087
1087
1087
1087
1087
1087
1087
1087
 | Native
T2 (ms) NA 46 NA 58 NA 48-62 39-50 NA 43 49-52 49-52 40 40 45 | ECV
(%)
NA
25
NA
NA
32
NA
23
23
29
29.5
24
27
23 | Cardise Mycoan
Cardise Mycoan
Racute Mycoan
no
no
NA
yes
NA
yes
yes
NA
no
no
no
no
no
no | Hise MRT
Hiddis Ischemic
Ves
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
NA
Ves
Ves
NA
Ves
Ves
NA
Ves
Ves
NA
Ves
Ves
Ves
Ves
Ves
Ves
Ves
Ves | Edema F no 1 no 2 NA 2 NA 2 NA 2 yes 2 NA 2 no 3 no 3 no 3 no 3 no 3 no 3
 | Perica
Perica
no
NA
no
NA
no
NA
no
no
NA
no
no
NA | Percardial Percardial Percardial 100 100 100 100 100 | Incute cute cicarditis in a cu | Hypok
Hypok
bodder
FRedu
Redu
Redu
 | hter
mo
no
NA
no
NA
no
NA
no
no
no
no
no
no
no
no
no
no | and ated model ated ated ated ated ated ated ated ated | app T pesa (ng/i) <14 | kk NTppeaka 2: 2: 4 11:11 11:1 11:11 11:1 15:11 11:11 15:11 11:11 15:11 11:11 15:11 11:11 15:11 11:11 15:11 11:11 15:11 11:11 15:11 11:11 15:11 11:11 15:11 11:11 15:11 11:11 15:11 11:11 15:11 11:11 15:11 11:11 15:11 11:11 15:11 11:11 16:11 11:11 16:11 11:11 16:11 11:11 16:11 11:11 16:11 11:11 16:11 11:11 16:11 11:11 16:11 11:11 16:11 11:11 16:11 11:11 16:11 11:11 <
 | Labor 14 37 14 2 775 367 377 377 377 377 377 377 377 377 377 377 377 377 375 300 1 37 37 37 37 37 37 37 37 37 37 37 37 37 37 37 37
 | altory p. K peak K peak (190) K peak (113) 222 84 (64) 131 74 (119) 91 58 (118) 383 34 (78) 1118 (338) (338)
 | Arrowski stranger
CK-MB peak
-24
95,1
31
NA
26,3
15,6
16,7
13,7
13,2
25,7
15,4
32,1
18,6
20,7
20,4
10,5 | CRP pask (Cmg) - - | BMI
(kg/m2)
20.8
24.7
33.4
22.3
25
23.15
27.2
24
19.9
21.4
19.9
21.4
35.6
22.3
24.8
22.5
7
24.8 | HF Risk fact
Hypertension
no
yes
no
no
no
yes
no
yes
no
yes
no
yes
no
no
yes
 | iors Smoking yes no no no no no yes no | Diabetes no | Relevant ongoing of
EMB collection
Categoricalismine /
Section in an application of
the section of the application of
BB, ACEI BB, ACEI BB, ACEI BB, ACEI, MENA
BB, ACEI BACKER
BB
BB
 |
| Patient 4 Non-COVID-19 1 Non-COVID-19 2 Non-COVID-19 3 Non-COVID-19 3 Non-COVID-19 4 Non-COVID-19 4 Non-COVID-19 5 Non-COVID-19 6 Non-COVID-19 7 Non-COVID-19 7 Non-COVID-19 8 post-COVID-19 1 post-COVID-19 9 post-COVID-19 3 post-COVID-19 4 post-COVID-19 4 post-COVID-19 5 post-COVID-19 5 post-COVID-19 7 Non-COVID-19 5 | Scanner
(Tosia)
NA
3
NA
1.5
NA
1.5
1.5
1.5
1.5
3
3
3
3
3
3 | EF (%) NA 56 NA 53 S3 NA 52 49 49 31 51 33 58 44 58 44 | LVEDD
(mm)
NA
53
NA
NA
NA
NA
51
51
51
47
55
55
55 | LVEDV
MA
NA
155
NA
167
NA
188
170
NA
149
277
142
113
113
113
158
158
 | Native
T1 (ms)
NA
1281
NA
1088
NA
1055-1088
1055-1088
1055-1088
1055-1088
1057-1095
1087-1095
1087-1095
1087-1095
1087-1095
1087-1095
1097
1097
1097
1097
1097
1097
1097
1097
 | Native Native Native 46 A6 NA 46 NA 48-62 39-50 NA 43 49-52 40-51 40 45 46 57 | ECV
(%)
NA
25
NA
NA
NA
32
NA
23
29
29.5
24
27
23
24 | Cardiae Mycoan
Cardiae Mycoan
Route Mycoan
no
NA
NA
yes
NA
yes
NA
no
no
no
no
no
no
no | Hise MRT
Willing Schemeine
Willing Schemeine
Version Schemeine
Ver | Edema F F NA I NA I yes I NA I yes I NA I yes I NA I yes I NA I no I yes I no I yes I yes I
 | Perica
no
NA
no
NA
no
no
NA
no
no
no
no
no | Percardia Percardia Percardia 1 Percardia Percardia 1 NA 1 | Incute cute cicarditis in a cu | Hypok
Hypok
Hypok
Hypok
Redu
Redu
Redu
Redu
Redu | NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
 | and atted of the second | ppT pesa
(ng/i)
3
90
728
9
428
NA
1371
7
87
276
48
6
6
56
56 | kk NTppeaka 2: 2: 4 11: 11: 11: 11: 11: 11: 11: 11: 11: 11: 11: 11: 11: 11: 11: 11: 11: 11: 11: 11: 11: 11: 11: 11: 11: 11: 11: 11: 11: 12: 11: 13: 3: 33: 3: 34: 3: 55: 9: 9: 2: 9: 2: 14: 4: 4: 6: 6: 6: 9: 9:
 | Laboro (SPR) C
(1997) C
77 C
77 C
77 C
77 C
77 C
75 C | altory p. K. peal K. K. peal (U/n) SK. K. peal (U/n) 1190 222 84 64 131 74 1199 91 58 75 138 383 34 78 1118 3338
 | Arran energy of the second sec | CRP pask (mg) -<5 | BMI
(kg/m2)
20,8
24,7
33,4
22,3
25
23,15
27,2
24
19,9
21,4
35,6
22,3
24,8
22,3
24,8
22,7
24,8 | HF Risk fact
Hypertension
70
998
00
10
10
10
10
10
10
10
10
10
10
10
10
 | iors Smoking yes no no no no no yes no | Diabetes
no
no
no
no
no
no
no
no
no
no | Relevant ongoing
Party at the time of
the application of the application
Categorithmine / Section
Section therapy
area 2AB
BB, ACEI
BB, ACEI
BB, ACEI
BB, ACEI
BB, ACEI
BB, ACEI
BB, ACEI
BB, ACEI
Diversion
BB, ACEI, MRAA
BB, ACEI, MRAA
BB
BB
Cone (but 2 months
before EME Lophawirf v40)
BB
ACEI
Cone
 |
| Patient S Non-COVID-19 1 Non-COVID-19 2 Non-COVID-19 2 Non-COVID-19 3 Non-COVID-19 4 Non-COVID-19 4 Non-COVID-19 5 Non-COVID-19 6 Non-COVID-19 7 Non-COVID-19 7 Non-COVID-19 8 post-COVID-19 1 post-COVID-19 1 post-COVID-19 3 post-COVID-19 4 post-COVID-19 4 post-COVID-19 5 post-COVID-19 5 post-COVID-19 6 post-COVID-19 7 post-COVID-19 7 post-COVID-19 7 | Scanner
Tresia)
NA
3
NA
1.5
NA
1.5
NA
1.5
NA
3
1.5
3
3
3
3
3
3
3 | EF
(%) I NA 56 NA 53 S3 0 S4 9 S51 33 58 44 58 42 | LVEDD
(mm)
NA
53
NA
NA
NA
NA
S1
S1
S1
S5
57
55
55
55
55 | LVEDY
IVEDY
NA
155
NA
167
NA
188
170
NA
149
2777
142
113
164
158
158
 | NA 1261 NA 1281 NA 1088 NA 1087-1088 1005-1086 NA 1005-1081 1007-1085 1087-1085 1027-1085 1034-1113 1287 1322 1214 1300 1231
 | Native Native Native 46 NA 46 NA 46 NA 48-62 39-50 NA 48-62 39-50 A48-62 39-50 445 40-51 40 45 46 57 49 | ECV
(%)
NA
25
NA
NA
NA
32
NA
23
29
29.5
24
27
23
24
24 | Cardiae Myocar
Cardiae Myocar
Route Myocar
no
no
NA
yes
yes
yes
NA
no
no
no
no
no
no
no
no | Jace MRT Works Ischernic Vers Vers NA Vers NA Vers NA Vers NA Vers NA Vers Vers Vers Vers NA Vers NA Vers NA Vers NA NA Vers NA | Edema / F Ro 1 NA 1 yes 1 NA 1 yes 1 NA 1 yes 1 NA 1 yes 1 no 1
 | Perica
Perica
no
NA
no
NA
no
NA
no
NA
no
no
no
no
no
no
no
no
no
no | Percardial Percardial Percardial indial Percardial Percardial indial non Percardial | cute | Hypok
Hypok
United
States
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypok
Hypoh
Hypok
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypoh
Hypo | htter
mmalitie
no
NA
NA
NA
NA
no
NA
no
no
no
no
no
no
no
no
no
no
no
no
no | And | APT Peea
(ng/)
<14
257
3
90
728
9
428
NA
1371
7
87
276
48
6
6
56
56
26
NA | k NTpeak <
 | Laboro (1997)
(1997) (1 | altory p. K. peai K. K. peai (U/n) SK. K. peai (U/n) 131 64 131 74 119 91 58 (U/n) 75 138 383 34 78 1118 338 25
 | Arran energy of CK-MB peek
(CK-MB peek
-224
95,1
31
NA
26,3
15,6
16,7
13,2
25,7
15,4
32,1
18,6
20,7
20,4
19,5
Na | CRP pask (mg) - 2.1 1.9 2.7.8 1.9 0.5 159,9 1.7 1.3 0,7 2.79 457,8 30,1 9,1 9,4 107,4 | BMI
(kg/m2)
20,8
24,7
33,4
22,3
25
23,15
27,2
24
19,9
21,4
35,6
22,3
24,8
22,3
24,8
22,5,7
300
27,2 | HF Risk fact
Hypertension
70
998
00
70
70
70
70
70
70
70
70
70
70
70
70
 | iors Smoking yes no no no no no yes no | Diabetes
no
no
no
no
no
no
no
no
no
no | Relevant ongoing of the time of
therapy at the time of
EMB collections of
Sedadocharms of
Sedadocharms of
Sedadocharms of
BB, ACEI Sedadocharms of
BB, ACEI Sedadocharms of
BB, ACEI Sedadocharms of
BB, ACEI, MRA
BB, ACEI, MRA
ACEI, MRA
AC
 |
| Patient 4 Nen-COVID-19 1 Non-COVID-19 2 Non-COVID-19 3 Non-COVID-19 3 Non-COVID-19 4 Non-COVID-19 6 Non-COVID-19 6 Non-COVID-19 7 Non-COVID-19 7 Non-COVID-19 8 post-COVID-19 1 post-COVID-19 1 post-COVID-19 2 post-COVID-19 3 post-COVID-19 4 post-COVID-19 4 post-COVID-19 5 post-COVID-19 5 post-COVID-19 7 post-COVID-19 7 | Scanner
Tresia)
NA
3
NA
1.5
NA
1.5
NA
1.5
NA
3
1.5
3
3
3
3
3
3
3 | EF
(%) I NA 56 NA 53 S3 0 S4 9 S1 0 S3 0 S4 0 S5 0 S4 0 S5 0 S4 0 S4 0 S5 0 S4 0 S5 0 | LVEDD
(mm)
NA
53
NA
NA
NA
NA
NA
S1
S1
S1
S1
S5
S5
S5
S5
S5
S5
S5
S5
S5
S5
S5
S5
S5 | LVEDY
IVEDY
NA
155
NA
167
NA
188
170
NA
188
170
NA
149
277
142
113
142
113
145
158
 | Native
T1(ms)
NA
1281
NA
1089
NA
1095-1088
NA
1055-1088
NA
1055-1088
NA
1275
1087-1095
1087-1095
1087-1095
1087-1095
1087-1095
1087-1095
1087-1095
1087-1095
1087-1095
1087-1095
1087-1095
1087-1095
1087-1095
1087-1095
1087-1095
1087-1095
1087-1095
1087-1095
1087-1095
1087-1095
1087-1095
1087-1095
1087-1095
1087-1095
1087-1095
1087-1095
1087-1095
1087-1095
1087-1095
1087-1095
1087-1095
1087-1095
1087-1095
1087-1095
1087-1095
1087-1095
1095
1095
1095
1095
1095
1095
1095 | Native Native Native A 46 NA 46 NA 48-62 39-50 NA 48-62 39-50 A4 49-52 49-51 40 45 46 57 49
 | ECV
(%)
NA
25
NA
NA
32
NA
32
23
23
29
29.5
24
27
23
24
24
24 | Cardiae Myocar
Cardiae Myocar
Route Myocar
no
NA
yes
NA
yes
NA
yes
NA
no
no
no
no
no
no
no | Jace MRT Will sincher Utilis schemic yes NA NA NA NA yes NA yes NA yes NA yes NA yes yes NA yes NA yes NA yes yes no yes | Edema P P no 1 no 1 NA 1 yes 1 yes 1 yes 1 yes 1 no 1 yes 1 yes 1 yes 1 no 1 yes 1 no 1
 | Perica
Eden
no
NA
no
NA
no
NA
no
NA
no
no
no
no | Percardial Percardial Percardial 1 Percardial | no cute cicarditis no NA no NA no NA no NA no NA no | Hypok
bogger
Redu
Perr
Redu
Redu
Redu
 | NA
no
NA
no
NA
no
no
no
no
no
no
no
no
no
no | and ated ated ated ated ated ated ated ate | apT pesa
(ng/)
<14
257
3
90
728
9
428
NA
1371
7
87
276
48
6
6
56
26
NA | k NTpeak <
 | Laboro (1997) C
 | altory p. kit peak (U/n) <190
 | Arranders
CK-MB peak
CK-MB peak
-24
95,1
31
NA
26,3
15,6
16,7
13,7
13,2
25,7
15,4
32,1
18,6
20,7
20,4
19,5
Na
46,5
Na | CRP peak cs 2.1 1.9 27.8 1.9 0.5 150,9 1.7 1.3 0.7 2.79 457.8 30.1 9.4 107.4 | BM((kg/m2))
20,80
24,7
33,4
22,3
25
23,15
27,2
24
24,8
21,4
35,6
22,3
24,8
22,3
24,8
22,7
30
22,2 | HF Risk fact
Hypertension
no
yes
no
no
no
yes
no
yes
no
yes
no
no
yes
no
no
yes
no
no
yes
 | smoking
yes
no
no
no
no
yes
no
no
no
no
no
no
no
no
no
no | Diabetes
Doubetes
no
no
no
no
no
no
no
no
no
no | Relevant ongoing of the time of the consolution of
 |
| Patient 4 Non-COVID-19 1 Non-COVID-19 2 Non-COVID-19 3 Non-COVID-19 3 Non-COVID-19 4 Non-COVID-19 4 Non-COVID-19 5 Non-COVID-19 6 Non-COVID-19 7 Non-COVID-19 7 Non-COVID-19 1 post-COVID-19 3 post-COVID-19 4 post-COVID-19 4 post-COVID-19 5 post-COVID-19 5 post-COVID-19 7 post-COVID-19 7 post-COVID-19 8 post-COVID-19 7 post-COVID-19 7 post-COVID-19 7 | Scarnor (Tresia) NA 3 3 NA 1.5 1.5 NA 1.5 1.5 1.5 3 3 3 3 3 3 3 3 3 3 3 3 3 3 | EF (%) NA 56 NA 53 52 49 53 749 749 749 751 753 333 588 444 554 552 555 551 551 551 551 | LVEDD
(mm)
NA
53
NA
NA
NA
NA
NA
51
S1
51
55
57
55
57
55
57
55
57
58
58 | IVEDU
(YEII) NA 155 A 157 A 167 B 188 I 188 I 197 I 149 I 149 I 141 I 142 I 143 I 144 I 153 I 144 I 154 I 164 I 164 I 165 I 164 I 164 I 165 I 165 I
 | NA 1281 NA 1281 NA 1085 1005-1080 NA 1005-1081 1007-1005 1024-1031 1025-1081 1025-1082 1031-1032 1032-1031 1287 13000 1231 1232 1234 13030 1235
 | Native Native Native 12 (ms) 46 NA 46 NA 48-62 39-50 NA 48-62 39-50 NA 43 49-52 49-51 40 45 46 57 49 57 49 57 49 57 | ECV
(%) NA 25 NA NA NA 32 NA 32 23 29 29.5 24 23 24 25 | Cardise Mycoan
Cardise Mycoan
Racute Mycoan
no
NA
NA
yes
NA
yes
NA
NA
yes
NA
no
no
no
no
no
no
no
yes
yes | jace MRT Withing Is Contention yes NA no No no No no No yes No yes No | Edema P P no 1 no 1 NA 1 yes 1 yes 1 no 1 yes 1 yes 1 yes 1 yes 1 yes 1
 | Pericaa
Pericaa
no
no
NA
no
no
no
no
no
no
no
no
no
no | Percardial Percardial Percardial 100 100 100 100 100 | Incute (icarditis) and (icardi |
Hypoto
border
Banco
Banco
Hypoto
Banco
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypoto
Hypot | NA
NA
NA
NA
NA
NA
NA
NA
NA
NA | and ated ated ated ated ated ated ated ate | PT Peea
((ng/))
2257
3
90
728
9
9
428
9
428
NA
1371
7
276
48
6
6
56
26
NA
5 | k NTpeakation <<
 | Labor 1 2 7 37 14 2 75 365 300 1 1 1 2 75 365 300 1 1 0 14 1
 1 1 1 1 1 1 1 1 1 1 | altory p. kit peak (U/I) <190
 | Action of the second se | CRP pask c-s 2.1 1.9 27.8 1.9 0.5 150.9 1.7 1.3 0.7 2.79 457.8 30.1 9.4 9.1 9.4 107.4 1.2 | BMI
(kg/m2) 24.7 33.4 22.3 25 23.16 27.2 24.7 19.9 21.4 35.6 22.3 24.7 25.7 30 27.2 23.3 | HF Risk fact
Hypertension
700
998
000
000
000
000
000
000
000
000
0
 | smoking
yes
no
no
no
no
yes
no
no
no
no
no
no
no
no
no
no
no
no
no | Diabetes
Doubetes
Doubetes
no
no
no
no
no
no
no
no
no
no | Relevant ongoing or
EMB politicion
Catecholamine /
Seducion threapy
arrow 246
BB, ACEI
BB, ACEI
BB, ACEI
BB, ACEI
BB, ACEI
BB, ACEI
BB, ACEI
BB, ACEI
Comparison
BB, ACEI
Activitationica
and
Disretics
Characteristics
BB, ACEI
Activitationica
BB, ACEI
Activitationica
BB, ACEI
Menocial
Disretics
BB
none (bud 2 months
Disretics
BB
none (bud 2 months
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
Disretics
 |
| Patient C Non-COVID-19 1 Non-COVID-19 2 Non-COVID-19 2 Non-COVID-19 3 Non-COVID-19 4 Non-COVID-19 4 Non-COVID-19 5 Non-COVID-19 6 Non-COVID-19 7 Non-COVID-19 7 Non-COVID-19 1 post-COVID-19 4 post-COVID-19 5 post-COVID-19 5 post-COVID-19 6 post-COVID-19 6 post-COVID-19 7 post-COVID-19 7 post-COVID-19 8 post-COVID-19 8 post-COVID-19 9 post-COVID-19 19 | Scanner
Scanner
Troslay
NA
3
NA
1.5
NA
1.5
1.5
1.5
3
3
3
3
3
3
3
3
3
1.5 | EF (%) NA 56 NA 53 52 49 52 49 NA 51 25 33 58 44 58 42 51 55 | LVEDD
(mm)
NA
53
NA
NA
NA
NA
NA
51
51
55
55
55
55
55
57
8
47 | NA 155 NA 167 NA 188 170 NA 188 170 142 113 164 158 161 158 161 158 161 162 188 181 182 183 184 185 184 185 184
 | NA 1281 NA 1281 NA 1088 NA 1089 NA 1080 NA 1081 NA 1082 NA 105-1080 NA 1087-1085 1084-1131 1287 1287 1287 1287 1287 1287 1287 1287 1287 1287 1287 1287 1287 1287 1287 1287 1287 1287 1283
 | Native Native Native 12 (ms) A6 NA 46 NA 46 NA 48-62 39-50 NA 43 49-51 40 45 46 577 49 500 53-58 | ECV
(%)
NA
25
NA
NA
NA
32
NA
23
29
29.5
24
23
24
23
24
23
24
23
24
24 | Cardiae Myocar
Cardiae Myocar
Route Myocar
no
NA
NA
yes
NA
yes
NA
no
no
no
no
no
no
no
no
no
no
no
yes | Jace MRT Willis Ischernic Visit Ischernic Visit Non Visit | Edema P P no 1 no 1 NA 1 yes 1 yes 1 no 1 <tr< td=""><td>Pericaa
Pericaa
no
no
NA
no
no
no
no
no
no
no
no
no
no
no
no</td><td>Percaratia Percaratia Percaratia 101 Percaratia Percaratia 102 Percaratia Percaratia 103 Percaratia Percaratia 104 Percaratia Percaratia 105 Percaratia Percaratia 104 Percaratia Percaratia 105 Percaratia Percaratia 105 Percaratia Percaratia 105 Percaratia Percaratia 105 Percaratia Percaratia 106 Percaratia Percaratia 106 Percaratia Percaratia 107 Percaratia Percaratia 108 Percaratia Percaratia</td><td>cute cute cute</td><td>Hypoloi
Hypoloi
Dodderi
Infess
Redu
Redu
Redu
and</td><td>NA
NA
NA
NA
NA
NA
NA
NA
NA
NA</td><td>Tree in the second seco</td><td>App T pesson <14</td> 257 3 90 728 9 428 NA 1371 7 87 276 48 6 56 28 NA 5383</tr<> |
Pericaa
Pericaa
no
no
NA
no
no
no
no
no
no
no
no
no
no
no
no | Percaratia Percaratia Percaratia 101 Percaratia Percaratia 102 Percaratia Percaratia 103 Percaratia Percaratia 104 Percaratia Percaratia 105 Percaratia Percaratia 104 Percaratia Percaratia 105 Percaratia Percaratia 105 Percaratia Percaratia 105 Percaratia Percaratia 105 Percaratia Percaratia 106 Percaratia Percaratia 106 Percaratia Percaratia 107 Percaratia Percaratia 108 Percaratia Percaratia | cute | Hypoloi
Hypoloi
Dodderi
Infess
Redu
Redu
Redu
and | NA
NA
NA
NA
NA
NA
NA
NA
NA
NA | Tree in the second seco | App T pesson <14 | k NTpeakation <
<
2'' 4 11 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111

 | Labor 1 2 1 4 5 5 2 2 14 14 14 15 16 11 11 11 11 11 11 11 11 11 11 11 11 11 12 13 14 14 14 15 16 17 17 18 18 19 10 11 11 12 13 14 14 15 16 17 17 18 18 | altory p. k pair 222 84 64 131 74 119 91 58 75 138 383 34 78 1118 338 25 1466 271
 | Arrowski stranger
CK-MB peek
-224
95,1
31
NA
26,3
15,6
16,7
13,7
13,2
25,7
15,4
32,1
18,6
20,7
20,4
19,5
Na
15,3
37 | CRP pask (mg) - 2.1 1.9 2.7.8 1.9 0.5 158,9 1.7 1.3 0.7 2.79 457,8 30,1 9,4 9,1 9,4 107,4 1.2 20,4 | BMU
(kg/m2)
20.8
24.7
33.4
22.3
25
23.15
27.2
24
19.9
21.4
35.6
22.3
24.8
22.3
24.8
22.3
24.8
22.3
24.8
22.3
24.8 | HF Risk fact
Hypertension
no
yes
no
no
no
yes
no
no
yes
no
no
no
no
no
no
no
no
no
no
no
no
no
 | smoking
yes
no
no
no
no
yes
no
no
no
no
no
no
no
no
no
no
no
no
no | Diabetes Doubletes no | Relevant ongoing
Party at the time of
Dark and the time of
Sector of the sector of
Sector of the
sector of
BB, ACEI
Dark and the sector of
BB, ACEI
BB, ACEI
Dark and
BB, ACEI
Dark and
Dark and
D |
| Patient S Non-COVID-19 1 Non-COVID-19 2 Non-COVID-19 2 Non-COVID-19 3 Non-COVID-19 4 Non-COVID-19 4 Non-COVID-19 5 Non-COVID-19 6 Non-COVID-19 7 Non-COVID-19 7 Non-COVID-19 8 post-COVID-19 1 post-COVID-19 9 post-COVID-19 3 post-COVID-19 4 post-COVID-19 4 post-COVID-19 5 post-COVID-19 5 post-COVID-19 7 post-COVID-19 7 post-COVID-19 8 post-COVID-19 8 post-COVID-19 9 post-COVID-19 10 | Scanner
Tresla
NA
3
NA
1.5
NA
1.5
1.5
NA
3
1.5
3
3
3
3
3
3
3
3
1.5 | EF (%) NA 56 NA 53 S3 0 52 49 A9 0 A1 51 25 33 58 44 58 44 58 42 51 55 | LVEDD
(MM)
NA
S3
NA
NA
NA
NA
NA
S5
S5
S5
S5
S5
S5
S5
S5
S5
S5
S5
S5
S5 | Iverbuy NA NA 155 NA 167 188 170 149 149 149 149 141 149 142 141 148 148 148 148 149 141 148 158 168 161 168 161 168 162
 | Native
T1 (ms) Na NA 1261 108 1088 NA 1088 NA 1055-1088 1005-1080 NA 1007-1095 1007-1095 10087-1095 1034-1113 12287 1322 12121 12231 12255 1248
 | Native
Native
T2 (ms)
NA
46
58
NA
48-62
39-50
NA
49-52
49-52
49-52
49-51
49-52
49-51
49-52
50
50
50
50 | ECV
(%)
NA
25
NA
NA
32
NA
23
29
29.5
24
27
23
24
27
23
24
24
24
24 | Cardiae Myocar
Cardiae Myocar
Route Myocar
no
NA
NA
yes
NA
yes
NA
no
no
no
no
no
no
no
no
no
no
no | Jace MRT Visit Ischernic Visit Ischernic Visit NA Visit NA Visit Visit Visit NA Visit Visit Visit Visit Visit Visit Visit NA Visit Visit Visit NA Visit NA </td <td>Edema P P no 1 no 1 NA 1 yes 1 yes 1 yes 1 no 1 no 1 no 1 no 1 yes 1 no 1 yes 1</td> <td>Pericas
no
NA
no
NA
no
NA
no
NA
no
no
no
no
no
no
no
no
no
no</td> <td>Percardial Percardial Percardial indial Percardial Percardial indial non Percardial</td> <td>cute cute cute</td> <td>Approximation of the second se</td> <td>no
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA</td> <td>Trd I</td> <td>App T pesson <14</td> 257 3 90 728 9 428 NA 1371 7 87 276 48 6 56 26 NA 5 383 | Edema P P no 1 no 1 NA 1 yes 1 yes 1 yes 1 no 1 no 1 no 1 no 1 yes 1 no 1 yes 1
 | Pericas
no
NA
no
NA
no
NA
no
NA
no
no
no
no
no
no
no
no
no
no | Percardial Percardial Percardial indial Percardial Percardial indial non Percardial | cute | Approximation of the second se | no
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA | Trd I | App T pesson <14 | k NTpeaka <
 | Labor Labor </td <td>altory
p.
(U/n)
≤190
222
84
64
131
74
119
91
75
138
383
34
78
118
338
25
1466
271</td> <td>Arran energy of CK-MB peek
(CK-MB peek
-224
95,1
31
NA
26,3
15,6
16,7
13,2
25,7
15,4
32,1
15,4
32,1
18,6
20,7
20,4
19,5
Na
15,5
37</td> <td>CRP pask <</td> 2.1 1.9 2.7.8 1.9 0.5 159,9 1.7 1.3 0,7 2.79 457,8 30,1 9,4 9,1 9,4 107,4 1,2 20,4 | altory p.
(U/n)
≤190
222
84
64
131
74
119
91
75
138
383
34
78
118
338
25
1466
271
 | Arran energy of CK-MB peek
(CK-MB peek
-224
95,1
31
NA
26,3
15,6
16,7
13,2
25,7
15,4
32,1
15,4
32,1
18,6
20,7
20,4
19,5
Na
15,5
37 | CRP pask < | (kg/m2)
20.8
24.7
33.4
22.3
25
23.15
27.2
24.1
19.9
21.4
35.6
22.3
24.8
25.7
30
22.2
30
22.2
30
22.2
24.6 | HF Risk fact Hypertension no yes no yes yes
 | smoking
yes
no
no
no
no
yes
no
no
no
no
no
no
no
no
no
no
no
no
no | Diabetes
Doubetes
no
no
no
no
no
no
no
no
no
no | Relevant ongoing of the time of time of the time of time o
 |
| Patient C Non-COVID-19 1 Non-COVID-19 2 Non-COVID-19 3 Non-COVID-19 3 Non-COVID-19 4 Non-COVID-19 4 Non-COVID-19 5 Non-COVID-19 6 Non-COVID-19 7 Non-COVID-19 7 Non-COVID-19 8 post-COVID-19 1 post-COVID-19 1 post-COVID-19 3 post-COVID-19 5 post-COVID-19 6 post-COVID-19 7 post-COVID-19 7 post-COVID-19 8 post-COVID-19 7 post-COVID-19 9 post-COVID-19 7 post-COVID-19 10 post-COVID-19 10 post-COVID-19 10 post-COVID-19 10 | Scanner
Trosia)
NA
3
NA
1.5
1.5
1.5
1.5
1.5
3
3
3
3
3
3
3
3
3
1.5
1.5 | EF (%) NA 56 NA 53 53 33 54 49 51 33 58 44 588 44 588 42 511 55 555 59 | LVEDD NA S3 NA S3 NA NA NA NA NA NA NA NA NA S1 S1 S57 57 55 57 56 57 S6 57 S7 S8 57 S9 57 S1 | Iverbuy Iverbuy NA 155 NA 167 167 188 1700 1 184 1 149 1 142 1 143 1 144 1 158 1 164 1 164 1 168 1 164 1 164 1 164 1 164 1 164 1 162 1 164 1 165 1 162 1 163 1 164 1 165 1 164 1 165 1 164 1 165 1 165 1 165 1 165 1 165 1 16
 | Native
N1 (ms)
NA
1281
NA
1085
NA
1005-1088
NA
1005-1080
NA
1025-1080
NA
1027-1085
1024-1173
1227
1227
1227
1227
1227
1227
1227 | Native
Native
T2
(ms)
NA
46
NA
48-62
39-50
NA
49-52
49-52
49-52
49-52
49-52
49-51
40
50
53-58
41 | ECV
(%) NA 25 NA NA NA 32 NA 32 PA 23 29 29.5 24 27 23 24 25 NA | Cardise MA
Cardise MA
Cardise MA
Cardise Ma
NA
NA
NA
Yes
NA
NA
Yes
NA
NA
NA
Yes
NA
NA
NA
NA
NA
Yes
NA
NA
NA
Yes
NA
NA
Yes
NA
NA
Yes
NA
NA
Yes
NA | Jack MRT Wittis Ischerribuic Varia Ischerribuic Varia Varia Varia Navaria Varia Varia Varia Varia Varia Varia | Edemail F Ro I NA I Yes I Yes I NA I Yes I NA I <t< td=""><td>Pericas
no
NA
no
NA
no
NA
no
NA
no
NA
no
no
no
no
no
no
no
no
no
no
no
no
no</td><td>Percardial Percardial Percardial 1 Percardial Percardial 1 no 1 1 no 1</td><td></td><td>Above and a second seco</td><td>no no NA NA</td><td>Index of the second sec</td><td>App T pees <14</td> 257 3 90 728 9 428 NA 1371 7 87 276 48 6 56 28 NA 50 383 501</t<> | Pericas
no
NA
no
NA
no
NA
no
NA
no
NA
no
no
no
no
no
no
no
no
no
no
no
no
no | Percardial Percardial Percardial 1 Percardial Percardial 1 no 1
 | | Above and a second seco | no no NA | Index of the second sec | App T pees <14 | k NTppexsuper <td>Labor Labor Labor<!--</td--><td>altory p. kit p.enaity (U/n) 222 84 64 131 74 119 91 58 75 138 383 34 78 1118 338 25 146 271 140</td><td>Action of the second se</td><td>CRP pask c-s- 2.1 1.9 27.8 1.9 0.5 156.9 1.7 1.3 0.7 2.79 457.8 30,1 9.4 107,4 1.17,4 1.22 2.24 8.9</td><td>BHU BHU BHU BHU 20.8 24.7 33.4 22.3 23.15 27.2 24 19.9 21.4 35.6 22.3 24.8 25.7 30 27.2 23 24.8 25.7 30 27.2 23 24.8</td><td>HF Risk fact Hypertension no yes no no no no yes yes no yes no</td><td>smoking
yes
no
no
no
no
yes
no
no
no
no
no
no
no
no
no
no
no
no
no</td><td>Diabetes Diabetes no no</td><td>Relevant ongoing of
EMB collection
Categoricalismine /
Sedimon margy
and the collection of
BB, ACEI
BB, ACEI
BB, ACEI
BB, ACEI, MRCA
BB, Distration, College
ACE, MRCA
BB, Distration, College
ACE, MRCA
ACE,
MRCA
AC</td></td> | Labor Labor </td <td>altory p. kit p.enaity (U/n) 222 84 64 131 74 119 91 58 75 138 383 34 78 1118 338 25 146 271 140</td> <td>Action of the second se</td> <td>CRP pask c-s- 2.1 1.9 27.8 1.9 0.5 156.9 1.7 1.3 0.7 2.79 457.8 30,1 9.4 107,4 1.17,4 1.22 2.24 8.9</td> <td>BHU BHU BHU BHU 20.8 24.7 33.4 22.3 23.15 27.2 24 19.9 21.4 35.6 22.3 24.8 25.7 30 27.2 23 24.8 25.7 30 27.2 23 24.8</td> <td>HF Risk fact Hypertension no yes no no no no yes yes no yes no</td> <td>smoking
yes
no
no
no
no
yes
no
no
no
no
no
no
no
no
no
no
no
no
no</td> <td>Diabetes Diabetes no no</td> <td>Relevant ongoing of
EMB collection
Categoricalismine /
Sedimon margy
and the collection of
BB, ACEI
BB, ACEI
BB, ACEI
BB, ACEI, MRCA
BB, Distration, College
ACE, MRCA
BB, Distration, College
ACE, MRCA
ACE, MRCA
AC</td> | altory p. kit p.enaity (U/n) 222 84 64 131 74 119 91 58 75 138 383 34 78 1118 338 25 146 271 140 | Action of the second se
 | CRP pask c-s- 2.1 1.9 27.8 1.9 0.5 156.9 1.7 1.3 0.7 2.79 457.8 30,1 9.4 107,4 1.17,4 1.22 2.24 8.9 | BHU BHU BHU BHU 20.8 24.7 33.4 22.3 23.15 27.2 24 19.9 21.4 35.6 22.3 24.8 25.7 30 27.2 23 24.8 25.7 30 27.2 23 24.8 | HF Risk fact Hypertension no yes no no no no yes yes no | smoking
yes
no
no
no
no
yes
no
no
no
no
no
no
no
no
no
no
no
no
no
 | Diabetes Diabetes no | Relevant ongoing of
EMB collection
Categoricalismine /
Sedimon margy
and the collection of
BB, ACEI
BB, ACEI
BB, ACEI
BB, ACEI, MRCA
BB, Distration, College
ACE, MRCA
BB, Distration, College
ACE, MRCA
ACE, MRCA
AC |
| Patient C Non-COVID-19 1 Non-COVID-19 2 Non-COVID-19 3 Non-COVID-19 3 Non-COVID-19 4 Non-COVID-19 4 Non-COVID-19 5 Non-COVID-19 6 Non-COVID-19 7 Non-COVID-19 1 post-COVID-19 1 post-COVID-19 3 post-COVID-19 4 post-COVID-19 4 post-COVID-19 5 post-COVID-19 5 post-COVID-19 6 post-COVID-19 6 post-COVID-19 7 post-COVID-19 7 post-COVID-19 8 post-COVID-19 7 post-COVID-19 9 post-COVID-19 10 Post-COVID-19 10 Post-COVID-19 10 | Scanner
Trosia)
NA
3
NA
1.5
NA
1.5
1.5
NA
3
3
3
3
3
3
3
3
1.5
1.5
1.5 | EF (%) NA 56 NA 53 S3 0 52 49 A9 0 51 0 52 33 58 0 44 58 42 51 53 55 54 55 | LVEDD
NA
53
NA
NA
NA
NA
NA
NA
NA
S1
S1
S1
S5
S8
S8
S7
S8
S8
S7
S1 | LVEDV NA 155 NA 167 NA 188 170 NA 189 1700 NA 184 170 NA 189 1701 142 184 113 184 161 185 188 1202 180
 | Native
T1 (ms) NA 1281 NA 1085 NA 1086 NA 1087 1005-1086 NA 1007-1095 1024-1031 1287 1287 13202 1214 1300 1225 1148 10014
 | Native
Native
Z(ms) NA 46 NA 46 NA 48 98 NA 48 146 98 4952 49-52 49-52 49-52 49-52 49-52 49-52 50 57 49 50 53-58 41 | ECV
(%)
NA
25
NA
NA
NA
32
NA
23
23
23
23
24
24
24
24
24
25
NA
25
NA | Cardise Mycoan
Cardise Mycoan
Route Mycoan
no
NA
NA
yes
NA
yes
NA
no
no
no
no
no
no
no
no
no
no
yes
no
yes | jace MRT Willing Ischerric Vers NA Vers NO Vers NO Vers NO Vers NO Vers NO Vers Vers Vers Vers Vers Vers | Edema F
no 1
NA 1
Yes 1
NA 1
Yes 1
NA 1
Yes 1
NA 1
NA 1
Yes 1
NA 1
NA 1
Yes 1
NA 1
 | Pericaa
Pericaa
no
no
NA
no
no
no
no
no
no
no
no
no
no
no
no
no | Percardia Percardia Percardia 100 100 100 100 100 | no no NA no NA no NA no NA no NA no NA no | Hypok
boot
boot
Redu
Redu
Redu
and
 | no
NA
NA
no
NA
no
NA
no
no
no
no
no
no
no
no
no
no | ind di control de la control d | App T pees <14 | k NTppextorm <td>Laboro (1997) [
100 - 1</td> <td>altory p. k peak 64 131 74 119 91 58 75 138 383 34 78 1118 338 25 146 2711 140</td> <td>CK-MB peak
CK-MB peak
-24
95,1
31
NA
26,3
15,6
16,7
13,2
25,7
15,4
32,1
15,4
32,1
18,6
220,7
20,4
19,5
Na
15,3
37
NA</td> <td>CRP peak <-s</td> 2.1 1.9 2.7.8 1.9 0.5 158.9 1.7 1.3 0.7 2.79 457.8 30.1 9.4 9.1 9.4 9.1 9.4 9.1 9.4 9.1 9.4 9.1 9.4 9.1 9.4 9.1 9.4 9.1 9.4 9.1 9.4 9.1 9.1 9.2 9.3 9.4 9.4 9.1 9.2 9.3 9.4 9.4 9.4 9.4 9.5 9.6
 | Laboro (1997) [
100 - 1
 | altory p. k peak 64 131 74 119 91 58 75 138 383 34 78 1118 338 25 146 2711 140 | CK-MB peak
CK-MB peak
-24
95,1
31
NA
26,3
15,6
16,7
13,2
25,7
15,4
32,1
15,4
32,1
18,6
220,7
20,4
19,5
Na
15,3
37
NA
 | CRP peak <-s | (Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)
(Bug)(| HF Risk fact Hypertension no yes no yes yes no | smoking
yes
no
no
no
no
yes
no
no
no
no
no
no
no
no
no
no
no
no
no
 | Diabetes
no
no
no
no
no
no
no
no
no
no | Relevant ongoing or
EMB politicion.
Cadecholamine /
Sedadon threapy
arros 246.
BB, ACEI
BB, ACEI
Minoxidi
Duretics
Charlissical
BB, ACEI
BB, ACEI
BB, ACEI
Minoxidi
Duretics
BB
none
Control Control
BB
BB
Duretics
Charlissical
Control
BB
BB
Diretics
BB
BB
Diretics
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control
Control |
| Patient 2 Non-COVID-19 1 Non-COVID-19 2 Non-COVID-19 2 Non-COVID-19 3 Non-COVID-19 4 Non-COVID-19 4 Non-COVID-19 5 Non-COVID-19 6 Non-COVID-19 7 Non-COVID-19 7 Non-COVID-19 8 post-COVID-19 7 post-COVID-19 9 post-COVID-19 3 post-COVID-19 4 post-COVID-19 6 post-COVID-19 7 post-COVID-19 7 post-COVID-19 8 post-COVID-19 8 post-COVID-19 9 post-COVID-19 10 Post-COVID-19 10 Post-Vaccination 1 Post-Vaccination 2 Post-Vaccination 2 | Scanner
Tresia)
NA
3
NA
1.5
NA
1.5
NA
1.5
1.5
3
3
3
3
3
3
3
3
1.5
1.5
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3 | EF Ma S6 NA 56 NA 52 49 62 49 63 NA 51 33 58 44 58 44 59 55 535 55 | LVEDD
(MM)
NA
53
NA
NA
NA
NA
NA
NA
S51
S51
S57
S57
S56
S58
S58
S57
S58
S57
S58
S58
S57
S58
S58
S58
S58
S58
S58
S58
S58
S58
S58 | NA I NA 155 NA 167 188 1 189 1 149 1 149 1 149 1 149 1 149 1 149 1 149 1 149 1 149 1 149 1 149 1 149 1 149 1 149 1 149 1 140 1 158 1 161 1 188 1 122 1 180 1 122 1 130 1
 | NA 1281 NA 1281 NA 1085-1080 NA 1055-1081 0007-1055 1007-1055 1034-1113 1287 1287 1287 1287 1287 1211 1287 1214 1297 1214 1297 1214 1297 1214 1297 1214 1297
 | Native
T2 (ms)
NA
46
58
58
3950
3950
4852
4951
4952
4951
4951
4951
4951
5550
5550
5358 | ECV
(%) NA 25 NA NA NA 32 NA 32 23 23 24 23 24 25 24 25 NA 23 24 25 NA 25 NA 26 23 | Cardiae My Card
Cardiae My Card
Racute My Card
NA
NA
NA
Yes
NA
NA
Yes
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA | Jack MRT Willing Ischermic Variation yass NA no NA yass NA yass NA yass NA yass | Edema P P no I NA I yes I yes I NA I yes I no I no I no I no I yes I no I yes I
 | Pericaa
Pericaa
no
no
NA
no
NA
no
no
no
no
no
no
no
no
no
no | Percaration Percaration Percaration indiant Percaration Percaration indiant indiant Percaration indiant indiant indiant indint i | no | Hypoki
Hypoki
boother
Redu
Redu
Redu
Redu
and
 | no
NA
NA
no
NA
no
NA
no
NA
no
NA
no
NA
no
NA
no
NA
no
NA
no
NA
no
NA
no
NA
no
NA
no
NA
no
NA
no
NA
no
NA
no
NA
no
NA
no
NA
NA
no
NA
NA
no
NA
NA
no
NA
NA
no
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA | Image: New Section 1 Image: New Section 1 and dided dide | App T pees cr(ng/n) cr(14) 257 3 90 728 9 428 NA 1371 7 87 2766 48 6 56 26 NA 5 383 501 513 | k NTp:/peaks/second <
 | Labor Labor </td <td>altory p. <190</td> <
 | altory p. <190 | Arran energy of CK-MB peek
(CK-MB peek
-224
95,1
31
NA
26,3
15,6
16,7
13,2
25,7
15,4
32,1
15,4
32,1
18,6
20,7
20,4
19,5
Na
15,3
37
NA
23,5
 | CRP pask (mg) 2.1 1.9 2.7.8 1.9 2.7.8 1.9 0.5 1.50.9 1.7 1.3 0.7 2.79 457.8 30.1 9.4 9.1 107.4 1.2 20.4 8.9 5 | (kg/m2)
20.8
24,7
33.4
22.3
25
23.15
27,2
24
24,8
25,7
24,8
22,3
24,8
22,3
30
27,2
23
24,8
22,3
30
27,2
23
24,6
22,3 | HF Risk fact Hypertension no yes no | ine
smoking
yes
no
no
no
no
yes
no
no
no
no
no
no
no
no
no
no
no
no
no
 | Diabetes no | Relevant ongoing
Parage at the time of
Bill Societion of
Seaton therapy
amo 2An
none
BB, ACEI
BB, ACEI
Comparison
ACE
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton
Seaton |
| Patient S Non-COVID-19 1 Non-COVID-19 2 Non-COVID-19 2 Non-COVID-19 3 Non-COVID-19 4 Non-COVID-19 4 Non-COVID-19 5 Non-COVID-19 6 Non-COVID-19 7 Non-COVID-19 7 Non-COVID-19 8 post-COVID-19 1 post-COVID-19 9 post-COVID-19 3 post-COVID-19 1 post-COVID-19 4 post-COVID-19 5 post-COVID-19 5 post-COVID-19 7 post-COVID-19 7 post-COVID-19 8 post-COVID-19 8 post-COVID-19 9 post-COVID-19 10 Post-COVID-19 10 Post-COVID-19 10 Post-COVID-19 10 Post-COVID-19 10 Post-COVID-19 10 Post-COVID-19 10 | Scanner Tresia) NA 3 NA 1.5 NA 1.5 NA 3 1.5 1.5 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 | EF Sec NA 56 NA 53 S3 52 49 52 49 53 51 33 58 44 58 44 58 53 42 51 51 55 59 58 | LVEDD
NA
S3
NA
NA
NA
NA
NA
S1
S1
S5
S5
S5
S5
S5
S5
S5
S5
S5
S5
S5
S5
S5 | IveEpy IveEpy NA 155 NA 167 186 170 170 149 1277 1 149 1 149 1 149 1 149 1 149 1 149 1 149 1 149 1 149 1 158 1 168 1 122 1 188 1 190 1 190 1 191 1
 | NA 1261 NA 1281 NA 1088 NA 1087-1085 1005-1080 NA 1005-1081 1005-1082 1027 10287 10247 10241113 12287 12121 12251 1148 10141
 | Mathem Mathem Mathem MA 46 NA 4862 3950 A4862 3950 A4862 4862 4951 40 40 40 40 550 5358 41 41 | ECV
(%) NA 25 NA NA NA 32 NA 32 23 29 295 24 27 23 24 25 NA 26 23 26 23 24 | Cardiae Myocar
Cardiae Myocar
NA
Cactie Myocar
NA
NA
NA
Yes
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA | Jace MRT Uits Ischernic Variation Ischernic Variation Variation NA NA | Edemail F no 1 no 1 NA 1 yes 1 yes 1 yes 1 no 1 no 1 no 1 no 1 yes 1 no 1 yes 1
 | Pericaa
no
no
NA
no
no
NA
no
no
no
no
no
no
no
no
no
no
no
no
no | Percardial Percardial Percardial indial reditionant reditionant indial non indial indindindindindindindindindindindindindi | no | Hypological
Hypological
Hypological
Hypological
Hypological
Hypological
Hypological
Redu
Redu
Redu
Redu
Redu
Redu
 | no no NA | Trd Image: second se | App T pees cr(ng/n) cr(14) 257 3 90 728 9 428 NA 1371 7 87 2276 48 6 56 283 501 513 60 | kk NTpipko 0<52
 | Labor 1 1 2 1 14 2 36 2 375 1 0 1 0 1 0 2 14 2 14 2 14 2 14 2 14 2 14 2 14 2 14 2 14 2 14 2 14 2 14 2 14 2 14 2 14 2 14 2 14 2 15 2 16 2 17 2 17 2 17 2 17 2 17 2 17 2 18 2 17
 | attory p: attory p: (U/n) <190 | Arran energy of CK-MB peek
(CK-MB
peek
-24
96,1
31
NA
26,3
15,6
16,7
13,2
25,7
15,4
32,1
15,4
32,1
18,6
20,7
20,4
19,5
Na
15,5
Na
15,5
16,7
13,2
25,7
15,4
32,1
15,4
32,1
15,5
15,5
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,3
37
NA
23,5
15,7
15,3
15,3
15,3
15,3
15,5
15,3
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15 | CRP pask (mg) 2.1 1.9 2.7.8 1.9 2.7.8 1.9 0.5 1.10 2.7.8 1.9 0.5 1.10 2.7.9 4.57.8 30.1 9.4 9.1 9.4 107.4 1.2 20.4 8.9 5 | (kg/m2)
20.8
24.7
33.4
22.3
25
23.15
27.2
24
19.9
21.4
35.6
22.3
24.8
25.7
30
27.2
23
24.6
22.3
24.6
22.8
24.5 | HF Risk fact Hypertension no yes no
 | smoking
yes
no
no
no
no
no
yes
no
no
no
no
no
no
no
no
no
no
no
no
no | Dabetes no | Relevant ongoing of the same o |
| Patient C Non-COVID-19 1 Non-COVID-19 2 Non-COVID-19 3 Non-COVID-19 3 Non-COVID-19 4 Non-COVID-19 5 Non-COVID-19 5 Non-COVID-19 6 Non-COVID-19 7 Non-COVID-19 7 Non-COVID-19 8 post-COVID-19 1 post-COVID-19 1 post-COVID-19 3 post-COVID-19 5 post-COVID-19 5 post-COVID-19 7 post-COVID-19 8 post-COVID-19 8 post-COVID-19 7 post-COVID-19 9 post-COVID-19 7 post-COVID-19 10 Post-COVID-19 10 Post-Vaccination 1 Post-Vaccination 2 Post-Vaccination 2 Post-Vaccination 3 | Scanner
Scranner
NA
3
NA
1.5
NA
1.5
NA
3
3
3
3
3
3
3
3
3
3
3
1.5
1.5
3
3
3
3
3
1.5
1.5
3
3
3
1.5
1.5
3
3
3
1.5
1.5
3
3
3
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5 | EF NA 56 NA 53 NA 53 NA 52 49 53 NA 54 33 551 33 58 34 58 51 51 55 53 54 54 55 55 59 56 56 | LVEDD
(mm)
NA
53
NA
NA
NA
NA
NA
51
S1
57
57
55
57
58
58
57
58
57
58
57
57
58
57
58
57
58
57
58
57
58
57
57
58
57
57
58
57
57
58
53
57
57
57
57
57
57
57
57
57
57
57
57
57 | LVEDV Na NA 155 NA 167 188 167 NA 167 188 170 NA 188 170 1 149 277 142 1 158 1 164 158 181 165 188 1 198 1 198 1 199 175 197 175
 | Native NA 1281 NA 1281 NA 1085 NA 1086 NA 1087 1005-1088 NA 1007-1095 1024-1031 1024-1031 12275 1214 12021 1214 12031 1225 1148 1024 1237 1237 | Native
T2
(ms)
NA
48
58
58
7
8
48
62
39
50
7
4
9
50
4
9
50
4
9
50
5
5
7
4
9
5
7
5
7
5
5
5
5
8
4
1
4
5
7
4
5
7
5
7
5
7
5
7
5
7
5
7
5
7
7
7
7 | E(%)
NA
25
NA
NA
32
NA
23
23
24
23
24
24
24
24
25
NA
24
25
NA
24
25
24
24
22
24
22
24
24
22
24
24
25
24
24
25
24
24
25
24
24
25
25
24
25
25
24
25
25
26
26
26
27
26
27
26
26
27
26
26
27
26
26
26
26
26
26
26
26
26
26
26
26
26 | Cardise MA
Caditse MA
Caditse Ma
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA | Jace MRT Witts Ischernic Vas NA | Edema P F no 1 NA 1 NA 1 NA 1 NA 1 Yes 1 NA 1 Yes 1 NO 1 NO 1 Yes 1
 | Pericaan
no
no
NA
no
no
NA
no
no
no
no
no
no
no
no
no
no
no
no
no | Percaratia Percaratia Percaratia 1 Percaratia Percaratia 1 NA 1 | | Reduce Point and a constraint of the second
 | no NA | Image: New Section 1 Image: New Section 1 Image: New Section 1 Image: New Section 1 Image: New Section 1 Image: New Section 1 Image: New Section 1 Image: New Section 1 Image: New Section 1 Image: New Section 1 Image: New Section 1 Image: New Section 1 Image: New Section 1 Image: New Section 1 Image: New Section 1 Image: Ne | PT Pees < | kk NTp:peak.org e 22: 22: 11: 11: 11: 11: 11: 11: 11: 11: 11: 11: 11: 11: 11: 11: 11: 11: 12: 29: 29: 29: 29: 29: 29: 29: 20: 29: 14: 4 6 6 6: 6 9: 77: 9: 9:
 | Labor 1 2 36 37 14 2 36 37 36 37 36 37 36 37 38 39 2 2 39 2
 | attory p: <190 | Arrowski stranger
CK-MB peak
-24
95,1
31
NA
26,3
15,6
16,7
13,7
13,2
25,7
15,4
32,1
15,4
32,1
15,4
32,1
15,4
32,1
15,4
32,1
15,5
Na
15,5
Na
15,3
37
NA
 | CRP peak <-s | (kg/m2)
20.8
24,7
33,4
22,3
25
23,15
27,2
24,1
30,6
22,3
24,8
25,7
30
27,2
23,3
24,8
25,7
30
27,2
23,3
24,8
25,7
2,3
24,8
25,7
2,3
24,8
25,7
2,3
24,8
25,7
2,3
24,8
25,7
25,7
25,7
25,7
25,7
25,7
25,7
25,7 | HF Risk fact Hypertension no yes no yes no | vors Smoking yes no
 | Diabetes
no
no
no
no
no
no
no
no
no
no | Relevant ongoing or
EMB collection Catecholonine /
Section for any content of
arrow 24 and 25 and |
| Patient C Non-COVID-19 1 Non-COVID-19 2 Non-COVID-19 3 Non-COVID-19 3 Non-COVID-19 4 Non-COVID-19 4 Non-COVID-19 5 Non-COVID-19 6 Non-COVID-19 7 Non-COVID-19 7 Non-COVID-19 1 post-COVID-19 1 post-COVID-19 2 post-COVID-19 3 post-COVID-19 4 post-COVID-19 4 post-COVID-19 5 post-COVID-19 5 post-COVID-19 7 post-COVID-19 8 post-COVID-19 9 post-COVID-19 9 post-COVID-19 10 Post-COVID-19 10 Post-COVID-19 10 Post-COVID-19 3 post-COVID-19 4 post-COVID-19 7 post-COVID-19 10 Post-COVID-19 10 Post-COVID-19 10 Post-COVID-19 10 Post-Vaccination 1 Post-Vaccination 3 Post-Vaccination 3 Post-Vaccination 4 | Tesia)
NA
3
NA
1.5
NA
1.5
1.5
1.5
3
3
3
3
3
3
3
3
1.5
1.5
1.5
3
3
3
3
3
3
3
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5 | EF % NA 56 NA 53 SA 53 A9 33 51 25 33 34 58 34 51 58 49 53 53 53 54 53 55 53 58 56 58 56 58 56 | LVEDD
NA
S3
NA
NA
NA
NA
NA
NA
S1
S5
S7
47
55
57
55
58
57
58
58
57
58
58
57
58
58
57
58
58
57
58
58
57
58
58
57
58
58
57
58
58
58
53
58
58
58
58
58
58
58
58
58
58
58
58
58 | NA I NA I 155 I NA I 167 I 188 I 170 I 184 I 149 I 149 I 141 I 142 I 143 I 144 I 142 I 143 I 144 I 142 I 143 I 144 I 158 I 164 I 188 I 188 I 188 I 198 I 198 <td< td=""><td>NA 1281 NA 1281 NA 1085 NA 1084 NA 1085 NA 1086 NA 1051080 NA 1051081 1005-1080 1041 1057 1054 12275 1300 12274 1300 12275 1448 1014 1225 1449 10241</td><td>Nation
T2 (ms)
NA
48
58
58
58
3950
3950
4852
4952
4952
4952
4955
40
5556
5358
40
55558
41
1
41
41
43</td><td>EGV
(%) NA 25 NA NA NA 32 NA 32 23 23 24 27 23 24 27 23 24 25 NA 23 24 25 NA 26 27 23 24 25 NA</td><td>Cardise Mycoan
Cardise Mycoan
Route Mycoan
NA
NA
NA
NA
NA
NA
NA
NA
NA</td><td>Jace MRT Varial Varial</td><td>Edema // F no 1 no 1 NA 1 yes 1 NA 1 yes 1 no 1 no 1 no 1 no 1 no 1 no 1 yes 1 no 1 yes 1 yes 1 yes 1 yes 1 yes 1 yes 1 no 1 yes 1 yes 1 no 1 yes 1 no 1 no 1 no 1 no 1 no 1 no 1</td><td>Pericaen
no
NA
no
NA
no
NA
no
no
no
no
no
no
no
no
no
no
no
no
no</td><td>Percaratia Percaratia Percaratia 1 Percaratia Percaratia 1 NA Percaratia</td><td></td><td>Hypok-
boot T-R
times s
Redu
Point R
Redu
Redu
and</td><td>no NA NA</td><td>Tref
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free</td><td>pr Peae
(reg/)
3
90
728
9
428
NA
1371
7
276
48
6
6
5
6
6
5
6
6
5
6
5
5
383
501
513
29
9
9</td><td>kk NTp:peak peak 22' 4 11' 15 3' 33 3' 33 3' 44(4) 2' 9 2' 141 15' 44(4) 4' 4 6' 66 6' 99 7'' 11' 5'' 12' 7'' 9'' 9'' 9'' 9''' 9'' 9''' 9''' 9'''' 9''' 9''''' 9''''
 9''''' 9'''' 9''''''' 9'''' 8''''''''''''''''''''''''''''''''''''</td><td>Labor 14 2 36 7 14 2 36 114 2 36 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 <t< td=""><td>attory p: > 190 84 64 131 74 119 91 58 75 138 383 341 78 1118 338 225 146 271 140 239 83 104 104</td><td>Action of the second se</td><td>CRP pask (mg) - 2.1 1.9 2.7.8 1.9 2.5 1.9 0.5 1.9 0.5 1.9 0.7 2.79 457.8 30.1 9.4 9.1 9.4 9.1 9.4 9.1 9.4 9.1 9.4 9.1 9.4 9.4 9.4 9.4 9.4 9.4 9.4 9.4 9.4 9.4 9.4 9.4 9.4 9.9 5 2.9.4 3.4</td><td>(kg/m2)
20.8
24,7
33,4
22,3
25
23,15
27,2
24
19,9
21,4
35,6
22,3
24,8
25,7
30
27,2
24,8
25,7
30
22,8
24,6
22,8
22,8
24,6
22,8
24,6
22,8</td><td>HF Risk fact Hypertension no yes no yes no no yes no <</td><td>vors Smoking yes no no no yes no no</td><td>Diabetes no no <td>Relevant ongoing of EMB politicion of the embedded o</td></td></t<></td></td<> | NA 1281 NA 1281 NA 1085 NA 1084 NA 1085 NA 1086 NA 1051080 NA 1051081 1005-1080 1041 1057 1054 12275 1300 12274 1300 12275 1448 1014 1225 1449 10241 | Nation
T2 (ms)
NA
48
58
58
58
3950
3950
4852
4952
4952
4952
4955
40
5556
5358
40
55558
41
1
41
41
43 | EGV
(%) NA 25 NA NA NA 32 NA 32 23 23 24 27 23 24 27 23 24 25 NA 23 24 25 NA 26 27 23 24 25 NA | Cardise Mycoan
Cardise Mycoan
Route Mycoan
NA
NA
NA
NA
NA
NA
NA
NA
NA | Jace MRT Varial
 | Edema // F no 1 no 1 NA 1 yes 1 NA 1 yes 1 no 1 no 1 no 1 no 1 no 1 no 1 yes 1 no 1 yes 1 yes 1 yes 1 yes 1 yes 1 yes 1 no 1 yes 1 yes 1 no 1 yes 1 no 1 no 1 no 1 no 1 no 1 no 1 | Pericaen
no
NA
no
NA
no
NA
no
no
no
no
no
no
no
no
no
no
no
no
no | Percaratia Percaratia Percaratia 1 Percaratia Percaratia 1 NA Percaratia
 | | Hypok-
boot T-R
times s
Redu
Point R
Redu
Redu
and | no NA |
Tref
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free
Free | pr Peae
(reg/)
3
90
728
9
428
NA
1371
7
276
48
6
6
5
6
6
5
6
6
5
6
5
5
383
501
513
29
9
9 | kk NTp:peak peak 22' 4 11' 15 3' 33 3' 33 3' 44(4) 2' 9 2' 141 15' 44(4) 4' 4 6' 66 6' 99 7'' 11' 5'' 12' 7'' 9'' 9'' 9'' 9''' 9'' 9''' 9''' 9'''' 9''' 9''''' 9'''' 9''''' 9'''' 9''''''' 9'''' 8''''''''''''''''''''''''''''''''''''
 | Labor 14 2 36 7 14 2 36 114 2 36 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 <t< td=""><td>attory p: > 190 84 64 131 74 119 91 58 75 138 383 341 78 1118 338 225 146 271 140 239 83 104 104</td><td>Action of the second se</td><td>CRP pask (mg) - 2.1 1.9 2.7.8 1.9 2.5 1.9 0.5 1.9 0.5 1.9 0.7 2.79 457.8 30.1 9.4 9.1 9.4 9.1 9.4 9.1 9.4 9.1 9.4 9.1 9.4 9.4 9.4 9.4 9.4 9.4 9.4 9.4 9.4 9.4 9.4 9.4 9.4 9.9 5 2.9.4 3.4</td><td>(kg/m2)
20.8
24,7
33,4
22,3
25
23,15
27,2
24
19,9
21,4
35,6
22,3
24,8
25,7
30
27,2
24,8
25,7
30
22,8
24,6
22,8
22,8
24,6
22,8
24,6
22,8</td><td>HF Risk fact Hypertension no yes no yes no no yes no <</td><td>vors Smoking yes no no no yes no no</td><td>Diabetes no no <td>Relevant ongoing of EMB politicion of the embedded o</td></td></t<> | attory p: > 190 84 64 131 74 119 91 58 75 138 383 341 78 1118 338 225 146 271 140 239 83 104 104
 | Action of the second se | CRP pask (mg) - 2.1 1.9 2.7.8 1.9 2.5 1.9 0.5 1.9 0.5 1.9 0.7 2.79 457.8 30.1 9.4 9.1 9.4 9.1 9.4 9.1 9.4 9.1 9.4 9.1 9.4 9.4 9.4 9.4 9.4 9.4 9.4 9.4 9.4 9.4 9.4 9.4 9.4 9.9 5 2.9.4 3.4 | (kg/m2)
20.8
24,7
33,4
22,3
25
23,15
27,2
24
19,9
21,4
35,6
22,3
24,8
25,7
30
27,2
24,8
25,7
30
22,8
24,6
22,8
22,8
24,6
22,8
24,6
22,8 | HF Risk fact Hypertension no yes no yes no no yes no < | vors Smoking yes no no no yes no
 | Diabetes no no <td>Relevant ongoing of EMB politicion of the embedded o</td> | Relevant ongoing of EMB politicion of the embedded o |
| Patient 2 Nen-COVID-19 1 Nen-COVID-19 2 Nen-COVID-19 3 Nen-COVID-19 3 Nen-COVID-19 4 Nen-COVID-19 4 Nen-COVID-19 5 Nen-COVID-19 6 Nen-COVID-19 7 Nen-COVID-19 7 Nen-COVID-19 8 post-COVID-19 1 post-COVID-19 9 post-COVID-19 3 post-COVID-19 4 post-COVID-19 4 post-COVID-19 5 post-COVID-19 5 post-COVID-19 6 post-COVID-19 7 post-COVID-19 7 post-COVID-19 8 post-COVID-19 10 Post-Vaccination 1 Post-Vaccination 2 Post-Vaccination 2 Post-Vaccination 3 Post-Vaccination 4 | Scanner Tresia) NA 3 NA 1.5 NA 1.5 NA 1.5 NA 1.5 NA 3 1.5 3 3 3 3 3 1.5 1.5 3 3 1.5 3 1.5 1.5 3 1.5 1.5 3 1.5 3 1.5 3 | EF NA NA 56 NA 53 SA 54 AA 52 49 54 53 53 33 54 54 55 55 55 55 59 56 56 57 55 58 55 59 56 58 56 59 56 58 56 59 56 58 56 59 56 | LVEDD
NA
S3
NA
NA
NA
NA
NA
NA
S1
S1
S5
S7
S5
S5
S5
S5
S5
S5
S5
S5
S5
S5
S5
S5
S5 | NA I NA 155 NA 167 188 1 189 1 149 1 149 1 149 1 149 1 149 1 149 1 149 1 149 1 149 1 149 1 149 1 149 1 149 1 149 1 149 1 149 1 149 1 149 1 158 1 161 1 188 1 122 1 180 1 190 1 190 1 191 1 192 1 193 1 194 1 195
 | NA 1281 NA 1281 NA 1085-1080 NA 1055-1081 007-1085 1087-1085 1087-1085 1087-1085 1087-1085 1087-1085 1087-1085 1034-1113 1287 1297 1297 1297 1297
 1297 1297 1297 1297 1297 | Native Native Native 122 (ms) NA 46 NA 46 NA 46 NA 4862 3950 A4862 4950 4951 400 455 4951 400 5570 53-58 41 41 48 NA | ECV
(%) NA 25 NA NA NA 32 NA 32 23 23 24 24 24 25 24 25 24 25 24 25 24 25 24 25 24 25 24 25 24 25 24 25 24 25 26 21 NA | Cardiae My Card
Cardiae My Card
Racute My Card
NA
NA
NA
NA
NA
NA
NA
NO
NO
NO
NO
NO
NO
NO
NO
NO
NO
NO
NO
NO | Jack MRT Will is Schembin Value | Edema P P no I NA I yes I yes I NA I yes I no I no I no I no I yes I no I yes
 | Pericas
no
NA
no
NA
no
NA
no
no
no
no
no
no
no
no
no
no
no
no
no | Percental Percental Percental Percental Percental Percental NA II NA III NA IIII NA IIII NA IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII | Inco Inco Inco Inco Inco Inco Inco Inco | C abno
 | no NA NO NA NO | ss Trid
n
n
n
n
n
n
n
n
n
n
n
n
n | pr Pese
(reg/i)
3
90
728
9
428
NA
1371
7
87
276
48
6
56
28
87
276
48
6
56
28
87
276
48
6
56
28
513
383
501
513
29
9 | kk NTp:peak peak 22 4 111 1111 111 111 <td>Labor 14 2 5 6 7 11 2 35 14 2 14 2 14 2 35 11 2 35 11 1 0 1</td> <td>attory p: > 190 222 84 64 131 74 119 91 58 75 138 383 34 78 1118 338 25 146 271 140 239 83 104</td> <td>Arran energy of CK-MB peek
(CK-MB
peek
-224
95,1
31
NA
26,3
15,6
16,7
13,2
25,7
15,4
32,1
13,2
25,7
15,4
32,1
18,6
20,7
20,4
19,5
Na
15,5
Na
20,7
20,4
15,5
15,4
32,1
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,7
15,7
15,4
32,1
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,7
15,4
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,3
15,5
15,3
15,3
15,3
15,3
15,3
15,3
15,3
15,3
15,3
15,3
15,3
15,3
15,3
15,3
15,3
15,3
15,3
15,3
15,3
15,3
15,3
15,3
15,3
15,3
15,3
15,3
15,3
14,8
13,7
14,8
13,7
14,8
13,7
14,8
13,7
14,8
13,7
14,8
13,7
14,8
13,7
15,4
13,7
14,8
13,7
14,8
13,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,</td> <td>CRP pask (mg) 2.1 1.9 2.7.8 1.9 2.7.8 1.9 0.5 1.50.9 1.7 1.3 0.7 2.79 457.8 30.1 9.4 9.1 9.4 107.4 1.2 20.4 8.9 5 2.9.4 3.4</td> <td>(kg/m2)
20.8
24,7
33.4
22,3
25
23,15
27,2
24
24,8
25,7
24,8
22,3
24,8
22,3
30
27,2
23
24,8
22,3
30
27,2
23
24,8
22,3
30
27,2
23
24,8
22,3
30
24,6
22,3
30
24,6
22,3
30
24,6
22,3
30
24,6
24,7
30
24,6
24,7
30
24,7
30
24,7
30
24,7
30
24,7
30
24,7
30
24,7
30
24,7
30
24,7
30
24,7
30
24,7
30
24,7
30
24,7
30
24,7
30
24,7
30
24,7
30
24,7
30
24,7
30
24,7
30
24,7
30
24,7
30
24,7
30
24,7
30
24,7
30
24,7
30
24,7
24,7
30
24,7
30
24,7
24,7
24,7
20
24,7
24,7
24,7
24,7
24,7
24,7
24,7
24,7</td> <td>HF Risk fact Hypertension no yes no no</td> <td>incore Smoking yes no no <t< td=""><td>Dabetes Dabetes no no</td><td>Relevant ongoing
Parage at the time of
Bill Societion of
Bill Societion of
Bill Societion of
Section therapy
amo 2Ah
none
Bill ACEI
Bill ACEI
Diversita
ACEI
Diversita
Bill ACEI
Diversita
Bill ACEI
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversi</td></t<></td> | Labor 14 2 5 6 7 11 2 35 14 2 14 2 14 2 35 11 2 35 11 1 0 1
 | attory p: > 190 222 84 64 131 74 119 91 58 75 138 383 34 78 1118 338 25 146 271 140 239 83 104 | Arran energy of CK-MB peek
(CK-MB
peek
-224
95,1
31
NA
26,3
15,6
16,7
13,2
25,7
15,4
32,1
13,2
25,7
15,4
32,1
18,6
20,7
20,4
19,5
Na
15,5
Na
20,7
20,4
15,5
15,4
32,1
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,7
15,7
15,4
32,1
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,7
15,4
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,3
15,5
15,3
15,3
15,3
15,3
15,3
15,3
15,3
15,3
15,3
15,3
15,3
15,3
15,3
15,3
15,3
15,3
15,3
15,3
15,3
15,3
15,3
15,3
15,3
15,3
15,3
15,3
15,3
14,8
13,7
14,8
13,7
14,8
13,7
14,8
13,7
14,8
13,7
14,8
13,7
14,8
13,7
15,4
13,7
14,8
13,7
14,8
13,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15,7
15, | CRP pask (mg) 2.1 1.9 2.7.8 1.9 2.7.8 1.9 0.5 1.50.9 1.7 1.3 0.7 2.79 457.8 30.1 9.4 9.1 9.4 107.4 1.2 20.4 8.9 5 2.9.4 3.4 | (kg/m2)
20.8
24,7
33.4
22,3
25
23,15
27,2
24
24,8
25,7
24,8
22,3
24,8
22,3
30
27,2
23
24,8
22,3
30
27,2
23
24,8
22,3
30
27,2
23
24,8
22,3
30
24,6
22,3
30
24,6
22,3
30
24,6
22,3
30
24,6
24,7
30
24,6
24,7
30
24,7
30
24,7
30
24,7
30
24,7
30
24,7
30
24,7
30
24,7
30
24,7
30
24,7
30
24,7
30
24,7
30
24,7
30
24,7
30
24,7
30
24,7
30
24,7
30
24,7
30
24,7
30
24,7
30
24,7
30
24,7
30
24,7
30
24,7
30
24,7
30
24,7
24,7
30
24,7
30
24,7
24,7
24,7
20
24,7
24,7
24,7
24,7
24,7
24,7
24,7
24,7 | HF Risk fact Hypertension no yes no
 | incore Smoking yes no no <t< td=""><td>Dabetes Dabetes no no</td><td>Relevant ongoing
Parage at the time of
Bill Societion of
Bill Societion of
Bill Societion of
Section therapy
amo 2Ah
none
Bill ACEI
Bill ACEI
Diversita
ACEI
Diversita
Bill ACEI
Diversita
Bill ACEI
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversi</td></t<> | Dabetes Dabetes no | Relevant ongoing
Parage at the time of
Bill Societion of
Bill Societion of
Bill Societion of
Section therapy
amo 2Ah
none
Bill ACEI
Bill ACEI
Diversita
ACEI
Diversita
Bill ACEI
Diversita
Bill ACEI
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversita
Diversi |
| Patient C Non-COVID-19 1 Non-COVID-19 2 Non-COVID-19 3 Non-COVID-19 3 Non-COVID-19 4 Non-COVID-19 5 Non-COVID-19 5 Non-COVID-19 6 Non-COVID-19 7 Non-COVID-19 7 Non-COVID-19 8 post-COVID-19 1 post-COVID-19 1 post-COVID-19 3 post-COVID-19 5 post-COVID-19 6 post-COVID-19 6 post-COVID-19 7 post-COVID-19 7 post-COVID-19 8 post-COVID-19 8 post-COVID-19 7 post-COVID-19 9 post-COVID-19 7 post-COVID-19 10 Post-COVID-19 7 Post-COVID-19 10 Post-COVID-19 7 Post-COVID-19 10 Post-COVID-19 10 Post-COVID-19 10 Post-COVID-19 10 Post-Vaccination 1 Post-Vaccination 2 Post-Vaccination 3 Post-Vaccination 4 MIS-C 1 MIS-C 1 | NA 3 NA 1.5 NA 1.5 NA 1.5 NA 3 1.5 1.5 3 1.5 3 1.5 3 1.5 3 1.5 3 1.5 3 1.5 3 1.5 3 1.5 | EF NA NA 56 NA 53 SA 44 51 1 25 33 74 56 33 58 44 58 42 51 53 58 54 53 54 53 55 56 58 56 58 56 58 56 58 56 58 56 58 56 58 56 | LVEDD
NA
53
NA
53
NA
NA
NA
51
S1
51
35
57
55
55
55
55
55
55
55
55
55
55
55
55 | NA NA 155 NA 167 NA 188 197 NA 188 170 NA 188 170 NA 189 170 149 170 149 170 149 170 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 180 190 191 192 193 193 194 195 195 195 195 195 196
 | Native NA 1281 NA 105-108 NA 1087-108 1087-108 1087-108 1084-113 1287 1287 1287 1280 1281 1282 1283 1284 1285 1284 1285 1284 1284 1284 1284 1284 1284 1284 1284 1284 1284 1284 1284 1284 1284 1284 1284 1284 | Nation
T2
(ms)
NA
46
50
NA
4952
39-50
NA
49-52
49-52
49-52
49-52
49-52
50
50
53-58
57
50
53-58
41
40
50
53-58
41
41
41
41
41
41
41
41
41
41
41
41
41 | E(%) NA 25 NA NA NA 32 7 23 24 24 24 24 24 25 24 25 24 25 24 25 24 25 24 25 24 25 24 25 24 25 24 25 24 25 24 25 24 25 24 25 26 21 21 21 | Cardise MA
Cardise MA
Cardise MA
Cardise Ma
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA | Jace MRT Value Ischernic Value Ischernic Value Value | Edemail F Ro I NA I Yes I Yes I NA I Yes
 | Pericaen no no NA | Pricestia Pricestia Pricestia 1 Pricestia Pricestia 1 NA 1 | no | C abno
 | no no NA no NA no NA no NA No NA No NA NO | s Trid
 | Appropriation Appropriation (reg/) 4:4 257 3 90 728 9 428 NA 1371 7 67 276 48 6 56 266 NA 5 383 5011 513 29 9 32 32 | kk NTppk 98 - 44 - 1111
 | Labor 1 2 35 36 14 15 16 17 16 17 16 17 17 17 17 17 17 17 17 17
 | attory p: > 100 > 100 222 24 84 64 131 74 119 91 58 75 138 383 344 78 1118 338 25 146 2711 1400 83 104 66 66
 | Action of the second se | CRP pask c-s 2.1 1.9 27.8 1.9 0.5 150,9 1.7 1.3 0.7 2.79 457.8 30.1 9.4 107,4 1.1,7 1.2 2.79 457.8 30.1 9.4 107,4 9.4 5 2.94 3.4 2.93,4 | (kg/m2)
20.8
24.7
33.4
22.3
25
23.15
27.2
24.1
30.6
27.2
23.3
24.6
25.7
23.0
27.2
23
24.6
22.3
24.6
22.8
26.3
24.5
26.3
24.5 | HF Risk fact Hypertension no no yes no no no no no yes no | intermediate Smoking yes no
 | Dabetes Dabetes no | Relevant ongoing of
EMB collection
Categoricalism in / See
Seeding on Practice
BB, ACEI
BB, ACEI
BB, ACEI
BB, ACEI
BB, ACEI
BB, ACEI
BB, ACEI
BB, ACEI
BB, ACEI
Acetylashicylic
BB, ACEI
Acetylashicylic
BB, ACEI
Acetylashicylic
BB, ACEI
Acetylashicylic
BB, ACEI
Acetylashicylic
BB, ACEI
Acetylashicylic
BB, ACEI
Acetylashicylic
BB, ACEI
Acetylashicylic
BB, ACEI
Acetylashicylic
BB, ACEI
Acetylashicylic
BB
ACB
ACB
BB, Duretics
BB
BB, Duretics
BB
BB, Duretics
BB
ACB
ACB
ACB
ACB
ACB
ACB
ACB
ACB
ACB |
| Patient C Non-COVID-19 1 Non-COVID-19 2 Non-COVID-19 3 Non-COVID-19 3 Non-COVID-19 4 Non-COVID-19 5 Non-COVID-19 5 Non-COVID-19 6 Non-COVID-19 7 Non-COVID-19 7 Non-COVID-19 8 post-COVID-19 1 post-COVID-19 9 post-COVID-19 5 post-COVID-19 10 post-COVID-19 8 post-COVID-19 7 post-COVID-19 7 post-COVID-19 8 post-COVID-19 7 post-COVID-19 9 post-COVID-19 7 post-COVID-19 8 post-COVID-19 7 post-COVID-19 9 post-COVID-19 7 post-COVID-19 10 Post-Vaccination 1 Post-Vaccination 2 Post-Vaccination 3 Post-Vaccination 4 MIS-C 1 | NA 3 NA 1.5 NA 1.5 NA 3 1.5 1.5 NA 3 3 3 3 3 3 3 1.5 1.5 NA 3 1.5 3 3 3 1.5 1.5 NA 3 3 3 1.5 1.5 3 1.5 1.5 3 3 3 1.5 3 1.5 3 1.5 3 1.5 3 1.5 3 1.5 3 1.5 3 1.5 3 1.5 3 1.5 3 1.5 3 1.5 3 1.5 3 | EF NA NA 56 NA 52 49 32 49 33 51 3 52 33 53 44 54 33 55 53 44 54 51 51 53 53 54 55 59 56 NA 56 NA 56 54 56 55 56 56 56 57 56 | LVEDD
NA
53
NA
53
NA
NA
NA
NA
55
65
55
55
55
55
55
55
55
55
55
55
55 | NA I NA I 155 I NA I 167 I 188 I 170 I 149 I 149 I 149 I 149 I 149 I 140 I 141 I 142 I 158 I 168 I 168 I 188 I 198 I 198 <td< td=""><td>NA 1281 NA 1281 NA 1281 NA 1085 1005-1080 NA 1005-1081 1005-1080 NA 1027-1005 1034-1032 1035-1081 1034-1032 1034-1032 1237 12381 12391 12391 1241 1201 1241 1201 1241 1255 1241 1255 1241 1255 1241 1255 1241 1255 1241 1255 1241 1255 1241 1255 1241 1255 1241 1255 1241 1255 1255</td><td>Nation Nation Nation Nation A 48 NA 48 NA 48 S8 AA 48622 39:50 A4 48 49:52 49:52 49:53 49:54 49:57</td><td>E(%)
NA
25
NA
NA
32
23
23
29
295
24
23
24
24
23
24
24
25
NA
25
NA
25
NA
25
NA
25
NA
24
21
25
NA</td><td>Cardise My Card
Cardise My Card
Racute My Card
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA</td><td>jac. MRT Wills Ischeric Vas scheric Vas sche</td><td>Edema P P No 1 No 1 Na 1</td><td>Pericaen no no NA NA</td><td>Percaratia Percaratia Percaratia 1 Percaratia Percaratia 1 no Percaratia 1 P</td><td></td><td>C abno</td><td>no no NA NA</td><td>Indext and and and and</td></td<> <td>Approprie Approprie (mail) </td> <td>kk NTp://paika 99 </td> <td>Labor 1 1 2 2 35 1 14 2 14 2 14 2 15 35 16 1 11 1 12 1 14 2 15 1 16 1 17 1 18 1 19 1 10 1 11 1 11 1 11 1 11 1 11 1 12 1 13 1 14 1 15 1 16 1 17 1 18 1 19 1 10 1 11 1 12 1 13 1</td> <td>attory p: <190</td> <
 | NA 1281 NA 1281 NA 1281 NA 1085 1005-1080 NA 1005-1081 1005-1080 NA 1027-1005 1034-1032 1035-1081 1034-1032 1034-1032 1237 12381 12391 12391 1241 1201 1241 1201 1241 1255 1241 1255 1241 1255 1241 1255 1241 1255 1241 1255 1241 1255 1241 1255 1241 1255 1241 1255 1241 1255 1255 | Nation Nation Nation Nation A 48 NA 48 NA 48 S8 AA 48622 39:50 A4 48 49:52 49:52 49:53 49:54 49:57 | E(%)
NA
25
NA
NA
32
23
23
29
295
24
23
24
24
23
24
24
25
NA
25
NA
25
NA
25
NA
25
NA
24
21
25
NA | Cardise My Card
Cardise My Card
Racute My Card
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA | jac. MRT Wills Ischeric Vas scheric Vas sche
 | Edema P P No 1 No 1 Na 1
 | Pericaen no no NA | Percaratia Percaratia Percaratia 1 Percaratia Percaratia 1 no Percaratia 1 P | | C abno | no no NA
 | Indext and and | Approprie Approprie (mail) | kk NTp://paika 99
 | Labor 1 1 2 2 35 1 14 2 14 2 14 2 15 35 16 1 11 1 12 1 14 2 15 1 16 1 17 1 18 1 19 1 10 1 11 1 11 1 11 1 11 1 11 1 12 1 13 1 14 1 15 1 16 1 17 1 18 1 19 1 10 1 11 1 12 1 13 1
 | attory p: <190 | Arrowski stranger
CK-MB peak
-24
95,1
31
NA
20,3
15,6
16,7
13,7
13,2
25,7
15,4
32,1
14,8
20,7
20,4
19,5
Na
15,5
Na
15,5
Na
22,7
20,4
19,5
Na
15,5
Na
23,7
NA
23,5
14,8
13,7
14,8
13,7
14,8
13,7
14,8
13,7
14,8
13,7
14,8
13,7
14,8
13,7
14,8
13,7
14,8
14,8
14,7
14,8
14,7
14,7
14,7
14,7
15,4
15,5
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,7
15,4
15,6
15,4
15,6
15,6
15,4
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,7
15,4
15,6
15,6
15,6
15,6
15,6
15,7
15,4
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,7
15,4
15,5
15,6
15,5
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,6
15,5
15,6
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5 | CRP pask c-s- 2.1 1.9 2.7.8 1.9 2.7.8 1.9 2.7.9 1.50.9 1.7 1.3 0.7 2.79 457.8 30.1 9.4 9.1 9.4 107.4 1.2 20.4 8.9 5 29.4 3.4 20.3 | (kg/m2)
20.8
24,7
33,4
22,3
23,15
27,2
24,1
30,6
21,4
35,6
22,3
24,8
25,7
30
27,2
23,3
24,8
25,7
30
27,2
23,3
24,8
25,7
30
27,2
23,3
24,6
22,3
24,6
22,3
24,6
22,3
24,6
22,3
24,6
22,3
24,6
22,3
24,6
22,3
24,6
22,3
24,6
22,3
24,6
22,3
24,6
22,3
24,6
22,3
24,6
22,3
24,7
24,7
24,7
24,7
24,7
24,7
24,7
24,7
 | HF Risk fact Hypertension no yes no yes no | smoking yes no | Diabetes no no <td>Relevant ongoing of
EMB collection
Cate-cholamine /
Section Harapy
urrow 240
BB, ACEI
BB, ACEI
BB, ACEI
BB, ACEI
BB, ACEI
BB, ACEI
BB, ACEI
BB, ACEI
BB, ACEI
Activitationica acid
(100mg)
Diuretics
BB, ACEI, MRAX
BB, Diuretics, L-Thyroxin
Alpha Blocker
none
ARB, If Channel
BCACEI
ACM Section
ACEI
BB, ACM Section
BB, AcM Section
ACEI
BB, ACM Section
ACEI
ACEI
ACEI
ACEI
ACEI
ACEI
ACEI
ACEI</td> | Relevant ongoing of
EMB collection
Cate-cholamine /
Section Harapy
urrow 240
BB, ACEI
BB, ACEI
BB, ACEI
BB, ACEI
BB, ACEI
BB, ACEI
BB, ACEI
BB, ACEI
BB, ACEI
Activitationica acid
(100mg)
Diuretics
BB, ACEI, MRAX
BB, Diuretics, L-Thyroxin
Alpha Blocker
none
ARB, If Channel
BCACEI
ACM Section
ACEI
BB, ACM Section
BB, AcM Section
ACEI
BB,
ACM Section
ACEI
ACEI
ACEI
ACEI
ACEI
ACEI
ACEI
ACEI |
| Patient C Non-COVID-19 1 Non-COVID-19 2 Non-COVID-19 3 Non-COVID-19 3 Non-COVID-19 4 Non-COVID-19 5 Non-COVID-19 5 Non-COVID-19 6 Non-COVID-19 7 Non-COVID-19 7 Non-COVID-19 8 post-COVID-19 1 post-COVID-19 9 post-COVID-19 1 post-COVID-19 9 post-COVID-19 5 post-COVID-19 9 post-COVID-19 6 post-COVID-19 10 Post-COVID-19 7 post-COVID-19 10 Post-COVID-19 10 Post-Vaccination 1 Post-Vaccination 3 Post-Vaccination 3 Post-Vaccination 4 MIS-C 1 MIS-C 2 | NA 3 NA 1.5 NA 1.5 NA 3 1.5 3 1.5 3 3 3 3 3 3 3 3 3 3 3 3 1.5 1.5 3 3 3 3 3 3 1.5 3 1.5 3 1.5 3 1.5 3 1.5 3 1.5 | EF NA NA 56 NA 52 49 52 49 53 53 63 54 53 55 63 63 63 54 53 55 53 54 53 55 53 56 54 57 56 58 56 56 56 56 56 56 56 56 56 57 56 58 56 59 56 56 56 57 56 | LVEDD
NA
53
NA
53
NA
NA
NA
51
51
57
47
55
57
55
55
57
55
55
57
55
57
55
57
55
57
55
57
55
57
55
57
55
57
55
57
55
57
55
57
57 | NA I NA I 155 I NA I 167 I 188 I 189 I 149 I 158 I 168 I 120 I 149 I 158 I 169 I 170 I 177 I
 | NA 1281 NA 1281 NA 1085 NA 1084 NA 1085 NA 1086 NA 105108 NA 105108 NA 1057108 104113 1287 1284 1297 1214 1297 1214 1297 1214 1297 1214 1297 1214 1215 1214 1215 1214 1215 1214 1215 1214 1215 1214 1215 1214 1215 1214 1215 1216 1216 | Nation Nation Nation 12 (ms) NA 4862 3950 A4862 3950 4862 3950 44862 3950 44862 3950 44862 4952 4952 4952 4952 4952 4952 4952 4953 4952 4953 4954 4955 495 5536 41 41 42 43 43
 44 43 44 44 44 44 44 44 44 44 44 44 44 44 44 44< | E(%)
NA
25
NA
NA
32
32
23
23
29
295
24
23
24
24
24
24
24
24
24
24
24
24
24
24
24 | Cardise My Card
Cardise My Card
Racute My Card
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA | Jace MRT Visit (Streme) Visit (Strem) | Edema // F no 1 no 1 NA 1 yes 1 yes 1 yes 1 no 1 no 1 no 1 no 1 no 1 no 1 yes 1 no 1 yes 1 yes 1 yes 1 yes 1 no 1 yes 1 no 1
 | Perices
no
no
NA
no
NA
no
no
no
no
no
no
no
no
no
no
no
no
no | Percentia Percentia Percentia 1 Percentia Percentia 1 NA 1 | | Reduce and
 | herrmalise
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monocological
monoc | | Appropriation Appropriation (mg/h) 4:24 257 3 90 728 9 428 NA 1371 7 87 2276 48 6 56 26 NA 501 513 29 9 32 1323 | kk NTpp/ski peak 2************************************
 | Labor 1 1 2 1 14 2 36 1 2 2 36 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
 | attory p: selection selection <td< td=""><td>Arrowski stranger
CK-MB peek
2-24
95,1
31
NA
26,3
15,6
16,7
13,2
25,7
15,4
225,7
15,4
32,1
13,2
25,7
13,2
25,7
13,2
25,7
13,2
25,7
13,2
25,7
13,2
25,7
13,2
25,7
13,2
25,7
13,2
25,7
13,2
25,7
13,2
25,7
13,2
25,7
13,2
25,7
13,2
25,7
13,2
25,7
13,2
25,7
13,2
25,7
13,2
25,7
13,2
25,7
13,2
25,7
13,2
25,7
13,2
25,7
13,2
25,7
13,2
25,7
13,2
25,7
13,2
20,4
15,6
15,6
15,6
20,7
20,4
15,5
15,5
15,5
15,6
20,7
20,4
15,5
15,5
15,5
20,7
20,4
15,5
15,5
15,5
15,5
20,7
20,4
15,5
15,5
15,5
15,5
20,7
15,5
15,5
15,5
15,5
15,6
15,6
20,7
20,7
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15</td><td>CRP pask <-s</td> 2.1 1.9 2.7.8 1.9 2.7.8 1.9 2.7.9 1.58,9 1.7 2.79 457,8 30,1 9,4 1,12 2,04 8,9 5 2,9,4 3,4 2,96,3 1,155</td<> | Arrowski stranger
CK-MB
peek
2-24
95,1
31
NA
26,3
15,6
16,7
13,2
25,7
15,4
225,7
15,4
32,1
13,2
25,7
13,2
25,7
13,2
25,7
13,2
25,7
13,2
25,7
13,2
25,7
13,2
25,7
13,2
25,7
13,2
25,7
13,2
25,7
13,2
25,7
13,2
25,7
13,2
25,7
13,2
25,7
13,2
25,7
13,2
25,7
13,2
25,7
13,2
25,7
13,2
25,7
13,2
25,7
13,2
25,7
13,2
25,7
13,2
25,7
13,2
25,7
13,2
25,7
13,2
20,4
15,6
15,6
15,6
20,7
20,4
15,5
15,5
15,5
15,6
20,7
20,4
15,5
15,5
15,5
20,7
20,4
15,5
15,5
15,5
15,5
20,7
20,4
15,5
15,5
15,5
15,5
20,7
15,5
15,5
15,5
15,5
15,6
15,6
20,7
20,7
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15,5
15 | CRP pask <-s | (kg/m2)
20.8
24,7
33,4
22,3
25
23,15
27,2
24
24,8
25,7
30
24,8
25,7
30
27,2
24,8
25,7
30
27,2
24,8
25,7
30
27,2
24,8
25,7
30
27,2
24,8
25,7
30
27,2
24,8
25,7
24,8
25,7
24,8
25,7
24,8
25,7
24,9
25,8
24,9
25,8
24,1
25,15
24,15
25,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,1524,15
24,15
24,15
24,15
24,15
24,15
24,15
24,15
24,1524,15
24, | HF Risk fact Hypertension no yes no yes no yes no yes no yes no yes no no no yes no yes no yes no no <td>iors Smoking yes no yes no</td> <td>Diabetes Diabetes no no</td> <td>Relevant ongoing
EMB value time of
EMB value time of
BB, ACEI
BB, ACEI
BB
Corrector
BB
BC
Corrector
BB
Corrector
BB
Corrector
BB
Corrector
BB
Corrector
BB
Corrector
BB
Corrector
BB
Corrector
BB
Corrector
Corrector
BB
Corrector
BB
Corrector
Corrector
BB
Corrector
BB
Corrector
Corrector
Corrector
BB
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corr</td> | iors Smoking yes no yes no
 | Diabetes Diabetes no | Relevant ongoing
EMB value time of
EMB value time of
BB, ACEI
BB, ACEI
BB
Corrector
BB
BC
Corrector
BB
Corrector
BB
Corrector
BB
Corrector
BB
Corrector
BB
Corrector
BB
Corrector
BB
Corrector
BB
Corrector
Corrector
BB
Corrector
BB
Corrector
Corrector
BB
Corrector
BB
Corrector
Corrector
Corrector
BB
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corrector
Corr |
| Patient State Nen-COVID-19 1 Nen-COVID-19 2 Nen-COVID-19 2 Nen-COVID-19 3 Nen-COVID-19 4 Nen-COVID-19 4 Nen-COVID-19 5 Nen-COVID-19 6 Nen-COVID-19 7 Nen-COVID-19 7 Nen-COVID-19 8 post-COVID-19 7 post-COVID-19 9 post-COVID-19 8 post-COVID-19 9 post-COVID-19 6 post-COVID-19 7 post-COVID-19 7 post-COVID-19 8 post-COVID-19 8 post-COVID-19 9 post-COVID-19 9 post-COVID-19 10 Post-Vaccination 1 Post-Vaccination 2 Post-Vaccination 2 Post-Vaccination 4 MIS-C 1 MIS-C 1 follow-up MIS-C 1 follow-up | NA 3 NA 1.5 NA 1.5 NA 3 1.5 1.5 3 1.5 3 1.5 3 1.5 NA 1.5 3 1.5 3 1.5 3 1.5 3 1.5 3 1.5 3 3 3 | EF NA NA 53 NA 53 SA 54 SA 55 SA 55 SA 55 SA 56 NA 55 SA 56 NA 55 SA 56 SA 56 NA 56 NA 56 SA 57 | LVEDD
NA
53
NA
53
NA
NA
54
57
55
57
55
57
55
57
55
57
55
57
55
57
55
57
55
57
55
57
55
57
55
57
55
57
55
57
55
57
55
57
55
57
55
57
55
57
55
57
55
57
57 | NA I NA 155 NA 155 NA 167 188 1 198 1 149 1 149 1 149 1 149 1 149 1 149 1 149 1 149 1 149 1 149 1 149 1 149 1 149 1 149 1 158 1 161 1 188 1 122 1 160 1 172 1 NA 1 177 1
 | NA 1281 NA 1281 NA 1085-1080 NA 1055-1081 1007-1055 1007-1055 1034-1113 1034-1131 1034-1131 1034-1131 1287 1287 13287 1214 13297 1214 1255 1148 1041 1237 1044 1054 | Nation Nation 122 (ms) NA 466 NA 4862 3950
 3950 4862 3950 4852 4952 4952 4952 4952 4953 4952 4953 4953 4953 4953 4953 4953 4953 4953 4953 4953 4953 4953 53568 4954 4957 4957 4957 4957 4957 4957 4957 4957 4957 4957 4957 4957 4957 4957 4957 4957 4957 4957 | E(%) NA 25 NA 25 NA NA 32 NA 32 23 24 24 24 25 NA 26 27 23 24 25 NA 26 21 NA NA 19 | Cardiae My Card
Cardiae My Card
Racute My Card
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA | Jace MRT Visit (Schernic
(Schernic)) Visit (Schernic) Visit | Edemail F Ro I NA I Yes
 | Pericas
Eden
no
NA
no
NA
no
NA
no
no
no
no
no
no
no
no
no
no
no
no
no | Percential Percential Percential Percential Percential no no no | | Redul
Redul
Redul
Redul
 | no no NA NA no NA | Trade Image: second | 2017 Pesa
(mg/) 3
(mg/) 3
(mg/) 4
257
3
90
728
9
9
428
NA
1371
7
7
7
87
276
48
6
6
6
6
6
6
6
6
6
6
6
56
26
NA
55
383
501
513
501
513
29
9
9
32
29
9
1323
1323 | kk NTppk peak 2" 4 11" 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 14 4 6 66 6 69 6 99 9 91 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 111 1111 111 1111
 | Labor 1 1 2 1 14 2 35 1 35 2 30 2 2 2 36 2 37 1 4 2 5 2 37 1 45 2 377 2 377 2 377 2 773 2 773 2 773 2 3338 8
 | attory p: attory p: c: attory p: c: attory p: attory p: <td>Active CK-MB peek
(CK-MB peek
</td> <td>CRP pask <-s</td> 2.1 1.9 2.7.8 1.9 0.5 1.50.9 1.7 1.3 0.7 2.3 0.7 1.3 0.7 1.3 0.7 1.3 0.7 1.3 0.7 1.3 0.7 1.3 0.7 2.79 457.8 30.1 9.4 107.4 1.2 20.4 8.9 5 2.24,4 3.4 228,4 3.4 228,3 155 1,4 | Active CK-MB peek
(CK-MB peek

 | CRP pask <-s | (kg/m2)
20.8
24,7
33.4
22,3
25
23,15
27,2
24
24,8
25,7
24,8
22,3
24,8
22,3
24,8
22,3
24,8
22,3
24,8
22,3
24,8
22,3
24,8
22,3
24,8
22,3
24,8
22,3
24,6
22,3
24,6
22,3
24,6
22,3
24,6
22,3
24,6
22,3
24,6
22,3
24,6
22,3
24,6
22,3
24,6
22,3
24,7
24,7
24,7
24,7
24,7
24,7
24,7
24,7 | HF Risk fact Hypertension no yes no yes no no no yes no yes no yes no no no yes no yes no yes no yes no no <td>ions Smoking yes no yes no yes no</td> <td>Dabetes no no</td> <td>Relevant ongoing of the set of th</td> | ions Smoking yes no yes no yes no | Dabetes no
 | Relevant ongoing of the set of th |

Patient information, clinical metadata and laboratory values.

Extended Data Table 2 | Clinical metadata of controls

Donor	Sex	Age	Age range	Ethnic Origin	Primary diagnosis	Cause of death (DBD or DCD)	Height (cm)	Weight (Kg)	Girth (cm)	вмі	Hypertensio n	Diabetes	Cancer	Pulmonary disease	Liver disease	Echocardiograph y (LVEF %)
D1	Female	NA	50-60	Caucasian	Stroke	DBD	155-160	50-55	80-85	20-25	Y	Ν	N	N	N	>60%
D2	Male	NA	60-70	Caucasian	Trauma	DCD	170-175	80-85	90-95	25-30	N	Ν	Ν	N	N	>60%
D4	Female	NA	70-80	Caucasian	Stroke	DCD	160-165	70-75	90-95	25-30	Y	Y	Ν	N	N	N/A
D5	Female	NA	60-70	Caucasian	Stroke	DCD	150-155	80-85	100-105	30-35	N	Ν	N	N	N	N/A
D6	Male	NA	70-80	Caucasian	Stroke	DCD	175-180	70-75	105-110	20-25	N	Ν	N	N	N	N/A
D7	Male	NA	60-70	Caucasian	Stroke	DCD	180-185	70-75	95-100	20-25	N	Ν	N	N	N	N/A
H2	Male	NA	50-59	Caucasian	Stroke	DBD	175-180	70-75	NA	20-25	N	Ν	Ν	N	N	>60%
нз	Male	NA	50-59	Asian	Suicide	DBD	170-175	70-75	90-95	25-30	N	Ν	N	N	N	60%.
Н4	Male	NA	50-59	Caucasian	Stroke	DBD	175-180	85-90	NA	25-30	N	Ν	N	N	N	60%.
Н5	Female	NA	50-59	Caucasian	Trauma	DBD	170-175	70-75	90-95	20-25	N	Ν	Ν	Y	N	55-60%
Н6	Female	NA	40-49	Caucasian	Suicide	DBD	170-175	70-75	100-105	20-25	N	Ν	N	N	N	50-55%
H7	Female	NA	40-49	Caucasian	Stroke	DBD	170-175	85-90	NA	25-30	N	Ν	Ν	N	N	>60%
H46	Male	28	20-29	NA	Stroke	DBD	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
H49	Female	40	40-49	NA	Stroke	DBD	160	60	NA	NA	NA	NA	NA	NA	NA	NA
H51	Male	50	50-59	NA	Stroke	DBD	180	70	NA	NA	NA	NA	NA	NA	NA	NA
H53	Male	61	60-69	NA	Stroke	DBD	180	80	NA	NA	NA	NA	NA	NA	NA	NA
H55	Male	44	40-49	NA	Stroke	DBD	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
H67	Male	45	40-49	NA	Stroke	DBD	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA

Control group information and clinical metadata.

nature portfolio

Corresponding author(s): Norbert Hubner

Last updated by author(s): 01/07/2025

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section. n/a Confirmed The exact sample size (*n*) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly The statistical test(s) used AND whether they are one- or two-sided

- $\square \square$ Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- A description of all covariates tested
- $|\times|$ A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g. *F*, *t*, *r*) with confidence intervals, effect sizes, degrees of freedom and *P* value noted *Give P values as exact values whenever suitable.*
- imes [] For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
 - Estimates of effect sizes (e.g. Cohen's *d*, Pearson's *r*), indicating how they were calculated

Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.

Software and code

Policy information	about <u>availability of computer code</u>
Data collection	Cellranger (v3.0.2); bcl2fastq (v2.20); Single-Cell Analysis in Python toolkit Scanpy (version 1.5.1); Solo (v0.3); Scrublet (v0.2.1)
Data analysis	All code used to generate the figures in this publication are available on GitHub (https://github.com/Norbert-Hubner-Lab/ Heart_Biopsy_Covid). All scripts run on jupyter notebooks are available as ".ipynb" files, and scripts executed in command line are available as .txts or .sh files. R scripts are available as ".R". Anaconda environments are available as yml files containing information on package versions.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a <u>data availability statement</u>. This statement should provide the following information, where applicable: - Accession codes, unique identifiers, or web links for publicly available datasets

- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

All data generated and analyzed in this study have been deposited at the European Genome-phenome Archive (https://ega-archive.org), which is hosted by the EBI

and the CRG, under accession number (EGAS50000000769). Processed single-nucleus transcriptomic data will be available through the cellxgene platform in the h5ad format (https://cellxgene.cziscience.com/collections/328d71f0-0ed7-4518-966f-be6bd0797324) and on Zenodo (https://zenodo.org/records/14258362). Metadata sheets and patient information are available in Extended Data Table 1.

Research involving human participants, their data, or biological material

Policy information about studies with human participants or human data. See also policy information about sex, gender (identity/presentation), and sexual orientation and race, ethnicity and racism.

Reporting on sex and gender	Sex and gender based analyses have not been performed due to limited numbers of individuals investigated.
Reporting on race, ethnicity, or other socially relevant groupings	Not reported due to limited number of individuals investigated
Population characteristics	Our clinical cohort consisted of i) "classical" lymphocytic myocarditis patients (Non-COVID-19, n=8), ii) patients with signs of acute myocarditis following SARS-CoV-2 infection (Post-COVID-19, n=10), iii) patients with signs of acute myocarditis (n=2), and v) control donor left ventricular tissue that we have analysed previously. All patients presented with symptoms including chest pain, palpitations, fever, shortness of breath, malaise, and/or general weakness and fatigue, and an overall increase of cardiac damage indicating biomarkers (troponin T, NT-pro-BNP, creatine kinase, or creatine kinase-MB) and CRP levels. ECG, echocardiography, or signs of recent or ongoing myocardial damage in cardiac magnetic resonance imaging ranging from normal or nonspecific to borderline low or abnormal are summarised in Extended Data Table 1. All patients underwent left ventricular EMBs and left heart catheterization after routine non-invasive diagnostic work-up and angiography had failed to elucidate any other specific cause of heart failure such as coronary artery disease. Post-COVID-19 and MIS-C patients were previously tested positive for SARS-CoV2 infection by nasopharyngeal swab test PCR. Most Post-Vaccination patients experienced symptom onset within days after the second dose of the vaccine. Consistent with prior reports, the cohort was predominantly male (87.5%; Non-COVID-19: 87.5%, Post-COVID-19: 80%, Post-Vaccination: 100%, and MIS-C: 100%) with an average age of 37 ± 16 years (ranging from 19 to 70 years). The age of the two MIS-C patients was 20 and 21 years. Post-COVID-19 patients was based on positive EMB results showing lymphocytic myocarditis and similarities in sex and age compared to the other disease groups. In the MIS-C group, one patient underwent an additional EMB, 6 months following combined immunosuppression with prednisolone and azathioprine. Clinical histopathology and immunostaning on EMB identified significant widespread increased interstitial macrophage infiltration in all patients and additional
Recruitment	We have addressed this in detail in the limitations section. The endomyocardial biopsies (EMBs) analyzed in this study are extremely difficult to obtain, leading to limited group sizes. Additionally, the patients in this study represent a clinically heterogeneous group, varying in the onset, degree of clinical symptoms, and diagnostic evidence. Non-COVID-19 lymphocytic myocarditis cases were selected to clinically match the other disease groups, excluding fulminant myocarditis cases to align with the mild symptoms typical of COVID-19 myocarditis.
Ethics oversight	This study complies with all ethical regulations associated with human tissue research. Acquisition of samples was approved by the Ethics Committee of Berlin and the Ethics Committee of the Charité – Universitätsmedizin Berlin (IRB approval number: EA2/140/16 and EA2/066/20) and conducted in accordance with the Declaration of Helsinki. All subjects gave their informed consent for inclusion before they participated in the study.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

K Life sciences

Behavioural & social sciences

Ecological, evolutionary & environmental sciences For a reference copy of the document with all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	Limited availability of cardiac biopsies; Group size estimations based on previous studies (Reichart, Lindberg, Maatz et al, Science 2022).
Data exclusions	No data has been excluded from analyses
Replication	Several patients for each group were included in this study, yielding robust statistically significant findings. No further patients and specimens

- Replication are available.
- RandomizationCardiac biopsies were obtained in the hospital from patients with clinical signs of myocarditis. Biopsies were sent to pathology and stored in a
biobank. All myocarditis samples in this study were randomized and blinded before biopsies were further processed and snRNAseq analyses
were carried out. Data from healthy donor controls were taken from previously published data (Reichart et al, Science 2022). Harmonization
of data was carried out at the patient level. After the first AnnData objects were generated, the study was unblinded to carry out group
comparisons.BlindingAt the time cardiac biopsies were taken, blinding was not possible since a strict clinical indication for such an invasive procedure is necessary
based on the symptoms of the patient. Subsequently and before further sample processing of all myocarditis samples investigators were

blinded. After the first AnnData object was generated, the study was unblinded to carry out group comparisons.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems Methods n/a Involved in the study n/a Involved in the study Antibodies \boxtimes ChIP-seq \boxtimes Eukaryotic cell lines Flow cytometry \boxtimes Palaeontology and archaeology \boxtimes MRI-based neuroimaging Animals and other organisms \mathbf{X} \times Clinical data \boxtimes Dual use research of concern \boxtimes Plants

Antibodies

Antibodies used	For immunohistological detection of cardiac immune cells, a monoclonal rabbit-anti-CD3 antibody (Clone SP7, 1:500, Novocastra Laboratories, Newcastle upon Tyne, GB), a monoclonal mouse anti-human CD68 antibody (Clone PG-M1, 1:50, DAKO), a monoclonal rabbit anti-CD4 (clone SP35, 1:50, Zytomed) and a monoclonal mouse anti-CD8 (clone C8/144B 1:300, DAKO) were used.
Validation	Monoclonal mouse anti-human CD68 antibody (Clone PG-M1, DAKO): "Labels human monocytes and macrophages. The antibody is of value for demonstration of monocytes and macrophages in normal and pathological specimens". Monoclonal rabbit anti-CD4 (clone SP35, Zytomed):"The antibody is used for the specific localization of CD4 in tissue sections of formalin-fixed, paraffin-embedded tissue and in frozen sections. For use as an in vitro diagnostic tool."https://www.zytomed-systems.de/assets/datasheets/GA_BRB042_DE_V01_Gef.pdf Monoclonal mouse anti-CD8 (clone C8/144B, DAKO): "Monoclonal Mouse Anti-Human, Ready-to-use antibody, Unconjugated, Immunohistochemistry. Synthetic peptide corresponding to the 13 C-terminal amino acids of cytoplasmic domain of human CD8α coupled to thyroglobulin. CD8 is a 68 kDa transmembrane glycoprotein expressed as a heterodimer by a majority of thymocytes, and by class I major histocompatibility complex restricted, mature, suppressor/cytotoxic T cells".

Plants

Seed stocks	Report on the source of all seed stocks or other plant material used. If applicable, state the seed stock centre and catalogue number. If plant specimens were collected from the field, describe the collection location, date and sampling procedures.
Novel plant genotypes	Describe the methods by which all novel plant genotypes were produced. This includes those generated by transgenic approaches, gene editing, chemical/radiation-based mutagenesis and hybridization. For transgenic lines, describe the transformation method, the number of independent lines analyzed and the generation upon which experiments were performed. For gene-edited lines, describe the editor used, the endogenous sequence targeted for editing, the targeting guide RNA sequence (if applicable) and how the editor
Authentication	was applied. Describe any authentication procedures for each seed stock used or novel genotype generated. Describe any experiments used to assess the effect of a mutation and, where applicable, how potential secondary effects (e.g. second site T-DNA insertions, mosiacism, off-target gene editing) were examined.

Flow Cytometry

Plots

Confirm that:

 \square The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).

The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).

 \bigwedge All plots are contour plots with outliers or pseudocolor plots.

A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

Sample preparation	Hoechst-positive single nuclei were sorted via FACS (BD Biosciences: Influx, XDP, or FACSAria, for gating strategy see Supplementary Figure 1). Purity and integrity of nuclei were confirmed microscopically and nuclei numbers were counted using a Countess II (Life Technologies) before processing with the Chromium Controller (10X Genomics) per the manufacturer's protocol.
Instrument	BD FACSAria Fusion
Software	BD FACSDiva 9.01
Cell population abundance	26% of total nuclei per samples was recovered. Purity and integrity of nuclei were confirmed microscopically and nuclei numbers were counted using a Countess II (Life Technologies) before processing with the Chromium Controller (10X Genomics) per the manufacturer's protocol.
Gating strategy	Size gating to remove doublets and aggregates was applied (FSC-A, SSC-A, FSC-H, FSC-W, SSC-W, SSC-H), followed by sorts for Hoechst-positive nuclei (population P4).

Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.